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The Academy of Science of South Africa (ASSAf) was inaugurated in May 1996 
in the presence of then President Nelson Mandela, the patron of the launch of 
the Academy. It was formed in response to the need for an Academy of Science 
consonant with the dawn of democracy in South Africa: active in its mission of 
using science for the benefit of society, with a mandate encompassing all fields of 
scientific enquiry in a seamless way, and including in its ranks the full diversity of 
South Africa’s distinguished scientists.
The Parliament of South Africa passed the Academy of Science of South Africa 
Act, Act 67 of 2001, and the Act came into operation on 15 May 2002. This 
has made ASSAf the official Academy of Science of South Africa, recognised 
by government and representing South Africa in the international community of 
science academies.
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F O R E W O R D
This report provides a review of the overall state of 
clinical research in South Africa. At the initiation of 
the study, the Study Panel’s task was to review the 
existing scientific evidence regarding the current 
state of clinical research in South Africa. The review 
focused mainly on key clinical research issues as 
they were outlined in the brief. Some highlights of the 
findings include the fact that there has been too little 
research on the public understanding of science 
or of public perceptions of clinical trials in South 
Africa, and that there is currently no national plan to 
provide coordinated support for the education and 
development of clinical researchers. More than half of the total expenditure 
on clinical research is by the private sector. Finally, since the public sector 
is playing too small role in this domain, it needs to become more actively 
engaged.
The study was initiated as a result of discussions with the Pharmaceutical Industry 
Association of South Africa (PIASA), which suggested that the Academy of 
Science of South Africa (ASSAf) should raise awareness of the value of good 
scientific clinical research to South Africa at top levels of government and 
academia. This also included raising awareness of the benefits of having 
clinical research units at universities, hospitals and research institutions in order 
to retain research scientists in the country, as part of the agenda of building 
a larger pool of researchers for the future. Proposers of the study were Prof. 
Wieland Gevers and Prof. Jimmy Volmink and former ASSAf staff member Ms 
Rudzani Ramaite. The ASSAf Council approved the study and approved the 
appointment of a 13-member Study Panel of experts.
The 13-member Study Panel, chaired by Prof. Bongani Mayosi, has completed 
the study and this report is the product of their work. The report has been peer 
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reviewed by one national and two international peers who recommended 
that the report be published. The ASSAf Council also has reviewed both 
the report and the reviewers’ comments, and has approved the report for 
publication. The Council hopes that this report’s recommendations and 
findings will lead to productive interventions, and the growth of high-quality 
clinical research in South Africa.
The report recognises that good clinical research is crucial for the development 
of the country, and thus recommends ways in which it can be revitalised and 
promoted. It proposes solutions to the challenges highlighted in the report. 
These recommendations are based on thorough analysis of the evidence 
obtained by the Study Panel. The report lists the recommendations in detail 
and further suggests which institutions and individuals can best facilitate the 
implementation of these recommendations. One of the key recommendations 
is that the South African Government should invest more money in clinical 
research.
The Council expresses its appreciation to Prof. Wieland Gevers and Prof Jimmy 
Volmink for proposing the study and thanks the chair of the Panel, Prof. Bongani 
Mayosi and all the Panel members for their participation and outstanding 
contributions to the development of the report. The support staff, Ms Phakamile 
Mngadi (Study Director), Dr Nthabiseng Taole (Project Manager) and Prof. 
Roseanne Diab (Executive Officer) are thanked for their contributions and 
assistance during the course of the study.
pROF. ROBiN cREwE
President: Academy of Science of South Africa
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The Study Panel would like to acknowledge the following individuals for their 
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Dr Liesl Grobler, University of Cape Town; Ms Lee Louw, Stellenbosch University; 
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1. what was the brief of the aSSaf council to the Study panel?
The brief of the Study Panel that was appointed by the Council of the 
Academy of Science of South Africa (ASSAf) was to examine and address 
the most relevant and reliable evidence on the key questions below, 
especially regarding clinical trials, and to make recommendations that 
were most appropriate and feasible, based on that evidence:
(i) How to build a national culture in which clinical research is seen as 
essential and clinical trials are widely accepted and promoted as 
the most reliable basis for establishing the efficacy and safety of new 
therapies, procedures and approaches? 
(ii) How to equip and encourage clinicians-in-training to embrace clinical 
research and evidence-based practice as indispensable elements in 
delivering effective health care?
(iii) How to improve the level of funding and execution of clinical 
research for investigator-driven clinical research, including clinical 
trials research?  
(iv) How to ensure that clinical research flourishes in South Africa under 
conditions that protect the rights and safety of individuals?
(v) How can government, parastatal institutions, academia and industry 
interact more constructively in creating a favourable and enabling 
environment for clinical research to be conducted? 
2. why was the topic addressed by aSSaf and not by another body?
According to its Act, Act 67 of 2001, ASSAf is obliged to:
C O N C I S E  B R I E F  O F  T H E  S T U D Y
C O N C I S E  B R I E F  O F  T H E  S T U D Y
REVITALISING CLINICAL RESEARCH IN SOUTH AFRICAxv
A STUDY ON CLINICAL RESEARCH AND RELATED TRAINING IN SOUTH AFRICA
“Provide ef fective advice and facili tate appropriate action in 
relation to the collective needs, oppor tunities and challenges of all 
South Africans”. The Academy may, “at the request of any person or on 
its own init iative, investigate matters of public interest concerning 
science and on the strength of the findings act in an opinion-forming 
and advisory manner”. 
ASSAf has influence as a high-level, independent and constructive 
body. This influence can be used more effectively in bringing about 
policy change to make a contribution in an interlocking area of national 
importance and opportunity that has resisted resolution and reform over 
many years, and caused considerable frustration in its participant sectors. 
ASSAf, through a panel of experts, could examine areas that would lead 
to significant improvements and influence government perceptions 
regarding the value of clinical research and related training to the South 
African economy and health system, by engaging with senior government 
officials in a number of ministries, e.g. the Presidency, Health, Education, 
Science and Technology, Finance, and Trade and Industry. Each of these 
departments has a vested interest in improving the health status of the 
nation and providing access to adequate, affordable health care in a 
framework of economic and social prosperity. It would be entirely feasible 
for ASSAf to examine identified special topics where further focused 
studies or workshops would be appropriate, including how funding would 
be sourced.
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Clinical research in a developing country like South Africa contributes to 
health care at all levels by identifying the causes of problems, facilitating 
diagnosis, improving the efficiency and effectiveness of care, and promoting 
good policy-making. It also supports the training of competent health 
professionals of all kinds, and contributes to global knowledge about locally, as 
well as generally, prevalent diseases in terms of prevention and treatment. 
The key narrative of clinical research in South Africa over the last two decades 
has been that of a largely unplanned, but cumulative, disinvestment in publicly 
funded programmes, resulting from the withdrawal of the health departments 
of provincial governments from this sector (academic hospitals are now 
funded for service functions only), the absence of discounts for research tests 
from the business model of the National Health Laboratory Service (NHLS), 
chronic underfunding of the Medical Research Council (MRC) despite its 
obviously important mandate for maintaining and developing medical/
clinical research capacity in the country, and the lack of funding streams 
to universities that might in principle have been applied to meet the overall 
shortfall in support. 
These intersecting developments are a kind of ’elephant in the room’, well 
known to all participants, but very poorly documented. Tertiary service units 
struggle to remain active in research, and to translate their expertise into 
improved health service. As a result, many clinical researchers have been left 
with no option but to turn to the pharmaceutical industry for the funding of 
those clinical trials in which the companies concerned have an interest, or to 
international donors who conduct large-scale, short-to medium-term, projects 
in South Africa, with local researchers drawn into international teams, often 
led by outsiders. The pharmaceutical investment is directed predominantly at 
the profitable areas of chronic diseases of lifestyle, mental illness and allergy, 
while most of the external donor funding is directed at the serious local HIV 
and TB pandemics. Local and international clinical conference activity has 
accordingly begun to reflect the agendas of donors and industry. There is 
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little likelihood that continuation of the present situation is compatible with 
rebuilding and sustaining solid research capacity in the clinical domain, nor 
can the ideal of well-coordinated state support for a health system, built on 
the ‘intelligence’ of good clinical research, ever be realised.
The serious decline in clinical research activity and capacity has prompted this 
study by ASSAf (http://www.assaf.org.za) in order to make recommendations 
on the overall revitalisation of clinical research in the country within the broad 
paradigm of essential national health research. An additional stimulus is the 
emphasis of government in its ten-year science and technology plan on the 
development of new medicines and other biologically useful agents (‘farmer 
to pharma’). 
*  *  *
In chapter 1 we engage with the questions as to what clinical research is, 
and why it is important. The following working definition of clinical research 
has been adopted:
Clinical research is research primarily conducted with human participants 
(and on material derived from them, such as tissues, specimens and 
cognitive phenomena) during which investigators examine the mechanisms, 
causation, detection, progression and reversal of human disease.
Clinical research is important because it can improve health outcomes by 
establishing the effects of health care interventions, and because it promotes 
and facilitates best-possible health care practice. It is a crucial element in the 
education of health care workers and the effective provision of appropriate 
clinical services. Revitalising clinical research is thus in the national interest 
and requires efficient and supportive management and encouragement at 
all levels.
*  *  *
In chapter 2 we engage with the history of scientific medicine in South Africa, 
and briefly assess its achievements and limitations. Specifically, we examine 
the legacy of colonialism, racism and inequality in medical research, and ask 
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how this history has shaped the relationship between researchers, government, 
industry and the South African public.
From the beginning of the 20th century, medical researchers in South Africa 
began to develop a strong scientific base for clinical research in terms of 
personnel and infrastructure, conducting important investigations into a wide 
range of medical problems. The present burden of disease in South Africa 
is significantly linked to the country’s history of racial and gender inequality, 
violence, oppression and enforced labour migration, and to some of the 
failures of post-apartheid independence. It is characterised by high levels of 
both communicable and non-communicable disease, particularly those that 
are related to poor working conditions and poverty, gender-based violence 
and injury. Because of the colonial context, clinical investigations (with some 
notable exceptions) were largely driven by the needs of the mining and 
agricultural industry, or focused on curative medicine in urban areas, and 
generally did not aim to improve the health of the population as whole.
Clinical research in the apartheid years was conducted by a cohort of 
investigators who were mainly white and male, within a system that provided 
racially unequal access to health care and research training. Institutional 
capacity to conduct clinical research was concentrated in a few historically 
white institutions. Some clinical research in the colonial and apartheid eras 
was racist and unethical, facilitated by an environment of racial inequality, 
discrimination and high status and wealth differentials under an oppressive 
state. 
After 1994, significant strides were made in reorienting health care and medical 
research towards the needs of the majority at a policy level, but in practice the 
tangible benefits of this have been limited by reduced government support 
for medical research within the health care system, a weak education system, 
and poor management of existing resources within the health care system, in 
the face of serious new challenges such as HIV/AIDS and tuberculosis.
Accordingly we recommend that clinical research should be repositioned 
within a more democratic political and societal context, to build on the 
advantages of past investment while actively addressing the legacy of 
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colonialism. Clinical research should contribute to the improvement of the 
health of the nation by purposefully addressing the largest burdens of disease 
as empirically determined and consultatively agreed. The training and 
promotion of clinical researchers should seek to address racial and gender 
imbalances, and ensure that a strong intellectual leadership is built. The 
funding of clinical research should seek to develop strengths wherever these 
can best and most sustainably be built. Finally, clinical research should be 
based on strong ethical codes of conduct.
*  *  *
In chapter 3 we ask what shape a national culture supporting clinical research 
would have to take for it to be supportive of good clinical research, what 
its principal components would be, and to what extent present conditions 
fall short of these requirements. We believe a national culture supporting 
clinical research will accept the value of clinical research based on the 
principle that ‘the proper study of humankind is humans themselves’; will 
understand that sustainable health care systems require guidance by a 
critical mass of clinicians experienced in research and the continuous training 
of new generations of research-informed clinical care-givers; will recognise 
the importance of investment in clinical research due to its complex and 
multi-dimensional nature; will enable an appropriate balance between risks 
and benefits in clinical research while ensuring ethical practice; will attain 
an appropriate balance between curiosity-driven and problem-directed 
research in addressing key health risks in society; will place a clear emphasis 
on public service and public benefit in the conduct of clinical research, will 
promote the protection and development of intellectual property; and will 
enhance public trust in, and understanding of, the role and contribution of 
research in society. 
Accordingly we recommend raising the status of clinical research, both within 
the broader domain of scientific research and within government programmes 
funding science; creating a strong public service and benefit ethos based 
on better programmes promoting public engagement with clinical science 
and better risk-benefit analyses that inform prioritisation of clinical research 
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in the country; capacitating local ethics and regulatory bodies for clinical 
research; developing an interdisciplinary local scientific community through 
scientific publishing and coordinated promotion activities while encouraging 
links between laboratory-based and clinical research; enhancing specialist 
knowledge and competence that is internationally visible without reducing 
interdisciplinary communication among clinical researchers within South 
Africa; creating targeted educational programmes, funding, career-pathing 
and institutional support for the development of new clinical researchers in the 
country; increasing, and better coordinating, the funding of clinical research; 
and working towards a concerted and coordinated effort by government, 
industry and research institutions to promote and develop clinical research 
capacity at the highest level possible.
*  *  *
In chapter 4 we ask how fostering better public engagement with science 
can promote a national culture supporting clinical research. What do we 
know about public opinion concerning clinical research in South Africa, and 
what can we do to improve public understanding of, and trust in, clinical 
research? 
We find that there has been too little research on the public understanding 
of science or on public perceptions of clinical trials in South Africa, that there 
is a legacy of distrust and ignorance in the relationship between research 
participants and clinical researchers because of the history of South Africa, 
and that mutually beneficial engagement between the public and clinical 
researchers has not been extensive enough in the past. Although South Africa 
is still an attractive location for clinical trials, and recruitment of subjects for 
clinical trials is still relatively easy in the country (due to a large treatment-
naïve urban population that is experiencing high unemployment and has 
difficulty accessing expensive drugs), this may change unless attention is 
given to public perceptions through careful engagement.
We therefore recommend raising the profile of clinical research on the African 
continent, for example, in the African Science Communication Network 
and the Southern African Science Communication Network (SASCON), and 
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including clinical research as a further flagship research and development 
cluster for the 2011-15 African Science and Technology Plan of Action. We 
also suggest raising the profile of clinical research within South Africa, for 
example by broadening National Science Week to incorporate a National 
Health Research Week, and by establishing an ASSAf award for Promoting 
Public Engagement with Clinical Science. 
We recommend that public engagement with science should be deepened, 
for example by funding qualitative and quantitative research about the public 
understanding of science, motivating for a National Research Foundation 
(NRF) Research Chair in Public Engagement with Science, ensuring that clinical 
research is included in the agenda, and by including public engagement 
with science in the NEPAD indicators for African science, technology and 
innovation.
We suggest reviewing the new curriculum statements in schools, making 
specific reference to therapeutic/clinical concepts based on an historical 
(longitudinal) approach in order to make useful connections between chem-
istry, human physiology (e.g. endocrinology as an internal ‘drug-administering 
system’), mathematics literacy, ethics and economics.
We wish to ensure a more democratic engagement between the public and 
researchers, so that they share a common understanding of the operation and 
purpose of clinical research, for example by developing locally appropriate 
public communication guidelines and ethical protocols for researchers, 
engaging with public views about clinical research, including geopolitical 
issues as part of research preparation activities, and promoting rights access 
and education for trial participants.
Attention must be given to strengthening the capacity of health and science 
journalists to assist in accurately conveying the essence of clinical research 
approaches and findings to the public, and permitting the public airing of 
concerns. 
*  *  *
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In chapter 5 we examine the current mechanisms of ethical oversight of 
clinical research in South Africa, and ask how well these mechanisms are 
functioning, how ethical oversight mechanisms for clinical research function 
elsewhere, and how we can improve ethical oversight of clinical research in 
South Africa.
We conclude that research should be viewed as a social enterprise, i.e. a 
contract with society, whereby ethically conducted research will serve to 
assure society that individuals will not be harmed. The primary function of 
Research Ethics Committees (RECs) is the protection of research participants, 
including adequate scientific review for excellence and relevance. The laws 
governing the conduct of research in South Africa are generally adequate, 
as are the institutional provisions for ethics governance and regulation; 
the National Health Act has set the standards for ethics in research but 
implementation of these standards is far from being realised.
While legislative changes have resulted in increasing numbers of research 
projects requiring ethics review and approval, there has not been a parallel 
increase in support of REC functioning, resulting in often unnecessary delays 
(this is particularly problematic regarding multi-centre studies). Very few RECs 
are in a position to honour their obligations to monitor and provide oversight of 
the research they approve, despite the fact that the majority of REC members 
in South Africa are health scientists and clinicians and that RECs operate 
largely within university environments. The shift of clinical trial commissioning 
from academic institutions to the private sector has weakened the access 
of academic institutions to funding and their ability to develop research 
capacity, so that only a handful of core researchers are doing trials, and 
conduct too many trials concurrently.
We recommend that institutions and the Department of Health must both 
support RECs both from an administrative and review perspective. This must 
include post-approval responsibilities, including passive and active monitoring 
of approved research; the monitoring and evaluation of REC functioning; and 
making information about clinical research widely available. 
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The National Health Research Ethics Council should register and accredit 
RECs and expedite their ability to process applications. A system of expedited 
review for minimal risk research would result in a significant reduction in the 
overall turn-around time for study proposals. Institutions and RECs should 
collaborate to reduce duplication in ethics review within South Africa, and 
thus facilitate multi-centre studies.
Focused, ongoing educational programmes for existing and potential REC 
members on ethics protocol review, current and past ethics research discourse 
and debate, and ethics regulation are required to ensure competent, high- 
quality review, which itself should be subject to quality assurance at prede-
termined intervals. 
The ethics of publishing needs ongoing attention to avoid the problems of 
sponsor-driven content, and to ensure complete disclosure of conflicts of 
interest.
*  *  *
In chapter 6 we investigate what key problems in South African clinical 
research can be identified by an analysis of published outputs, and explore 
specific interventions that might best promote overall productivity of clinical 
research in terms of both quality and quantity.
We find that while South African scientific publishing represents a small fraction 
of world output, it comprises a large proportion of scientific research on the 
African continent. Clinical research has formed an important part of South 
Africa’s scientific output, in terms of quality and quantity. Although the total 
number of clinical medicine journal articles has declined since 2003, nearly 
half of the fields in clinical research have recorded above-average field-
normalised and journal-normalised citation rates for the period 2002 to 2006. 
The trend has been towards increased publication of clinical medicine journal 
articles in international journals, particularly in a wide variety of specialty 
journals. Although more female and black authors have been publishing than 
before, progress has been slow and the proportion of older authors has been 
rising. 
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We recommend that more high-quality clinical research should be published in 
local, especially multidisciplinary, journals, requiring specific steps such as fully 
recognising and rewarding publications in local journals of high quality. We 
also recommend increasing opportunities for local publication, for example 
by establishing vibrant supplements to existing journals and/or establishing a 
new, open access, multidisciplinary journal for clinical research, possibly as 
a ‘daughter’ of the existing flagship publication, the South African Medical 
Journal. A national society for clinical research should be established.
*  *  *
In chapter 7 we seek to address the declining size and increasing age of the 
workforce actively engaged in clinical research, and the paucity of effective 
training programmes and unattractive career-pathing in the clinical research 
sector.
We find that the clinical research force is ageing and has been steadily 
declining in numbers since the early 1990s. The combined burden of clinical 
teaching and training, health service, and research thus falls on a shrinking 
and ageing pool of academics in health science faculties. This means that 
there is limited capacity to increase the production of properly trained health 
care workers and to train and inspire a new generation of clinical researchers. 
Simultaneously, the situation has brought about an inability to cope with the 
increasing demands of clinical service imposed by the colliding epidemics of 
infectious disease (TB and HIV/AIDS) and non-communicable disease (heart 
disease and stroke).
There is currently no national plan to provide coordinated support for the training 
and development of clinical researchers, and grossly insufficient support for 
research professorships and training fellowships in the clinical research field. 
There is little incentive for clinicians to train in doctoral programmes, resulting 
in a very small number of the clinical professoriate having doctoral degrees. 
We recognise that the National Human Resources Plan for Health that was 
launched by the national Department of Health (DoH) in 2006 emphasises 
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the general shortage of health professionals in South Africa, and consider that 
clinical research needs to be identified as a priority area for implementation. 
The Colleges of Medicine of South Africa (CMSA) has a policy forum on tertiary 
academic medicine and specialist training, which should support these aims. 
The DST’s Ten-Year National Plan for Innovation aims to develop a knowledge-
based economy in which the production and dissemination of knowledge 
leads to economic benefits and enriches all fields of human endeavour: 
clinical research should clearly be one of the most important focus areas in 
the Plan. 
We recommend the creation of a national plan for research capacity develop-
ment in the clinical sciences (a ‘National Clinical Scholars’ Programme’) for 
undergraduate and postgraduate students, and for junior and senior faculty 
in clinical research, based partly on the idea of the PhD as the key driver 
for progress in this area, as part of the human capital generation project of 
the Department of Science and Technology’s (DST’s) Ten-Year National Plan 
for Innovation. This should be a publicly funded training programme for the 
production of the clinician research workforce from undergraduates with the 
necessary talent and aptitude (through student research fellowships), and 
from 20% of postgraduates (through clinical research fellowships). A target 
should be set for 500 PhDs to be produced in the clinical research field over 
the next 10 years, while 30 national research chairs should be earmarked for 
the clinical sciences. 
The objectives of the proposed ‘National Clinical Scholars’ Programme’ may 
be achieved through expansion of the intercalated research year model of 
selective training of motivated undergraduates in carefully planned curricula 
designed to establish a life-long interest in research, re-design of the MMed 
research component to enhance its effectiveness in research training and 
competence, and to serve as the basis for MD/PhD study, and stimulating PhD 
degrees for professional graduates by widening the necessary opportunities 
and support mechanisms, including use of modules and learning methodolo-
gies from BSc Med honours programmes. Provision should also be made for 
the purposeful training and career-pathing of non-clinical graduates who 
can become important partners in clinical research programmes. 
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We also propose the creation of a flexibly managed and supported clinical 
academic career track in all disciplines in the Academic Health Complexes 
under the Health Sciences Academic Development Programme of the DoH. 
A new cadre of clinical lectureships and clinical professorships needs to be 
established in all clinical disciplines to rejuvenate and expand the pool of 
clinical research trainers and academic clinicians in general. We suggest 
the promotion of training for biostatisticians and other supporting professions 
for clinical research at universities. We propose the incorporation of ethics 
into clinical research training and education. We ask for the establishment 
and funding of learnerships for graduates in the research facilities of large 
multinational and national companies, and suggest the development and 
support of a network of skilled mentors who can lead the development of 
young clinical researchers.
The establishment of large-scale research institutes dedicated to collaborative 
clinical research and innovation is a cost-effective and efficient way of 
developing high-level capacity at the cohort level, recognising as it does the 
integration of multiple skills and disciplines in order to address complex health 
problems and create new approaches to health promotion and treatment of 
prevalent and burdensome diseases.  
We also ask for the creation of a ‘National Clinical Research Coordinating 
Centre’ at the MRC to link and coordinate clinical research centres and 
clinical trials programmes at universities, research councils, government and 
industry. Such a network (which would operate best if accorded a large 
measure of operational independence while retaining overall accountability) 
would foster collaborative research efforts, training programmes and research 
projects aimed at strengthening patient-orientated research. The Centre 
should seek to increase the participation of foundations, pharmaceutical 
companies, health insurance firms and the managed care industry in the 
clinical training enterprise.
*  *  *
In chapter 8 we ask how much developing countries should be spending 
on medical and particularly clinical research. Specifically, we look at how 
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much the South African Government spends on research and development 
(R&D), and of this, how much is spent on medical, and specifically clinical, 
research. How are funding priorities determined? Through which institutions is 
government funding allocated? What are the other sources of funding?
We believe that 2% of the gross domestic product (GDP) of developing 
countries is a necessary minimum investment in indigenous science and 
technology development, with health research receiving at least 20% of that 
amount. 
South Africa is spending more on R&D than before, but this is still less than 1% 
of GDP. The largest part is spent on engineering and technological sciences, 
and on the natural sciences (40% of total R&D expenditure; about 20% each), 
while expenditure on the health sciences is 15% of the total (about 0.15% of 
GDP). The government spends a large amount on services in the public health 
sector (about 10% of all state expenditure), but much too little of this money is 
spent on health research, which is also poorly coordinated and inadequately 
documented. Clinical trial expenditure by industry is not included in this figure. 
Most of the current funding for health research comes from donors outside 
the country and the pharmaceutical industry. More than half of the total 
expenditure on clinical research is done by the private (business) sector.
We encourage the DoH to enable the National Health Research Committee, 
or a similar body, to perform the key functions of creating an enabling 
environment to conduct research in South Africa; building better relationships 
between scientists and clinicians and between clinician-researchers and 
policy-makers; promoting clinical research in South Africa; communicating 
between the research community, National Treasury and the various national 
departments; ensuring that institutions provide technical and managerial 
support services to all their researchers; and improving regulatory procedures. 
A non-politicised modus operandi would provide the best results.
We believe there has to be more effective tracking and monitoring of funding 
streams for clinical research and substantially increased public funding of 
clinical research, applied in such a way that national health priorities are more 
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effectively addressed than is currently the case. The DoH should apportion 2% 
of its allocation to health research.
Regional clinical research centres/hubs should be established, each with 
clinical and preclinical expertise and facilities.
We believe that the policies and operational plans of various participants 
such as the DoH, and the Departments of Higher Education and Training, 
Science and Technology and Trade and Industry, the NHLS, the MRC and 
the provincial health departments should be more effectively coordinated, 
facilitated by the new Ministry of Coordination and Planning. 
A ‘National Joint Agreement’ should be formed between universities and 
departments of health and education, which should systematically provide 
a ‘research platform’ alongside the clinical and teaching platforms of the 
Academic Health Complexes, as envisaged in the National Health Act of 
2003.
*  *  *
In chapter 9 we look at the existing institutional arrangements for specific 
investments in clinical research in South Africa, and ask what kinds of interaction 
are needed between government, parastatal institutions, academia and 
industry to revitalise clinical research.
We believe South Africa could and should be recognised internationally as 
a centre of excellence for clinical trials that could attract more investment 
in trials. This would ensure retention of skilled scientists, sustain the ability of 
medical research facilities at universities or research institutions to continue to 
conduct basic research and novel medicinal research, and attract foreign 
direct investment to the benefit of the South African economy.
The present Medicines Control Council’s (MCC’s) Clinical Trials Committee 
performs a review function on all clinical trials. This process, which has 
improved recently after its legislated change into a Regulatory Authority (RA), 
is still experiencing serious problems, including approval delays, variation in 
reviewer quality and inadequate supervision of trials.
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We recommend that the new RA should rigorously meet its newly set statutory 
requirements to ensure that any medicines used in the country are safe and 
effective. The authority should rely on sound ethics review. 
An increase in the number of clinical trials conducted in South Africa (with 
recognition of South Africa as a ‘centre of excellence’ for conducting such 
studies) would require agreement on a reasonable time-to-approval for clinical 
trial applications (e.g. a reduction of approval time to less than eight weeks), 
efficient processing of all applications with clearly understood requirements, 
and regular dialogue between the new South African Health (products) 
Regulatory Authority and all role-players. The regulatory process for approval 
of clinical trials could be expedited in a number of ways. For example, after 
auditing, standardisation and accreditation of RECs by the National Health 
Research Ethics Council (the NHREC), a system could be envisaged in which 
RECs approve or reject clinical trials and simply notify the RA of the clinical 
trials concerned. In addition, once an application to conduct a clinical trial 
had been submitted to the RA, the company or institution could proceed 
with the trial if a no objection letter is received from the RA within a specified 
time frame. Where application has been made for the registration of an 
identical product under another trade name for strategic marketing reasons, 
only one ’Master Dossier’ could be submitted and reviewed. There could be 
recognition of prior approvals in selected countries. To make these measures 
work, the RA could require local RECs to conduct ongoing audits of studies 
they have approved. 
The implementation of the Intellectual Property Rights for Publicly Financed 
R&D Act, Act 51 of 2008, needs to be carefully aligned with the ethical-
regulatory framework to maximise benefits in both sectors and to prevent 
them from impeding the proper functioning of the other. 
*  *  *
In chapter 10 we ask what kinds of interventions have been used successfully 
elsewhere in the world to address the kinds of challenges South African clinical 
research is facing. 
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We find that although health research, and especially clinical research, is 
acknowledged as indispensable for improving health, promoting equity and 
stimulating development, it tends inexplicably to be neglected in sub-Saharan 
Africa in terms of planning, status and funding. Much attention has been 
paid to promoting clinical research in the North, in the face of challenges 
similar to those afflicting the South, so it is possible that solutions already found 
elsewhere could also be applied here. These include maintaining the supply of 
skilled clinical researchers, improving facilities for clinical research, increasing 
funding and strengthening translational research.
We believe that government commitment and partnership is needed to 
revitalise clinical research. The government of Singapore, for example, invests 
in clinical research to translate the biomedical research emanating from its 
highly competitive research institutes into clinical applications; to inculcate a 
knowledge- and evidence-based approach to health care; and to retain the 
highest level of medical talent in the public hospitals.
There must be a closely cooperative and mutually trusting relationship between 
researchers and health policy-makers and implementers. The National Health 
Service (NHS) in the UK, the Department of Health and Social Services in the 
US (through the National Institutes of Health [NIH]), and the Ministry of Health 
in Singapore all engage in partnership with the research community through 
numerous channels and at numerous levels to support clinical research.
Efforts should be targeted at building indigenous research capacity. Singapore 
has a definite career path for clinician-researchers, and promotes and 
rewards performance in clinical research through special awards for research 
excellence.
High-profile advocates are required to promote clinical research. One example 
of an advocacy body is the Initiative to Strengthen Health Research Capacity 
in Africa (ISHReCA), bringing together health researchers in Africa to promote 
the creation of self-sustaining pools of excellence capable of initiating and 
carrying out high-quality health research in Africa.
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Better strategic planning and coordination for health research is required. An 
example of such an initiative is the Health Research Capacity Strengthening 
Initiative partnerships in Kenya and Malawi.
*  *  *
In chapter 11, the final chapter, we list what we consider to be the barriers to 
revitalising clinical research in South africa: 
1. inadequate public engagement with clinical research
Government does not promote clinical research sufficiently in the • 
public domain;
Researchers do not engage sufficiently with issues of importance to • 
research participants and policy-makers.
2. lack of research planning, regulation and coordination
Lack of a coordinated national plan to balance excellence on the • 
world stage (i.e. quality and impact) with relevance to local problems;
An inefficient regulatory framework for clinical trials and registration of • 
new medicines is hindering the conduct of innovative clinical trials. 
3. inadequate capacity for clinical research (human resources and 
infrastructure)
Poor teaching of and matriculation rates in mathematics and science • 
in schools;
Lack of appropriately trained clinical scientists and career structure to • 
support them (i.e. ‘frozen demographics’ of ageing white male clinical 
scientists with too few young, black and woman researchers);
Lack of appropriate facilities and infrastructure (i.e. virtual absence of • 
dedicated clinical research centres).
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4. lack of adequate and appropriate funding
Inadequate funding for clinical trials and other types of clinical research • 
(e.g. the MRC project grant has an upper limit of R130 000 p.a.);
The cost-recovery regimen of the provincial departments of health and • 
the National Health Laboratory Service (NHLS) prohibits investigator-
driven, non-industry clinical research in academic health complexes.
5. absence of monitoring and evaluation
No monitoring of adherence to standards and performance of • 
individual  researchers, academic institutions, research councils, govern- 
ment departments, the health industry and other funders of research.
We now list the proposed synergistic solutions: 
1. National Strategic planning, Regulation and coordination of clinical 
Research:
We propose the formation of a ‘South African Clinical Research • 
Coordinating Centre’ at the MRC, with maximum possible operational 
independence, to serve as an advocacy group and a partnership 
of organisations working to establish South Africa as a world leader in 
clinical research by harnessing the power of all stakeholders, including 
universities, government departments, the NHLS, the health industry and 
research councils;
The proposed Coordinating Centre should engage with a re-energised • 
National Health Research Committee on how optimal planning, 
regulation and coordination of clinical research may be achieved, in 
consultation with the Departments of Health, Higher Education, Science 
and Technology, and Trade and Industry;
The proposed Coordinating Centre should interact with the newly • 
established National Planning Unit in the Presidency on the planning 
needs of clinical and health research;
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The proposed Coordinating Centre should seek to play an advisory role • 
to the proposed Medicines Regulatory Authority (MRA; successor to 
the Medicines Control Council) and the National Ethics Committee in 
order to deal with the regulatory environment and ethical oversight for 
clinical trials and health research in general;
The proposed Coordinating Centre should ensure the alignment of • 
the clinical and health research effort with the principles of Essential 
National Health Research and other policies of the government;
The proposed Coordination Centre should oversee the implementation • 
of the Intellectual Property Rights Act and ensure that it results in a 
proper alignment between the ethical-regulatory regimens and the 
protection of new intellectual property in the clinical domain. 
2. human and infrastructural capacity:
A ‘National Clinical Scholars’ Programme as part of the Ten-Year Plan • 
for Innovation of the DST;
A target of 500 PhDs to be produced in clinical health sciences over the • 
next ten years as part of the plan by the DST to increase the graduation 
rate of PhDs in general to 6 000 per year between 2008 and 2018, plus a 
target of 150 postdoctoral fellows per annum working in South African 
clinical research environments;
A target of 30 research chairs in clinical research areas to help tackle • 
the ‘Farmer to Pharma’ Grand Challenge and other strategic areas.
3. the creation of clinical research centres and research institutes as national 
hubs in the academic health complexes and other sites:
Develop a National Joint Agreement between universities and the • 
Departments of Health, Education and Science and Technology in order 
to provide a ‘research platform’ alongside the clinical and teaching 
platforms in the academic health complexes and other sites;
Create a ‘National Clinical Research Training Coordinating Initiative’ • 
to link and coordinate clinical research training at universities, 
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research councils, government and industry. This initiative will serve 
as a warehouse of education and training opportunities (i.e. projects, 
funding, courses, degrees), and a meeting place for supervisors and 
potential students at a national level;
Establish large-scale research institutes where opportunities for high-• 
level collaborative clinical studies exist, and a critical mass of principal 
investigators, postdoctoral fellows, graduate students and research 
assistants can be assembled.  
Establish attractive, high-capacity training programmes for under-• 
graduate and postgraduate students in the clinical health sciences, as 
well as for junior faculty in clinical research, as part of the human capital 
generation project of the DST’s Ten-Year Plan for Innovation;
Fund learnerships for graduates in the research facilities of large • 
multinational companies;
Foster a clinical-plus-research academic career track (lectureships and • 
professorships) in all clinical disciplines in South African institutions;
Develop and support a network of skilled mentors who can lead the • 
development of young clinical researchers.
4. National Funding Scheme for clinical and health Research:
Raise the national R&D budget to 2% of the GDP, of which 20% should • 
be allocated to health research (DST);
Implement the Mexico declaration commitment by the national DoH to • 
spend 2% of the national health budget on research and development, 
and amend the Research and Development Tax Incentives Policy to 
encourage innovative R&D in South Africa by removing the specific 
exclusion of clinical trials (DTI);
Incentivise the health care industry (pharmaceuticals and private • 
hospitals) to spend 2% of its turnover on R&D (pharmaceutical manufac-
turers and others);
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Follow up on the recently implemented Clinical Training Enhancement • 
Initiative with a well-aligned approach to clinical research training. 
5. Monitoring and Evaluation of the clinical and health Research Enterprise:
Evaluation of the performance of the clinical research enterprise in • 
South Africa, possibly under the aegis of the Academy of Science of 
South Africa, by reviewing the implementation of the recommendations 
of this report at five-yearly intervals;
Monitoring by the National Health Research Committee of the efficiency • 
of the research spend of the MRC and other statutory bodies entrusted 
with publicly funded health research;
Monitoring by the new Monitoring and Evaluation Unit in the Presidency • 
of government’s ability to meet the target of spending 2% of GDP on 
R&D, and 2% of the health budget on health research.
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C H A P T E R  1 :
I N T R O D U C T I O N :
CLINICAL RESEARCH IS THE kEY TO BETTER HEALTH CARE
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I N T R O D U C T I O N :  C L I N I C A L  R E S E A R C H  I S  T H E  k E Y  T O  B E T T E R  H E A LT H  C A R E
C H A P T E R  1
in this chapter, we engage with the following questions:
1. What is clinical research?
2. Why is it important?
INTRODUCTION
The term clinical research means different things to different people. Broadly 
speaking, it can be taken to be that part of scientific enquiry which is directly 
aimed at improving patient care, by studying affected patients themselves. 
Formulating a more precise definition of clinical research, however, offers 
greater challenges. Clinical researchers comprise individuals from different 
disciplines, who work in diverse settings and employ a variety of tools and 
instruments in seeking answers to the wide array of questions that arise in 
clinical practice. As a result of this diversity, the way in which they characterise 
their activity often varies markedly, rendering elusive a universally acceptable 
definition of clinical research.
In this chapter, we begin with an overview of the dominant paradigms within 
which clinical research can be understood. Thereafter, we present the most 
common operational definitions of clinical research currently in use and 
specify the definition ultimately adopted by the Panel; this section also draws 
attention to the intimate linkages between clinical research and other types of 
medical or health care research. Next, we examine the central role of clinical 
trials in the evaluation of the effects of treatments, and introduce systematic 
reviews as a relatively new form of scientific endeavour aimed at weighing 
existing clinical evidence. Finally, we offer a brief discussion of the importance 
of the clinical research enterprise within the South African context. 
PERSPECTIVES ON CLINICAL RESEARCH
Three major paradigms exist within which clinical research can be understood. 
These will, for the sake of convenience, be referred to as ’epidemiological’, 
‘pharmaceutical’ and ‘translational’.
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From an epidemiological perspective, clinical research is seen as the 
application of the methods and techniques of epidemiology (a population 
science) to clinical decision-making. The main focus is thus on the fact that 
groups of patients or healthy people are studied in order to make health 
predictions about individuals. The term ‘clinical epidemiology’ has been 
coined to distinguish this research domain from classical epidemiology, which 
focuses on guiding decisions at the aggregate public health level. As shown 
in the box below, clinical researchers (also known as clinical epidemiologists) 
study a wide selection of issues that are pertinent to patient care. 
The classification of clinical research provided by Grimes and Schultz (2002) 
offers further insight into the epidemiological paradigm (see Figure 1.1). In this 
approach, clinical research can be divided into experimental and observational 
studies, depending on whether or not the investigator allocates the exposure 
(treatment). Experimental studies are further subdivided into randomised and 
non-randomised trials, and observational studies into analytical or descriptive 
categories. Analytical studies incorporate a comparison (control) group, 
whereas descriptive studies do not. Furthermore, within analytical studies, 
cohort studies follow people forward from exposure to outcome, contrasting 
with case-control studies in which individuals are traced backwards from 
outcome to exposure. cross-sectional studies in turn are snapshots of exposures 
and outcomes within a group at one instant in time. Finally, descriptive studies 
such as case series lack a comparison group and therefore cannot examine 
associations, although they can be important for generating hypotheses. 
RESEaRch iNtEREStS OF cliNical EpidEMiOlOgiStS (Fletcher and Fletcher, 2005)
abnormality  Is this patient sick or well?
diagnosis  How accurate is this test?
Frequency  How often does this disease occur?
Risk  What factors increase the risk of this disease?
prognosis  What are the consequences of this disease?
treatment  Does treatment change the course of this disease?
prevention  Does early intervention keep this disease from occurring?
cause  What conditions lead to the disease?
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Clinical researchers are able to choose from any of the above study designs. 
As each design offers specific strengths and limitations, the choice should be 
determined by the research question being examined. 
A second, considerably narrower perspective on clinical research is encountered 
in the biopharmaceutical industry where clinical research is seen as part of the 
drug development process, comprising distinct preclinical and clinical phases. 
Preclinical research involves laboratory screening for promising chemical 
compounds, as well as research on laboratory animals to assess the toxicity 
and biological activity of these entities. A small percentage of the compounds 
so tested proceed to the stage of clinical research, with four phases of human 
experimentation. phase i trials concentrate on dose determination, safety 
and pharmacokinetics, and typically involve small numbers (<100) of human 
volunteers. phase ii trials are also small-scale, and are often placebo-controlled 
studies of efficacy and safety conducted among patients suffering from 
a particular target disease. phase iii trials are fully powered in the statistical 
sense, and are usually randomised studies in which the efficacy of a new drug 
is assessed in relation to placebo or another active drug as comparator. Finally, 
phase iV trials consist of post-marketing surveillance studies that can provide 
useful information on drug adverse effects, but are not infrequently initiated 
with the purpose of bringing the new drug to the attention of a large number of 
clinicians, often on a geographic or regional basis.
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Figure 1.1: Algorithm for classification of types of clinical research
translational science is the third lens though which clinical research may 
be viewed. The establishment and growth of laboratory-based biomedical 
science from the 20th century onwards contributed greatly to a better 
understanding of human biology and disease mechanisms, and this in turn 
has led to many important medical breakthroughs, such as the discovery of 
antibiotics, cures for many nutritional disorders, eradication of smallpox and 
treatments for diabetes and HIV/AIDS. Concern has, however, often been 
expressed about the fact that many basic science discoveries have not (yet) 
resulted in direct benefits to patients. Organisations such as the US National 
Institutes of Health (NIH) have strongly promoted and supported ‘translational 
research’ in order to bridge this gap between basic science and clinical 
application.
The pathway of discovery within a translational science paradigm typically 
begins at ‘the bench’ where scientists study the mechanisms of disease at 
a molecular or cellular level, with subsequent progress to the clinical level 
(‘the bedside’) where studies are conducted to determine whether findings in 
animal models apply to human disease states. Proof-of-concept evidence has 
to be generated prior to potential therapies being tested in clinical trials. Much 
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of this research tends to emphasise ‘mechanistic studies’ aimed at furthering 
the understanding of physiological or pathological processes in humans, 
rather than evaluating the effects of rational interventions. Understanding 
these underlying processes is nevertheless very important for accelerating the 
development of novel approaches to treatment, improving the safety profile 
of existing interventions and advancing new diagnostic methods. 
It is well understood, however, that new discoveries are not always initiated at 
the bench. Observations by astute clinicians of variations in disease processes 
in different patients may generate important hypotheses for testing in the 
laboratory, which in turn can spur important new innovations. Translational 
research can thus be regarded as being a bi-directional (‘bench-to-bedside 
and back-to-the-bench’) process in which basic scientists and clinical 
researchers are engaged in a symbiotic relationship. 
in summary, three main perspectives on clinical research are currently 
identifiable. For some, clinical research is the application of epidemiological 
methods in the search for valid answers to questions regarding diagnosis, 
prevention, therapy, prognosis, aetiology and other issues relevant to 
patient care. Others view clinical research as experimental research aimed 
at establishing the risks and benefits associated with new pharmaceutical 
products. A third group regards clinical research as a scientific activity 
directed at testing or generating hypotheses about disease mechanisms, with 
the ultimate aim of accelerating the translation of basic science discoveries 
to useful clinical applications. it is obvious that the three perspectives are 
mutually interdependent.
CLINICAL RESEARCH DEFINED
There is a lack of agreement among clinicians and scientists on the type and 
scope of activities that constitute clinical research. Various scientific and 
medical bodies have, nonetheless, sought to formulate operational definitions 
of clinical research mainly for the purposes of tracking research activity or 
documenting funding flows in research. In this section, we highlight the most 
widely used of these definitions and clarify the working definition adopted by 
the Panel.
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Clinical research is defined by the US National Institutes of Health as health-
related research conducted on human beings or on specimens collected from 
specific patients, but not on human tissues, where the identity of the people 
from whom the cells or tissues are derived is unknown (NIH Directors’ Panel 
Clinical Research Report,1997). The NIH Directors’ Panel Clinical Research 
Report of 1997 grouped clinical research into three parts:
a. patient-oriented research: research conducted with human participants 
(or on material of human origin such as tissues, specimens and cognitive 
phenomena) for which an investigator (or colleague) directly interacts 
with humans. This area of research includes:
Mechanisms of human disease;• 
Therapeutic interventions;• 
Clinical trials;• 
Development of new technologies;• 
b. Epidemiologic and behavioural studies;
c. Outcomes research and health services research (NIH Directors’ Panel 
Clinical Research Report, 1997).
This definition excludes in vitro studies that utilise human tissues but do not deal 
directly with patients (i.e. where it not necessary to know the identity of the 
patients from whom the cells or tissues under study have been taken).
A similar broad-based definition has been adopted by the Medical Research 
Council in the UK, which views clinical research as human research involving 
at least one of the following categories (http://www.mrc.ac.za): 
a. human participation: studies that require face-to-face contact with 
patients and/or healthy human participants and may involve the use of 
patient records, e.g. a clinical trial; 
b. Record-based studies: studies that require access to personal data on 
health or lifestyle without involving face-to-face contact with any people, 
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e.g. epidemiological studies, health economic studies, public health 
interventions, health services research and meta-analyses; 
c. clinical samples: studies that involve laboratory studies on human material 
which are specifically designed to understand or treat a disease/disorder. 
Basic biomedical research of remote relevance to a disease/disorder, 
e.g. use of immortalised human cell lines in model biological systems is 
excluded;
d. technology development for clinical use: development or adaptation of 
technologies for diagnosis or therapy, e.g. instrument development for 
diagnostic or surgical use; development of new techniques for clinical 
use, such as photodynamic therapy.
The UK Medical Research Council has also offered a conceptual model for 
understanding the linkages between clinical research and other forms of 
medical research (Figure 1.2) (Sutton, 2004). Within this framework, the term 
‘medical research’ is seen to encompass a broad range of activities aimed 
at improving or maintaining human health, and comprises both basic and 
clinical research. Clinical research involves research on human participants, 
while ‘basic research’ refers to underpinning research from areas such as 
animal studies, psychology, epidemiology, statistics, economics, physics, 
chemistry, and so forth. Furthermore, it can observed that experimental 
medicine and population science do not exclusively fall into the domain of 
clinical research, but cross the boundary between clinical and basic research. 
Finally, translational research is depicted as a two-way bridge from basic 
science to clinical application and health care delivery. 
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Figure 1.2: a conceptual uK model for understanding the linkages 
between clinical research and other forms of health 
research
Given the considerable blurring of traditional boundaries between basic 
and applied science, or experimental and observational research, it is not 
surprising that definitions of clinical research adopted by most professional 
bodies have tended to be inclusive. This Panel has followed this trend and 
decided upon the following working definition: 
Clinical research is research primarily conducted with human participants 
(and on material derived from them, such as tissues, specimens and 
cognitive phenomena) during which investigators examine mechanisms, 
causation, detection, progression and reversal of human disease.
CLINICAL TRIALS – THE CORNERSTONE OF CLINICAL RESEARCH
As the ultimate goal of clinical research is to improve health outcomes, it 
stands to reason that establishing the effects of clinical interventions and 
strategies would be its central concern. In the past, judgments about what 
treatments do or do not work were based on theories about how the body 
functions, and anecdotal clinical reports concerning treatment outcomes. 
While these approaches remain important, there is greater awareness today 
of their many limitations. 
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Theoretical models of disease mechanisms, derived from laboratory research 
on cells, animals or human tissues, may be imperfect, incorrect or lack 
applicability to humans. Consequently, application of knowledge derived 
from theoretical constructs does not automatically translate into effective 
treatment, and in some instances may result in harm. Clinical experience, 
unlike preclinical research, offers the advantage of being able to directly 
observe health-related events in humans. Unless careful steps are taken to 
reduce bias in the course of making these observations, however, clinicians 
may reach dangerously false conclusions regarding treatment effects. It is 
now widely accepted that clinical trials provide the most reliable evidence for 
establishing the efficacy and safety of therapies, procedures and strategies 
in health care. 
This section accordingly explains what a clinical trial is and discusses the 
reasons why this particular study design has come to assume favoured status 
within clinical research. 
clinical trials are organised experiments in which outcomes in participants 
who are assigned active treatment are compared with those receiving an 
alternative active treatment, a placebo (inactive treatment) or no treatment. 
Clinical trials, however, vary in the rigour of their design. Not all trials use a 
concurrent control group, and where they do, participants may or may 
not be randomly allocated to comparison groups. Furthermore, blinding of 
participants, providers and those assessing treatment outcomes to the group 
to which participants were assigned, while desirable, is not always undertaken 
and may in some instances not be feasible. 
Historically, the first known controlled clinical trial appears to have been the 
study of scurvy treatments conducted by James Lind in 1753 (see text box 
below). It took two centuries for the approach now known as the randomised 
controlled trial (RCT) to be introduced. The relevant landmark study, an 
evaluation of streptomycin in the treatment of pulmonary tuberculosis, 
represented a significant step forward in the scientific evaluation of health 
care. The RCT has since been widely embraced as the gold standard for 
assessing the effects of new treatments. Before setting forth some theoretical 
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arguments for the superiority of RCTs within this context, we will briefly illustrate 
(with examples from practice) the dangers inherent in drawing conclusions 
about treatment effects from alternative types of evidence. 
An important early example of experimental research 
in clinical medicine 
In the mid-18th century, long before the discovery of vitamin C, the 
Scottish naval surgeon, James Lind, conducted a controlled study 
among 12 sailors at sea in search of a cure for the then deadly 
disease of scurvy. Taking care to select patients who were at a 
similar stage of the disease, on a similar diet and accommodated 
in similar conditions, he separated them into pairs in order to test 
six different treatments in use at the time: cider, sea water, vinegar, 
dilute sulphuric acid, oranges and lemons and a concoction of 
nutmeg, mustard and garlic. Lind reported: “The consequence was, 
that the most sudden and visible good effects were perceived from 
the use of oranges and lemons; one of those who had taken them, 
being at the end of six days fit for duty.” This work was remarkable 
for its role in the elimination of scurvy from the British Royal Navy, 
sadly however, only fifty years later, due to delay in implementing 
the findings of this important study.
The tale of bloodletting can next be considered as a medical therapy widely 
adopted without proper evidence. During the 1832 cholera epidemic in 
France, treatment consisted of bloodletting by surgical venesection and the 
application of leeches. The practice was based on the theory that the redness, 
heat and swelling seen as local inflammation were due to an excess of blood 
which led to a build-up of pressure. It seemed logical that the removal of 
blood would lessen the pressure, thus mitigating the inflammation. On this 
basis, the practice of bloodletting was used in Europe for over a hundred 
years, including by such luminaries as Sir William Osler, before it was finally 
accepted that the practice was harmful and should be discontinued. 
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Such instances of dangerous clinical practice are not limited to the pre-
scientific era. Take for example the exposure of more than three million 
pregnant women to the ‘wonder drug,’ diethylstilboestrol (DES) from the 
1950s to the early 1970s. Supported by promising findings in animal studies and 
anecdotal clinical evidence in humans, the hormone was widely promoted 
for preventing miscarriages and other complications of pregnancy. Twenty 
years later, many of the daughters of women given DES developed a rare 
vaginal cancer (adenocarcinoma), as well as other cancers and primary 
infertility, while many of their sons developed testicular malformations. 
This tragedy was all the more significant given the knowledge that an RCT 
published as far back as 1953 had demonstrated that DES had no effect on 
pregnancy complications compared with placebo. Had these findings been 
taken seriously, the disaster may well have been averted. 
A more recent example is the routine prophylactic use of class I anti-arrhythmic 
drugs in patients suffering a heart attack. Based on the finding that these 
drugs could suppress abnormal heart rhythms in the laboratory, they were 
introduced into clinical practice in the belief that they would reduce mortality 
in the early period after a heart attack when such abnormalities are most 
common. Contrary to expectation, when RCTs were eventually carried out 
to test this hypothesis, the risk of death was found to be significantly higher 
among those on anti-arrhythmic treatment, compared with those receiving 
placebo. 
When the effects of treatment are inferred from the findings of observational 
clinical research rather than from systematic clinical experience, bias in 
the selection of participants and confounding factors can still result in false 
conclusions. The following examples illustrate why caution is required in 
interpreting the results of observational research. Recently, prospective 
observational studies found that people with higher intakes of vitamin E, 
vitamin C and other antioxidants had reduced rates of cardiovascular disease 
and cancer, compared with those with lower intakes. In contrast, subsequent 
RCTs demonstrated that risks were either similar in these groups or higher in 
those taking antioxidant supplements. Similarly, the notion, based on findings 
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of observational research that the use of hormone replacement therapy (HRT) 
resulted in lower risks of heart attacks and strokes in post-menopausal women, 
was dispelled by a recent large RCT finding that was exactly the opposite. 
The question may reasonably be asked: what makes the RCT so special that 
its findings should be regarded as being more trustworthy than those of other 
types of studies? There are key features of RCTs which underpin their special 
status as dependable sources of evidence:
First, RCTs provide direct evidence for an effect of a particular treatment 
in human populations. Such proof is more reliable than indirect evidence 
derived from animal models which may or may not be applicable in 
humans; such evidence remains valid even when the reasons for the 
treatment effect are not fully understood. 
Second, RCTs are prospective studies, which means that the exposure 
(treatment) is known to precede the disease outcome; a prerequisite for 
inference about causality. By contrast, assurance of a correct temporal 
relationship between cause and effect is lacking in retrospective or cross-
sectional clinical studies. 
Third, in RCTs the exposure (treatment) is under the control of the 
investigator, i.e. the investigator assigns the treatment. This is different from 
observational studies where the investigator relies on historical information 
about whether or not participants have been exposed, which is more 
susceptible to bias. 
Fourth, RCTs employ comparative information (controls). Control groups 
limit bias in the evaluation of treatment by addressing two issues: a) 
people may recover from illness without any treatment, and b) natural 
fluctuations in the course of a disease may make it seem that a treatment 
is helping or hurting when in reality it may be having no effect. Comparing 
the experience of those receiving treatment with that of people not on 
treatment therefore helps reduce the likelihood of falsely attributing a 
particular clinical outcome to the effect of treatment. The importance of 
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this principle has long been recognised as can be seen in the quotation 
from Claude Bernard, the famous 19th century physiologist: “Comparative 
experience is a prerequisite for experimental and scientific medicine, 
otherwise the physician may walk at random and become the sport of a 
thousand illusions” (Tröhler, 2000).
Finally, and perhaps the most powerful reason of all: RCTs can ensure the 
comparison of ‘like with like’. An important consideration in the evaluation 
of the effects of treatment is that participants in comparison groups should 
be sufficiently similar at baseline so that any differences in outcomes 
can be confidently attributed to treatment rather than to other factors. 
Randomisation, which ensures that participants have an equal chance 
of being allocated to intervention or control groups, is the only available 
method that can reduce bias resulting from unequal distribution of known 
or unknown factors than can influence clinical outcomes.
BEYOND CLINICAL TRIALS
the value of clinical research studies as guides to clinical practice (or future 
research) depend on the extent to which three important conditions are 
fulfilled: a) all relevant research that has addressed a particular question is 
available for assessment; b) an appraisal of the validity of each study has 
been undertaken; and c) a scientific synthesis has been conducted that 
provides insight into apparent conflicts in study findings or, where appropriate, 
an overall summary of the findings.
This idea is contained in the now famous statement by the epidemiologist 
and physician Archie Cochrane in 1979: “It is surely a great criticism of our 
profession that we have not organised a critical summary, by specialty or 
subspecialty, adapted periodically, of all relevant randomised controlled 
trials” (Cochrane, 1979). 
A scientific methodology for conducting research syntheses (known as the 
’systematic review’) has been developed in response to this challenge, as well 
as in respect of mounting proof of the shortcomings of traditional methods 
of review, including individual RCTs. Systematic reviews are considered to 
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be more reliable than traditional (informal) reviews or expert group review 
for weighing existing evidence, and therefore for informing health care 
decisions. 
Systematic reviews are increasingly regarded as the most authoritative source 
of evidence on the efficacy of preventive, therapeutic and rehabilitative in-
terventions in clinical medicine. They are widely promoted by the interna-
tional Cochrane Collaboration, a not-for-profit, independent organisation 
(http://www.cochrane.org), dedicated to making up-to-date and reliable 
information about the effects of health care readily available worldwide. The 
organisation is also strongly endorsed by the World Health Organisation.
FINDINGS
1. The following working definition of clinical research has been adopted for 
the purpose of this study:
Clinical research is research primarily conducted with human participants 
(and on material derived from them, such as tissues, specimens and cognitive 
phenomena) during which investigators examine mechanisms, causation, 
detection, progression and reversal of human disease.
2. Clinical research is important because it can improve health outcomes 
by establishing the effects of health care interventions and because it 
promotes and facilitates best-possible health care practice. 
3. Clinical research is a crucial element in the education of health care 
workers and the effective provision of appropriate clinical services.
4. Revitalising clinical research is thus in the national interest and requires 
efficient and supportive management and encouragement at all levels.
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in this chapter, we engage with the following questions:
1. What is the history of scientific medicine in South Africa, its achievements 
and limitations? Specifically, what is the legacy of colonialism, racism and 
inequality in medical research?
2. How has this history shaped the relationship between researchers, govern-
ment, industry and the South African public?
THE BIRTH OF SCIENTIFIC mEDICINE 
The emergence of scientific medicine in Europe during the Renaissance was 
characterised by greater interest in gathering and documenting observable, 
replicable, experimental data on diseases and their treatment, and to explain 
the mechanisms underlying what was observed. Although there were some 
ancient medical experiments and investigations, and the development 
of long-standing folk or traditional health care practices would necessarily 
have depended on various forms of trial and error, these mostly remained 
undocumented and unchallenged. The formal experimental method in 
clinical research is generally assumed to have arisen in Europe during the 
Renaissance and the following Enlightenment era. Lind’s small clinical trial in 
the 1750s – discussed in Chapter 1 – was part of an experimental tradition in 
Western medicine that emerged through physiological studies in the sixteenth 
century and was subsequently applied to the testing of medical therapies 
(Sutton, 2004). 
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 ,
South AfricAn contributionS to the development of Scientific 
thinking in europe
Science in Britain’s American, Asian and African colonies influenced metropolitan 
science both by expanding the available natural history data for European 
scientists and by providing a channel for new kinds of knowledge, for example 
about indigenous medicines (Tröhler, 2000). Cook (2007) has suggested that the 
search for objective evidence based on investigations, characteristic of the new 
scientific thinking in Europe, grew out of the needs of commerce rather than 
the shortcomings of religion. In particular, one of the key drivers for the scientific 
revolution in 17th and 18th century Europe was the requirement for information 
of organisations like the Dutch East India Company (DEIC). The Cape was 
established as an outpost of the DEIC, ensuring that its ships revictualled en route 
to the East. There were a number of visitors to the Cape in the 18th century who 
took medical information back to Europe, on which basis some plants indigenous 
to the Cape (buchu and aloe) were exported and included in European 
pharmacopoeia (Deacon, 2004). Even before there was a strong local cadre of 
scientists, South Africa was contributing in this indirect way to the development 
of scientific thinking in Europe.
Close connections were maintained with Europe through immigration, visits and 
the training of doctors, and some therapies based on early clinical trials came 
to be more widely used in South Africa. The folk method of smallpox inoculation 
(variolation), for example, was tested in the Netherlands in 1756 by de Monchy. 
He and other Rotterdam doctors conducted a trial on 32 people, including 
De Monchy’s own daughter (Haagsche, 1757). De Monchy subsequently 
recommended variolation to the Cape Governor and it was implemented before 
the epidemic of 1767 (Burrows, 1958). In 1798, Jenner published experimental results 
(using children) showing the safety and effectiveness of cowpox vaccination 
against smallpox (Booth, 1993). This information was brought to the Cape by a 
British doctor on his way to India two years later, and when a Portuguese ship 
later brought slaves vaccinated with cowpox into the port, local trials using arm-
to-arm vaccination to test its safety and non-infectiousness were done on slave 
children. Local doctors testified to the beneficial consequences of vaccination 
observed in Europe. The Batavian government at the Cape set up a Vaccination 
Committee to provide free voluntary vaccination for the public (Burrows, 1958), 
and in 1805 smallpox vaccination was taken into the Cape hinterland by the 
German doctor Lichtenstein (Sandler, 1974).
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The establishment of research-oriented universities and specialised clinics 
during the late 19th century in Europe and later in the US encouraged the 
detailed study of specific diseases. Scientific medicine depended on new ways 
of seeing disease (e.g. microscopes), and new mathematical concepts such 
as sampling and randomisation. By the mid-19th century, better microscopes 
enabled German histologists to show that all living organisms were made out 
of cells, and helped Virchow to develop a new concept of disease based 
on disturbances of the cellular structure of the human body (Booth, 1993). 
Western doctors began to see mathematics and physics as essential to their 
experimental work, providing statistical tools as well as measuring instruments 
to assess physiological phenomena. Increasingly, it was scientific investigation 
that differentiated ‘medical school’ (orthodox) medicine from other forms of 
health care. 
In the 19th century, South African-based doctors, lacking a critical mass of 
researchers and a local medical school, were somewhat slower to develop 
institutionalised medical research than their European counterparts. The 
absolute number of doctors was relatively low in the Cape, and there were 
only 45 licensed doctors in 1807-8 (in a settler population of just under 30 000), 
increasing to 629 in 1904 (in a settler population of around 580 000) (Deacon, 
2004). The polymath Atherstone’s successful experiment with anaesthesia in 
1847 was perhaps the most famous Cape medical experiment of the time. 
Because it was one of many similar experiments elsewhere in that decade, 
however, it did not substantially change the practice of anaesthesia (Burrows, 
1958). A. Smith, the first Superintendent of the South African Museum in 1825, 
was a regular correspondent of Darwin (Cluver and Smith, 1988); J. Herschel 
mapped the Southern sky from Cape Town before returning to Britain to 
become the President of the Royal Society, and other local scientists also 
directly and indirectly influenced scientific thinking in Europe.
Science offered new ways of testing old remedies, for example the use of a 
decoction of willow-tops for fevers, common as a folk remedy among Khoisan 
and Dutch settlers at the Cape (Volmink, 2008), but local trials were few. 
Mackrill, Barry and Atherstone conducted experiments on folk, settler and 
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indigenous plant remedies (Price, 1959). In the 1830s, a Cape Town surgeon, 
S. Bailey, reportedly used “a … [Xhosa] medicine … made of herbs from the 
Eastern Cape” which “he put ... great faith in” (Quarterly Bulletin of the SA 
Library, 1969). Even so, experimentation with local medicinal plants was not 
very widespread at the Cape. When district surgeons were asked to send 
in accounts of indigenous plants and their medicinal use to government in 
1829, very few responded (Deacon, 2004). The results of this kind of scattered 
experimentation were not systematically shared among the profession, which 
lacked a local medical school or strong professional organisations. South 
African doctors tended to distance themselves from indigenous and folk 
healers who used indigenous plants (Deacon, 2004). 
A great deal of European colonial science was focused on supporting the 
economic and political objectives of empire and its local representatives. 
Although doctors were not simply agents of empire, there was a close 
relationship between the medical profession and the colonial state from 
the 19th century onwards. The medical profession thus focused initially on 
the plant sciences and meteorology in the development of cash crops, 
mapping, surveying and anthropology in the maintenance of colonial rule, 
and entomology and clinical medicine in the control of disease that affected 
black workers and white colonists (Palladino and Worboys,1993). British 
imperial policy after 1918 aimed to “create research and technical assistance 
agencies in individual territories where they could be guided by and best 
serve local economic and political interests” (Palladino and Worboys, 1993). 
By the 1950s, South African research interests were strongly influenced by the 
growing international scientific research community, mainly in Europe, the 
US and Japan, rather than in other developing countries. Dependence on 
imported equipment from these countries, and their dominance in scientific 
publishing, increased the importance of close relationships with their scientists. 
Even while some South African researchers did world-class research and 
participated in international scientific organisations, the general relationship 
between South African researchers and their Western counterparts was 
generally not an equal one. The relationship between local and international 
research institutions has been described as a form of ‘scientific imperialism’, 
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in which funding was usually controlled by wealthy Western institutions, and 
the research agenda was set by them; in the worst cases, research findings 
from external or collaborative programmes were therefore not relevant or 
implementable in addressing local problems, and local research capacity 
was not developed (Tucker and Makgoba, 2008). 
The burden of disease in South Africa is linked to its history of racial and gender 
inequality, oppression and enforced labour migration, as well as to some of 
the failures of post-apartheid independence. It is characterised by high levels 
of both communicable and non-communicable diseases, particularly those 
which are related to poor working conditions and domestic poverty, gender-
based violence and injury. There have historically been significant racial and 
gender differences in disease burden and life expectancy, and these remain 
today (Coovadia, 2009). 
Medical research in South Africa did not address the national burdens of 
disease equitably for most of the 20th century. Researchers and their funders 
were often interested in the problems of the African majority primarily to 
support white-owned industry. South Africa’s colonial and apartheid economy 
was aimed at minerals and resource extraction, while industrial development 
was aimed at import substitution as early as the 1920s and did not shift to 
export-oriented industrialisation until the early 1990s. Mining was dependent 
on cheap black labour, and import substitution was highly dependent on 
skilled (white) labour and capital-intensive production processes (Altman and 
Mayer, 2003, cited in Kraak, 2004). Much of the health services infrastructure 
was thus located in urban areas serving the needs of the white population 
– the basic health needs of rural Africans were not prioritised. Mines were 
willing to address migrant workers’ health needs in the short term through the 
provision of vaccines and by sending sick workers home, but avoided paying 
for more expensive long-term health benefits which required the provision of 
better working conditions and sick benefits. 
Because of its increasing status as a symbol of modernity, medical science 
also played a broader political role on the international stage, representing 
South Africa as a mature nation worthy of independence and respect 
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within the British Empire. Public institutions like museums, universities, hospitals 
or mental asylums helped the small South African colonies in the late 19th 
century to represent themselves as civilised, mature outposts of the Empire 
which deserved a degree of independence in local governance. During his 
period of office as prime minister, J.C. Smuts, himself a noted philosopher and 
amateur scientist, used national scientific achievements to position South 
Africa as a nation deserving of respect within the British Commonwealth, 
capable of bringing Western ‘civilisation’ to the country through industrial 
development and judicious handling of ‘the native question’ (Dubow, 2006). 
In South Africa, medical research was thus seen as playing a particular role 
in potentially returning “to the rest of the world some of the benefits which 
she has received from the development of scientific research in overseas 
countries” (Schonland, 2005). Scientific research that was valued and 
validated in the developed world was equally important to the apartheid 
government in its quest to display South Africa’s modernity to the world 
and encourage its acceptability (Logan, 2003). In 1967, L. Munnik, MEC for 
Hospital Services, informed the prime minister, B. J. Vorster, that Barnard had 
put South Africa and its medical institutions ”on the world map” (Logan, 2003). 
Funding was not therefore denied to broad-based clinical research, though 
the government and its agencies were partisan or narrowly focused on their 
electorate in some research-funding decisions (Dubow, 2006). Since the end 
of apartheid, the nature and quality of scientific research have continued 
to be important in the debate about South Africa’s ‘new’ national identity, 
and its intellectual and political standing in the world. In 1996, T. Mbeki, then 
deputy president, envisaged a key role for science and technology in aiding 
the intellectual and spiritual renewal of Africa – the African Renaissance. 
The scientific revolution thus marked an important turning point in the way 
doctors have understood disease and its treatment in Europe, and coincided 
with the development of a South African medical profession which had strong 
connections to European science. Historical investment in medical research in 
South Africa developed a strong scientific base that can be used to promote 
clinical research, and national health, in the future. The fact that the history of 
medical science is as much a political as a scientific history renders it necessary 
to re-think many of the trajectories of the past. 
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THE LEGACY OF RACISm AND INEqUALITY IN mEDICAL 
RESEARCH
The first Western-trained doctors working in South Africa were ships’ surgeons 
employed by the Dutch East India Company (DEIC), whose willing or unwilling 
clients would have included Company employees and slaves. A few of the 
early settlers were also doctors, with private practices among burghers and 
DEIC officials. The number of private practitioners expanded in the 19th century, 
and many of them also worked as district surgeons and in new state-funded 
hospitals. As missionaries or state employees, or even as private practitioners 
with roles in magistrate’s courts, Western-trained doctors were often linked to 
other political and cultural interventions of the colonial order. Many of these 
public health interventions were biased against working-class people, and 
linked to the political agenda of the state, for example the racial segregation 
within towns. There was a degree of popular resistance to some colonial public 
health interventions, such as the treatment of sex workers in Lock Hospitals in 
the mid-19th century (Van Heyningen, 1984), the compulsory segregation of 
people with leprosy, especially between 1891 and the 1910s (Deacon, 1994), 
and urban removals of black people associated with plague outbreaks in the 
early 20th century (Swanson, 1977), but these did not significantly disturb the 
system as a whole. 
Strong state support for the Western medical profession dates back to 1807 
in the Cape Colony, when European-trained doctors secured state support 
for a monopoly on legal practice. This allowed the profession to entrench its 
position within both private practice and public institutions, even while most 
inhabitants still used traditional medicines. Similar legislation was passed in 
England only half a century later, in 1858, but even then British legislation did 
not ban unlicensed medical practice, as Cape law had done. Under Cape 
law, nurses and midwives were registered from 1891, some years before their 
British counterparts received legal protection and government ratification of 
their training (Deacon, 2004). From the 18th century, Western-trained doctors 
attended black and white patients, especially in dealing with diseases 
associated with colonialism (smallpox, measles, and tuberculosis) and those 
H I S T O R I C A L  S T R E N G T H S  A N D  W E A k N E S S E S  O F  C L I N I C A L  R E S E A R C H  I N 
S O U T H  A F R I C A
C H A P T E R  2
REVITALISING CLINICAL RESEARCH IN SOUTH AFRICA25
A STUDY ON CLINICAL RESEARCH AND RELATED TRAINING IN SOUTH AFRICA
requiring surgery (Digby, 2006). They distanced themselves from indigenous 
healers, who were banned in some parts of the country. Yet Western medicine 
has never universally displaced other forms of health care in South Africa, 
and the public to this day continues to seek assistance from alternative 
and traditional healers (Peltzer, 2008). The relationship between alternative 
and orthodox medical practitioners remains adversarial, even as the post-
apartheid state set out to regulate rather than prohibit non-evidence-based 
medical practice, both in its alternative Western forms and indigenous African 
practices (Wreford, 2006). 
By the early 20th century, public health policies were linked to racial 
segregation and this affected public perceptions of the biomedical system. For 
example, the Transvaal Native Pass Act of 1909 linked permission for Africans 
to work in urban areas with compulsory smallpox vaccination and inspection 
for tuberculosis (TB) and syphilis. Tax collection by magistrates was also linked 
to examinations to detect sexually transmitted infection (STI) and smallpox 
vaccinations. Africans with syphilis were either isolated on their homesteads or 
brought to the local jail for treatment (Jochelson, 1999). The Public Health Act 
of 1919 amended some overtly racist provisions, but blacks were still treated 
very differently from whites: the process of identifying and treating STIs among 
Africans, for example, was ‘coercive and authoritarian’ and focused on fitness 
to work (Jochelson, 1999). The new welfarism in public health policy towards 
Africans that emerged in the 1940s was focused mainly on urban Africans 
(Jochelson, 1999), and provision for birth control, for example, was linked to 
political agendas such as the restriction of African population growth under 
apartheid.
In the 19th and early 20th century, South African medical research was also 
frequently explicitly racist (Dubow, 1995). After the 1940s, although research 
was not free of racism, clinical researchers began to position themselves within 
a growing international body of universal scientific research in which racial 
differences were thought to exist but were not explained by immutable and 
hereditary racial typologies (Stepan, 1982). In this, the researchers concerned 
were (ironically) supported by a racist government that valued South Africa’s 
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international scientific reputation and generally refrained from using medical 
science as a justification for apartheid or white supremacy. Yet even as explicit 
racism became unacceptable in scientific publications, racial discrimination 
continued at a social level (alongside gender and class), and influenced the 
question of who would be likely to be trained or employed to do research, 
in what professional capacities, and the way in which research data were 
investigated (Deacon, 2008). 
The demographics of the medical profession (and by extension, medical 
researchers) in South Africa, viz. predominantly middle-class white men, 
affected the approach (including the languages) used in medical research 
and how it was perceived by the general public. Until the first medical 
school was opened in Cape Town in the early 20th century, Western-trained 
doctors came to South Africa from Europe and South African-born doctors 
trained in Europe. Although black students and later women were accepted 
in European medical schools, it was expensive for locals to go and study 
abroad, so most of those who did so were from white families with the means 
to do so. Only a handful of black and white women doctors were formally 
registered for practice in South Africa by 1900. Science formed an important 
pillar of middle-class white identity in South Africa from the 1920s, and even 
today, white citizenship in South Africa continues to be framed in terms of skills 
and expertise (Dubow, 1995; 2006). In the course of the 20th century, barriers 
to the entry of black people into the medical profession increased further 
until this was reversed gradually in the 1980s. Barriers to the entry of white 
women began decreasing much earlier. Even when black matriculants were 
able to cross educational and class barriers in entering medical schools, they 
were limited to a few schools across the country and excluded from white 
residences on campuses (which made their education more expensive). 
They were not allowed to participate in the full range of educational activities 
(being excluded from white wards and autopsies on white patients) and were 
excluded from some of the informal networks of support and patronage from 
white doctors (although some white doctors made special efforts to tutor black 
students). After graduation, professional specialisation was difficult because 
black-owned offices could not be opened in white areas, black doctors could 
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not attend white patients, and specialist hospital appointments for black 
doctors were limited (Deacon, 2008). Today, the majority of medical students 
and specialists in training at South Africa medical schools are not white, and 
the opportunity to tap the entire talent of the population for health care 
and its necessary ‘yeast’ (clinical research) finally exists. Making this happen, 
however, requires thorough situational investigation and analysis, which the 
present report sets out to provide. 
As an example of the non-trivial nature of the challenge, there are the facts 
that past institutional investments in research were unequally allocated, and 
that this inequality continues to mark medical research outputs today. As 
Volmink (2005) has noted, “Research capacity — comprising the institutional 
and regulatory frameworks, infrastructure, investment, and sufficiently skilled 
people to conduct and publish research — varies widely across African 
countries.” Even within a country like South Africa, which performs reasonably 
well overall in terms of national investments and productivity in science and 
technology, long-standing inequalities between different universities affect 
current research outputs. Under apartheid, “Institutional differentiation was 
achieved through a binary divide between universities and technikons 
(polytechnics) and also, unacceptably, by building institutions for different 
race groups – those for whites were well-resourced urban, often research-
oriented institutions, and those for other races were poorly supported, mostly 
teaching institutions, often in rural areas” (Cloete, 2008). 
The democratic transition of 1994 brought a new focus on primary health 
care and equity in the sector, which, along with the much more widespread 
provision of social grants, was designed to reduce disease and poverty and 
redress socio-economic imbalances. Many positive benefits have resulted. 
More clinics have been built, and important health care services such as 
immunisations and key drugs have become more accessible and available 
to the poor. Professional organisations and policies have been reoriented, 
new categories of health care worker have been created and compulsory 
community service has been instituted for doctors and nurses, among others. 
Yet the benefits of redistributive policies have been limited by “inadequate 
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human resource capacity and planning, and poor stewardship, leadership 
and management,” exacerbated by problems such as increasing levels of 
medical emigration. The resource gap between the public and private health 
care systems has increased, and there is at present a staffing crisis in the public 
health service, especially at district and community-level facilities (Coovadia, 
2009). The inequalities in the South African health care system, and to some 
extent in its research capacity, have thus not been reversed, and in some 
cases they have increased or have been entrenched.
TWENTIETH-CENTURY SOUTH AFRICAN MEDICAL RESEARCH: 
ACHIEVEmENTS AND LImITATIONS
Although South African scientific research was relatively low-key during the 
18th and 19th centuries, clinical research in South africa came into its own 
in the second half of the 20th century. South Africa was considered a good 
natural laboratory for acquiring knowledge about certain diseases that were 
relatively rare in Europe. Research units and centres were established, and 
local funding became easier to acquire. Government and the mining houses 
funded most medical research and health care provision. Government 
investment in medical research began with the establishment of the Colonial 
Bacteriological Institute in 1891 for laboratory work on rinderpest and leprosy 
(Spinage, 2003). The South african institute for Medical Research (SaiMR), 
established in 1912, was funded partly by the Chamber of Mines (Meiring-
Naudé and Brown, 1977). By mid-century, the Council for Scientific and 
industrial Research (cSiR) provided a more general channel for government 
funding of medical research, leading to the hiving-off of the Medical Research 
council (MRc) from the CSIR in 1969, and its establishment in Cape Town.
The mining industry and government encouraged and influenced research 
on asbestosis, pneumococcal pneumonia, tuberculosis and silicosis, all of 
which affected mineworkers (McCulloch, 2005; Katz, 1995; Packard, 1989). 
A ‘TB Commission’ was created by the Union Government in 1912, and a 
‘TB Research Committee’ was established by the Union Government and 
the Chamber of Mines in 1926, collecting considerable data about the 
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epidemiology and pathology of tuberculosis. Local scientists, funded by the 
mining companies, developed a physiological theory of black susceptibility to 
the disease, but there was little consensus about how to manage the problem 
until the use of specific antibiotics in the 1950s (Packard, 1987). By this time, 
racial explanations of disease were becoming scientifically unacceptable 
and environmental theories of the cause of TB on the mines were reasserted. 
A TB Research Unit was established at the CSIR in 1963. 
the development of A pneumococcAl pneumoniA vAccine
In the early 20th century, A. Wright, from St Mary’s Hospital Medical School in 
London, was asked to lead a South African project to develop a pneumococcal 
pneumonia vaccine, based on his experience with typhoid fever vaccines. The 
vaccine trial, published in 1914, involved about 50 000 gold miners, and showed 
a decrease in pneumonia among those receiving the vaccine. In 1917, S. Lister, 
one of Wright’s researchers based at the SAIMR, “identified the multiple serotypes 
causing infection in miners … and included them in a single inactivated whole-
cell vaccine”, again tested on mineworkers (Kazanjian, 2004). The success of this 
vaccine was disputed in various quarters. Packard (1993) suggests that it was the 
mining companies’ reluctance to invest in better working conditions for migrant 
labourers that encouraged their initial investment in pneumonia vaccines – doing 
so medicalised the problem and limited their liability to improve living conditions 
and wages. He suggests that mining funding for the SAIMR vaccine initiative also 
fuelled their optimism about the vaccine. The widespread use of sulphonamide 
therapy after 1939 and antibiotics in the 1940s later overshadowed the use of 
vaccines to treat pneumonia (Packard,1993). South Africa was the site of a major 
pneumococcal vaccine trial led by R. Austrian, a US doctor, in the 1970s. On the 
basis of this trial, the US Federal Drug Administration (FDA) licensed a fourteen-
valent polysaccharide vaccine to Merck in 1977 (Kazanjian,  2004). 
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Unfortunately not all the research that was done on these diseases resulted 
in better working conditions, or in reduced prevalence rates in the general 
population (Butchart, 1996). Packard (1989) argues that TB prevalence 
among Africans may not have declined as significantly after the 1950s as the 
MRC’s TB Research Institute suggested, because the quality of the prevalence 
data collected was poor and not comparable over time. Although there was 
considerable investment in TB research in South Africa, there was little progress 
in reducing the burden of disease from TB because of the socio-economic 
conditions under which most Africans continued to live. Similarly, although 
South African researchers were central players in the global circulation of 
scientific knowledge about asbestosis and silicosis, this information was often 
silenced at home. Researchers such as the mine medical officer G. Slade 
showed in 1931 that there was a high incidence of asbestosis in black mill 
workers, for example, but he concluded because they did not complain 
that the disease was clinically more benign than in the UK. Scientific data on 
asbestosis prevalence was suppressed by industry in the 1960s, researchers 
at the Pneumoconiosis Research Unit (PRU) in Johannesburg did not include 
black workers in their longitudinal studies of asbestosis, and surveillance data 
kept by the mining companies were inaccurate. Because these companies 
had little interest in improving working conditions, and the affected black 
workers were denied political power, research did not lead to improved 
measurement or management of the problem (Braun, 2008; Myers, 2006). 
Some of the earliest health research areas funded by the CSIR focused on 
parasitic diseases such as amoebiasis and bilharzia, for which research units 
were established in 1949. Under Elsdon-Dew, South African research made a 
major international contribution to the diagnosis and treatment of amoebiasis 
in the 1950s and 1960s (Schutte et al., 1988). In the SAIMR in the 1930s, Elsdon-
Dew had already been internationally recognised for his pioneering work 
on blood typing (Gear, 1988). A. Theiler, who established the Onderstepoort 
veterinary research institute, laid the foundation for work on viral diseases 
in South Africa among others. His son, M. Theiler, received the Nobel Prize 
for his work in the US in developing an effective yellow fever vaccine. The 
SAIMR developed typhus and influenza vaccines for allied troops in World 
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War II, and later yellow fever and polio vaccines (Dowdle, 1988). M. Isaacson 
later worked on a plague vaccine there in the 1970s (Hallett et al., 1973). 
The Poliomyelitis Research Foundation (PRF) laboratories were opened in 
1953, where J. Gear led research culminating in the production of a polio 
vaccine at the same time it was developed in the US (Metz, 1988). This 
laboratory became the National Institute for Virology (NIV) in 1976, and the 
National Institute for Communicable Diseases (NICD) from 2002, working more 
generally on prevalent infectious diseases (Schoub, 2003). An MRC hiV/aidS 
research programme was initiated in 1987, and many groups spread across 
the country now do world-class research in this area. The South African AIDS 
Vaccine Initiative (SAAVI) was formed in 1999 as a lead programme of the 
MRC of South Africa. It coordinates the research, development and testing of 
AIDS vaccines in South Africa (http://www.saavi.org.za/index.htm).
Research on nutrition was partly sparked by the needs of the mining companies, 
and to address concerns from the early 20th century onwards that both white 
and black South Africans were deteriorating physically (Wylie, 2001). Nutrition 
was also a major research focus in the UK in the first half of the 20th century, 
prompted by the poor quality of military recruits. Scurvy was a major problem 
on the Witwatersrand mines from the very beginning, as the mineworkers’ 
diet mainly consisted of maize meal. Researchers like F. Fox (Brock, 1979) and 
M. Delf studied scurvy at the SAIMR in the 1920s, conducting fieldwork in the 
Eastern Cape, analysing samples in the Pretoria laboratories and making 
recommendations for feeding miners on the Rand (Malan, 1988). Fox argued 
that the problem did not lie in racial predisposition to scurvy, or predisposing 
conditions in rural areas, as others had argued before and were to argue 
again, but in the low vitamin C content of mine rations and poor working 
conditions (Malan, 1988). A series of major nutritional studies were initiated in 
1937, involving S. Kark and J. F. Brock, who were early public health activists in 
the country. Brock established the connection between protein malnutrition 
and kwashiorkor; the research of his group on malnutrition, particularly 
kwashiorkor and scurvy, was funded by the Union Department of Health, the 
CSIR and the WHO (Louw, 1969), and developed an important later focus on 
paediatric malnutrition. The CSIR established a National Nutrition Research 
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Institute in the 1950s, which came under the MRC in 1969. Researchers in 
the Institute demonstrated links between dietary fat, lipid metabolism and 
coronary heart disease (Brock, 1979). In the 1960s, work on iron overload in 
Africans caused by iron release from food containers and cooking utensils 
showed that a ‘Westernised’ diet raised the risk of bowel cancer (Malan 1988). 
Research that identified the specific geographical locations of mineworkers 
suffering from liver cancer (Inhambane Province of Mozambique) in the 
1960s pointed the way to the finding that dietary aflatoxins were linked to 
liver cancer, and to further internationally recognised research on food-borne 
fungal toxins in South Africa (Marasas, 1988).
Nutritional and epidemiological research in South Africa established a clear 
connection between living conditions and disease, and made the case for 
preventive health care by the end of the 1950s, but this approach lacked state 
support and was hampered during the conservative 1960s. Key epidemiological 
research included the comprehensive Gluckman Commission of 1942-44 and 
fieldwork conducted in the 1950s by Burrell, Oettlé and Higginson (Bradshaw 
and Yach, 1988). The epidemiological work in South Africa during this period in 
fact helped to establish the discipline internationally. The early public health 
initiatives of the 1940s faded under apartheid (Marks, 1997). Work done at the 
SAIMR and Medunsa produced some research that “missed the wider social 
context of national health” (Wylie, 2001). A. Walker’s research, for example, 
focused on the limitations of public health interventions and the importance 
of educating the poor, suggesting that malnutrition in poor African children 
should not be measured against Western standards (Wylie, 2001). The 
Department of Health de-listed kwashiorkor as a notifiable disease in 1968 
and the MRC shifted funding away from diseases of poverty like kwashiorkor, 
towards the study of diseases of affluence (e.g. the effects of high cholesterol) 
in the 1970s (Wylie, 2001; Baldwin-Ragaven et al., 1999). There were, however, 
broader trends towards public health and epidemiological research in the 
1970s and 1980s that affected research in South Africa and were linked to anti-
apartheid discourse. Building on trends in the WHO towards public health, a 
strong critique developed of hospital-based medicine in South Africa (Niewijk, 
1999). After 1994, more attention was paid to public health research as the 
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health system was reoriented towards the needs of the general population. 
The MRC and other institutions restructured their research to take account of 
national health priorities.
In general, disease-specific investigations were favoured over public health 
research during the colonial and apartheid years, a pattern that continues 
to some extent today. In the 1950s and 1960s, an era of heroic surgery 
internationally (Amsterdamska and Hiddinga, 2000), heart, liver and kidney 
transplants were an important focus of South African clinical research. The 
world’s first open-heart transplant in 1967, led by C. N. Barnard, was built on 
decades of work on vascular and cardiac disease by R. Goetz and V. Schrire. 
It was followed by other transplant firsts at Groote Schuur Hospital, where B. 
Cohen performed the world’s first vascularised human fallopian tube transplant 
in 1975 (Groote Schuur Hospital Annual Report, 1975). These breakthroughs 
depended not only on clinical research, but also on international collaborations 
and on technical advances such as the development of the heart-lung 
machine in the US. In conducting transplants, the less litigious environment 
around medical practice in South Africa made it easier for surgeons to risk 
a ‘first’ (Logan, 2003). Following the heart transplant in 1967, it was relatively 
easy for local institutions to find funding to support cardiology research. The 
mining industry, for instance, came forward to fund a Research Centre for 
Cardiac Disease and Organ Transplantation (Cape Argus newspaper, 1970). 
From the 1960s, South African immunology research was closely linked to the 
needs of the transplantation programme. M. C. Botha and E. du Toit became 
well known for their study of rare MHC (Major Histocompatibility Complex) 
antigens in the San and other South African populations. A. Myburgh and 
J. Smit at the University of the Witwatersrand (Wits) experimented with total 
lymphoid radiation as a technique for the control of organ rejection (Dowdle, 
1988).
Disease-specific investigations were conducted into genetic diseases and 
diseases of lifestyle including porphyria, cancer and cardiac and liver disease. 
Genetic abnormalities in small populations who then intermarry over decades 
can create a situation (a founder effect) in which certain genetic diseases 
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become unusually prevalent (Botha and Beighton, 1983). Afrikaners (and a 
small group of Africans in the Eastern Cape) show unusually high levels of the 
disease porphyria (Day, 1988). Recognition of the problem in the Afrikaner 
population attracted government attention and research funding in the 
1950s, at a time when it was also receiving some international attention. In 
1957, the CSIR funded a Porphyria Research Group at the University of Cape 
Town (UCT) under L. Eales, which pioneered internationally and locally useful 
new techniques in porphyria diagnosis and classification in the 1960s and 1970s 
(Day, 1988). Following on from earlier physical anthropology studies, genetic 
research on these and other more common diseases formed a cornerstone of 
South African research activity from the 1960s onwards, marked for example 
by the work of P. Beighton on skeletal diseases in Cape Town, and the work 
by T. Jenkins and H. Soodyall on human population genetics at the SAIMR and 
Wits University. Familial lipid disorders associated with early heart attacks were 
studied in detail by W. Gevers and A. E. Retief. Cardiac and liver diseases 
have continued to be a research focus at academic hospitals such as Groote 
Schuur (Bonner et al., 2007). Today, research on coronary heart disease, cancer, 
diabetes and obesity has become more relevant to the current burden of 
disease as they have become more common in black communities (Steyn et 
al., 2006). Many poor black communities also experience a high incidence of 
rheumatic fever which causes heart disease (Commerford, 1988).
South African researchers contributed to the development of some major 
innovations in diagnostic medical equipment, perhaps because this was 
particularly expensive to import, and in diagnostic techniques, because of 
a strong link between preclinical and clinical research. Besides the examples 
mentioned above, H. Zwarenstein and H. Shapiro pioneered a method for 
the diagnosis of human pregnancy using frogs in 1933 (Louw, 1969). R. Goetz, 
based at UCT from 1937 until the late 1950s, earned an international reputation 
for his work on digital plethysmography (the measurement of changes in blood 
flow in the fingers or toes), the sympathetic control of peripheral blood vessels, 
Raynaud’s disease, diabetic gangrene and progressive systemic sclerosis 
(Louw, 1969). His plethysmograph (1943) assisted in the diagnosis of peripheral 
vascular disease (Goetz, 1948). Later work at the MRC in Johannesburg on 
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blood circulation led to further pioneering work on the use of radioactive 
microspheres for the measurement of tissue blood flow (Rosendorff, 1988). The 
1979 Nobel prize for Medicine or physiology was a joint award for computerised 
axial tomography (cat) scanning, shared by a South African, a. cormack, 
who had become interested in the mathematical problem of creating a 
correct radiographic cross-section in a biological system when he worked as a 
hospital physicist at Groote Schuur Hospital in the mid-1950s. A British computer 
specialist later used Cormack’s ideas to develop the first CAT scanner machine 
(Cormack, 1979; Vaughan, 2008). A recent collaboration between the Groote 
Schuur Hospital Trauma and Radiology departments and the De Beers 
Diamond Mining Organisation resulted in the development of Lodox, a special 
low-dose radiation X-ray screening apparatus that can accurately pinpoint 
foreign objects such as bullets in trauma patients and monitor organ function 
for research purposes (Groote Schuur Hospital Annual Report, 1999/2000).
In spite of the idea that medical research was important for South Africa’s 
international reputation and that promoting science would help transformation, 
state expenditure on medical research in academic hospitals decreased from 
the beginning of the 1980s. This trend towards disinvesting in medical research 
was exacerbated by the redistribution of state investment in the health care 
system towards primary health care after 1994 and the simultaneous stagnation 
of public health care spending (Coovadia, 2009). An increasing burden of 
health care service provision falling on health care workers in the public service, 
has left little in the way of time and resources for research.
RANDOmISED CONTROLLED CLINICAL TRIALS 
The first randomised controlled clinical trial in the modern era was published 
in the UK on the use of streptomycin in the treatment of TB. The design of 
the trial followed the work of R. A. Fisher in agriculture which emphasised the 
importance of randomisation, and it became a model for future randomised 
controlled trials (Booth, 1993). Clinical trials became ever more widely used 
in the latter part of the 20th century, with evidence-based medicine driving 
public health provision and the expansion of the pharmaceutical industry. 
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In spite of increased funding and emphasis on clinical trials, however, many 
of the therapies used in biomedical practice, well into the present day, 
have not been subject to formal clinical trials. Trial results are also not always 
implemented.
More clinical trials began to be conducted in developing countries such as 
South Africa after rules on the use of foreign data in pharmaceutical research 
were liberalised in places such as the US (Ford and Tomossy, 2004). Fewer 
randomised clinical trials are being published in leading medical journals 
such as the South African Medical Journal (Pienaar et al., 2002), but this may 
be because trial results are not being published, or they are being published 
elsewhere.
A further two studies have attempted to document the number and type of 
trials conducted within South Africa. Eight hundred and fifty-eight randomised 
controlled trials were published in the South African Medical Journal since 1948, 
mostly in the period 1968–1987: only two such trials were identified before 1957 
(Pienaar et al., 2002). In a subsequent and fuller analysis of 1 179 randomised 
controlled trials done on sub-Saharan African people from 1965–1999, it was 
found that only 12 trials were published between 1949 and 1964 – about half 
were conducted in South Africa, and the number of trials increased over time 
as shown in Figure 2.1 (Isaakidis et al., 2002).
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Figure 2.1: Number of randomised controlled trials in sub-Saharan 
africa from 1965–1999 (isaakidis et al., 2002: 324)
Currently no comprehensive database of completed trials exists. The National 
Department of Health has established a publicly accessible National health 
Research database (NHRD) (http://www.researchdatabase.org.za) but it is 
not possible to search this specifically for clinical trials. The primary purpose 
of the NHRD is to provide a central storage database of all health research 
conducted in South and southern Africa. Closely allied to this is the NHRD’s 
function as a knowledge management tool for health research that is 
planned, produced, published or documented by both South African and 
other researchers conducting research in southern African communities and 
facilities. Possible addition of study type and/or study design to the search 
engine of this database would greatly assist in the retrospective documentation 
of clinical trials.
Historically, clinical trials in South Africa have tended to be hospital based, 
focused on testing treatments rather than on prevention measures, and on 
chronic rather than infectious diseases (Pienaar et al., 2002). The spread of 
trials conducted does not accord with the burden of disease in the country 
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(Isaakidis et al., 2002). Problems in addressing burden of disease may arise not 
only from gaps in medical knowledge about how to manage the disease, but 
also from problems of implementation including political will. This has been 
well demonstrated in state attitudes towards the use of anti-retrovirals in the 
treatment of HIV/AIDS since the 1990s (Nattrass, 2006; Hirschhorn et al., 2007). 
The long history of state support for evidence-based medicine, the historically 
mainly white and male composition of the pool of medical doctors, and the 
often adversarial relationship between medicine and indigenous healing 
traditions, have influenced experiences and perceptions of medical research 
and willingness to participate in clinical trials (Baldwin-Ragaven et al., 1999). 
Doctors and other health care workers were complicit in the mistreatment of 
detainees in the 1980s, and research was explicitly used to further the aims of 
the apartheid government through a secret chemical and biological warfare 
programme, Project Coast, whose extent only became widely known with 
the trial of Wouter Basson (Gould et al., 2002). Given this history, the Truth and 
Reconciliation Commission recommended a focus on primary health care, 
increasing the number of black students and health care professionals, training 
in human rights and ethical research practices, and the prevention of human 
rights abuses (Baldwin-Ragaven et al., 1999). Continued vigilance has to be 
exercised in the light of recent fraudulent clinical trials by W. Bezwoda (Horton, 
2000) and state support for Virodene and the multivitamin preparations in 
treating AIDS in spite of opposition from the Medicines Control Council and 
the scientific community (Youde, 2007). There have also been concerns about 
deaths arising from poor safety and informed consent procedures in some of 
the HIV/AIDS trials (Sidley, 2000).
CONCLUSIONS
South African medical science was strongly influenced by its colonial context 
and by the needs of local industry and general economic development. this 
broader political and economic context affected what research was done, 
how it was done, how it was used and who did the research, contributing to a 
history of unequal access to health care and inappropriate priority setting in 
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medical research. understanding this context does not lessen the value of the 
research that was done, but helps us to understand the nature of some current 
problems, including the unusually diverse and heavy burden of disease, 
the mismatch between local burden of disease and medical research, a 
racially and gender-skewed cohort of medical researchers, under-developed 
institutional capacity in the production of research and, in some cases, public 
mistrust of medical research.
The mining industry and government encouraged and influenced medical 
research (especially of vaccines as potential ‘magic bullets’) in South Africa. 
Because of social disruption caused by migrancy, land dispossession and poor 
working conditions, there was a high prevalence of pneumonia, tuberculosis 
and silicosis in mineworkers, and nutritional, parasitic and viral disease in 
mineworkers and farm workers. Internationally, research on these health 
problems generated highly regarded scientific data, partly because of the 
large sample sizes, but it did not always lead to in lower disease prevalence 
in the general population. Nutritional and epidemiological research in South 
Africa during the 1940s and 1950s was also internationally recognised, but 
in spite of early initiatives such as the Gluckman Commission, a preventive 
approach to health care did not emerge until the 1990s. 
South African medical research focused more on hospital-based medicine 
and diseases of affluence than was warranted by the burden of disease at 
the time, although some of this research has become more relevant today. 
Diseases affecting more white than black South Africans in the past, such as 
porphyria, coronary heart disease, diabetes and myocardial infarction (heart 
attacks), received significant, although not exclusive, research attention under 
apartheid. Equipment and funding shortages contributed to innovation in 
locally developed diagnostic equipment. Local genetic diversity and founder 
effects in the Afrikaner population, reflective of the increased influence by 
Afrikaner researchers and institutions under apartheid, fostered important 
South African research strengths in blood typing, medical genetics and 
certain genetic diseases. Considerable funding was available for transplant-
related research after the first heart transplant in 1967, and this encouraged 
world-class research in heart and liver disease, and also in immunology and 
genetics. 
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Public perceptions of clinical research today are still negatively affected by 
the close historical relationship between medicine and the colonial state, 
the often adversarial relationship between medicine and indigenous healing 
traditions, racism and unethical practice in medical research (real and 
perceived), and the skewed demographics of medical researchers. Yet there 
is hope. From the beginning of the 20th century, medical researchers in South 
Africa began to develop a strong scientific base that can be used to build 
clinical research in the future. This scientific infrastructure has been gradually 
reorienting itself to the current burden of disease within a more democratic 
political context that prioritises the health needs of the majority, promotes 
more community involvement, and addresses the skewed demographics of 
health researchers. The challenge now is to find ways of promoting clinical 
research that builds on the advantages of past investment while actively 
addressing the legacy of colonialism and racism.
FINDINGS
1. Medical researchers in South Africa from the beginning of the 20th century 
began to develop a strong scientific base for clinical research in terms of 
personnel and infrastructure, conducting important investigations into a 
wide range of medical problems. 
2. The burden of disease in South Africa is significantly linked to its history of 
racial and gender inequality, violence, oppression and enforced labour 
migration, and to some of the failures of post-apartheid independence. 
It is characterised by high levels of both communicable and non-
communicable diseases, particularly those that are related to poor working 
conditions and poverty, gender-based violence and injury.
3. Because of the colonial context, clinical investigations (with some notable 
exceptions) were largely driven by the needs of the mining and agricultural 
industry, or focused on curative medicine in urban areas. Thus, clinical 
research did not always improve the health of the population as whole.
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4. Clinical research in the apartheid years was conducted by a cohort 
of investigators who were mainly white and male within a system that 
provided racially unequal access to health care and research training. 
Institutional capacity to conduct clinical research was concentrated in a 
few historically white institutions.
5. Some clinical research in the colonial and apartheid era was racist and 
unethical, facilitated by an environment of racial inequality, discrimination 
and high status and wealth differentials under an oppressive state. 
6. After 1994, significant strides have been made in reorienting health care 
and medical research towards the needs of the majority at a policy level, 
but in practice the tangible benefits of this have been limited by reduced 
government support for medical research within the health care system, 
a weak education system, and poor management of existing resources 
within the health care system, in the face of new challenges such as 
HIV/AIDS. 
RECOmmENDATIONS
1. Clinical research should be repositioned within a more democratic political 
context to build on the advantages of past investment while actively 
addressing the legacy of colonialism.
2. Clinical research should actively contribute to the improvement of the 
health of the nation by actively addressing the largest burdens of disease.
3. The training and promotion of clinical researchers should actively seek to 
address racial and gender imbalances, and ensure that strong intellectual 
leadership is built.
4. The funding of clinical research should actively seek to develop strengths 
wherever these can be best and most sustainably built.
5. Clinical research should be based on strong ethical codes of conduct.
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DEVELOPING A NATIONAL CULTURE THAT IS SUPPORTIVE OF 
CLINICAL RESEARCH, AND AN AGENDA FOR CHANGE
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in this chapter, we engage with the following questions:
1. What is a national culture that is supportive of good clinical research?
2. What principal components make up a productive national culture sup-
portive of good clinical research?
3. What is the status of clinical research in the country?
DEFINITIONS
There are many difficulties in the notion of a ‘national culture’, a term which 
means many different things to different people and communities. We will 
use the term in this report as connoting generally accepted patterns of 
thinking or acting that are relatively stable over time, and have some sectoral 
or functional specificity or scope. Because we are ultimately dealing with 
a summative ‘national culture’, each specific domain is to some extent 
nested within a bigger one. This can be readily seen when one considers 
the domain of clinical research (with its particular complement of active 
and trainee researchers, direct partners such as funders and institutions, and 
other stakeholders, regulators who scrutinise and approve their projects, and 
sponsors and funders who make their work possible), and extends this to 
the much larger domain of the citizenry at large, for each of whom clinical 
research is a field that potentially impinges on a vital interest, namely good 
health and longevity for self, family and community. Layered between these 
core and macro domains are further sectors of relevant business and industry, 
government policy-making, systemic health care provision, and the like. 
A particular ‘culture’ might mean that one or the other contrasting standpoints 
is embraced by the majority of participants in the sector concerned. Wise and 
effective policy-making requires that both well-based minority opinions and 
generally held majority opinions be taken into account. In the case of the 
research sector itself, the establishment of a national association for clinical 
research might permit evidence-based harmonisation of such positions 
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through round-table discussions or task teams, while at the level of the broad 
public particular methods might be followed. An example of the latter are 
the expert panels in the UK which engage with randomly selected members 
of the public in television programmes, and in invited correspondence 
with all comers, including representatives of vociferous and/or opinionated 
minorities.
DEVELOPING A PRODUCTIVE CULTURE OF CLINICAL 
RESEARCH 
We must assume that the researchers, the hospitals and clinics where the 
research is done, the regulatory bodies and funders are all uniformly in favour 
of a system of clinical research that will improve health care to the greatest 
possible extent, in a cost-effective, sustainable and equitable manner. 
In this report we have identified six principal components that make up a 
common, productive ‘culture’ that is highly promotive of research that is high 
quality, wide and relevant in scope, beneficial to translational outcomes, and 
sustainable in the clinical sector. These are:
1. The acceptance of the principle that ‘the proper study of humankind is 
humans themselves’;
2. The understanding that sustainable health care systems require guidance 
by a critical mass of research-experienced clinicians and the continuous 
training of new generations of research-informed clinical care givers;
3. Recognition of the complex, multi-dimensional, and challenging nature of 
clinical research;
4. An appropriate balance between risks and benefits;
5. An appropriate balance between curiosity-driven and problem-directed 
research;
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6. A clear emphasis on public service and public benefit;
7. Protection and development of new intellectual property.
We start by returning to the first, narrowly-focused question posed above. In 
words that are slightly altered from the cited original propositions, is the ‘proper 
science and study of humankind, humans themselves’? (Pope, 1733.) Many 
years of reductionism in health sciences have revealed countless instances 
where assumptions of equivalence between humans and laboratory mammals 
such as rats, mice and primates of various kinds have proved to be incorrect 
(Casanova and Abel, 2007). A good example is in the complex field of clinical 
immunology, where detailed studies of genetic immunopathies in human 
participants have consistently shown the risks of assuming that information 
gleaned from mice is necessarily applicable to humans (Schnabel, 2008). 
Some models of human diseases have been deliberately engineered in 
laboratory animals (Peh et al., 2002; Wine et al., 2002; Itoh and Narushima, 
2005; Aliev and Burnstock, 1998; Lieschke and Currie, 2007), and much drug 
testing is conducted on selected animal species. In most cases, the validity 
of the reductionistic or comparative models has proved problematic, even 
if much useful knowledge has been generated that has made the design 
of human studies simpler, less open-ended and more focused. It seems, 
nevertheless, that in general only studies of humans can yield a true picture 
of human disorders, especially because this generalisation is in any case itself 
subject to the enormous genotypic and phenotypic variation that is present 
in the human species itself. 
A second aspect of the sectoral ‘culture’ is the belief that a cadre of 
research-experienced clinicians is essential in the health care system for 
well-informed, direct health care provision, for the teaching and training of 
succeeding generations of practitioners, and for the design of health care 
systems that provide best-possible preventive and therapeutic health care to 
both individuals and populations (this applies to the deeply established health 
‘cultures’ in India and China as much as it applies to the prevailing and much 
more recent ‘Western’ model). 
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A third, narrowly focused ‘cultural’ issue concerning clinical research is its cost 
and multi-dimensional complexity compared with studies that are purely 
laboratory based, which is the main reason why animal and in vitro studies still 
vastly predominate in the broad health research area. Clinical researchers 
have to provide clinical service in order to underpin their investigative 
skills. Their involvement in patient care and also frequently in the training 
of new clinicians makes heavy time demands. The research itself requires 
theoretical and conceptual knowledge that is difficult to acquire, and even 
more difficult to maintain. The costs of subject hospitalisation or recruitment, 
frequently repeated special investigations, multiple subject work-up and 
skilled monitoring are often so high that grants have to be much larger than 
for other types of research. Meeting regulatory requirements makes demands 
on time and patience not found in other areas. Teams of diversely skilled 
researchers have often to be put together and managed in order to address 
different dimensions of clinical problems, with appropriate risk management. 
Simply put, clinical researchers, who must frequently also have access to the 
same kind of expensive equipment and consumables used by laboratory-
based researchers, require a great deal of courage, resilience and energy, 
and must make a considerable, concerted effort on a variety of fronts. It is 
part of a certain ‘culture’ in which this kind of uphill research activity is valued, 
supported and deliberately fostered; it is easy to regard it in another ‘culture’ 
as ‘causing too much trouble and cost’.
The fourth important ‘cultural’ issue in the sector is the balance of risks and 
benefits. Clinical research is unique in its interfaces, firstly with human rights 
and secondly with risk analysis. In both areas, certain kinds of ‘cultures’ can 
create significant impediments to the conception and execution of research 
projects and programmes, while others can have facilitatory and enhancing 
effects. Because of the element of novelty and uncertainty, there is a popular 
perception that clinical trials are more risky than everyday activities, while in 
fact this is not the case. A more precise adjustment of risks to benefits can 
bring about a prevailing ‘culture’ that promotes both clinical research and its 
positive impacts on the health of the population. 
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The fifth, often controversial consideration is context and relevance, which 
amounts in practice to translational purpose. It is possible in a particular culture 
to consider clinical science to be part of the ‘blue sky’ search for knowledge 
which sometimes ‘spins off’ benefits as serendipitous outcomes. An alternative 
culture seeks out topics that are obviously related to major health problems, 
and addresses them according to deliberate project designs, usually with 
carefully assembled multidisciplinary teams, to maximise the probability of 
beneficial public outcomes, and to underpin the attainment of those benefits 
in evidence-based ways. A balance between these polar opposites must be 
found in a resource-constrained system. 
An overridingly important ‘cultural’ issue that directly affects the sector is 
motivation in respect of private as opposed to public benefit. Compared with 
a systemic prevalence of public-sector clinical research projects which are 
initiated and funded only in support of profits by pharmaceutical companies, 
and/or one where researchers are mainly hunting for personal glory and/or 
tangible benefits such as salary supplements, conference travel and other 
perks, the widespread existence of an ethos of public service and public benefit 
undoubtedly represents a desirable and necessary ‘cultural’ polarisation.
The last, but by no means least, of the dominant issues in a national culture 
supporting good clinical research concerns the imperative to protect and 
develop new discoveries in an efficient and effective intellectual property 
rights regimen that can bring benefits to both the health care practice and 
economic development of the country. This implies careful construction of 
partnerships, adequate funding of patent registration applications, and a tax 
system that incentivises innovation. It is a mind set as much as a regulatory 
approach.
THE PRESENT SITUATION
While there appears to be a broad acceptance of the need for studies 
on humans of human disease mechanisms and treatment and prevention 
strategies, the extensive domain of animal-based and in vitro studies (usually 
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intensively motivated for funding and support because of their relevance 
to human diseases), is not closely linked to the domain of clinical studies, 
organisationally or functionally. Clinical specialities, and in some cases even 
sub-specialities, have tended to withdraw into individual, small, internally 
interactive domains with their own national societies, conferences and 
periodicals or newsletters. Their better-quality publications have over- 
whelmingly appeared in international speciality journals indexed in the 
Thomson Reuters ISI Web of Science (ISI) system, something which in itself is 
a laudable aim and part of the national policy of ‘internationalising’ South 
African research. Unfortunately, it makes much of this good work effectively 
invisible to South African colleagues in other specialities, or to the non-
clinical, laboratory researchers in the same or related fields (see Chapter 6 
for details). 
There is thus a distinct lack of cross-fertilisation, peer consultation and 
functional community in the local clinical research domain, which minimises 
the value of animal or in vitro models to the understanding of human diseases, 
and results in distrust and lack of communication between those who perform 
clinical studies and those who work reductionistically in laboratories. As the 
latter often have significantly more time to devote to their research activity, 
and can more readily assemble teams of associate scientists, graduate 
students and postdoctoral fellows, a sense of inferiority on the part of clinical 
researchers readily develops, which often leads to resentful closure of the few 
communication channels that do exist. 
Ultimately, the deeper meaning of ‘the proper study of humankind is humans 
themselves’ is not compatible with a real or perceived position of clinical 
research as intellectually or methodologically second rate, compared with 
laboratory studies. 
The specific training and mentoring required to capacitate researchers 
who are fully equipped to carry out studies on humans is mostly inadequate 
compared with that for laboratory investigators. This may or may not be 
due to significant extra costs and a lack of willing trainees, but it may also 
be symptomatic of a reluctance to embrace the principle of human studies 
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as core to human health. What is visible and highly problematic is a virtual 
absence of ‘MD: PhD’ programmes at the health science faculties, the lack 
of facilitation of participation of professional graduates in post-basic research 
honours and master’s degree programmes through appropriate bursaries, 
career structures and organisational arrangements, and the paucity of centres 
of excellence and research chairs in this field (see below in this chapter and 
elsewhere in this report). 
Research centres and institutions in developed countries have an enormous 
depth of human and other resources, augmented by easy communication 
and the willingness to put research at the top of priority lists. The teaching 
and service loads of clinical academics are very much lower than is the 
case for their counterparts in developing countries such as South Africa. 
Establishing and maintaining a critical mass of actively researching clinicians 
is accordingly extremely difficult in our situation, with emigration to greener 
fields in the North an ever-present temptation. It is thus understandable that the 
managers of health science faculties and the budget-challenged providers 
of health services have drifted to a model where the outcomes of clinical 
research performed elsewhere are incorporated into teaching and practice 
locally as far as that is possible, and truly investigative clinical research is 
‘given up’ as too costly, too difficult and too frustrating. Sponsored ‘me too’ 
clinical trials and low-level ‘action research’ in pressurised clinical practice is 
often all that remains, presented to the world and society as relevant activity 
and appropriate to local conditions. But this kind of clinical research is not 
what is needed to promote best-possible health care and the most effective 
training and education of young clinicians, nor is it anything more than the 
acceptance of a kind of permanent ‘colonial status’ vis-à-vis the developed 
countries of the North.
It is symptomatic of the ‘giving up’ culture described above in relation to 
clinical research that the kinds of opportunities recently created for talented 
researchers in other fields by the Department of Science and Technology (DST) 
and the National Research Foundation (NRF) have not targeted the area of 
clinical research more than tangentially. The schemes for nationally selected 
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research chairs and centres of excellence, equipment catch-up programmes, 
and a national ‘PhD project’ have been enthusiastically implemented in 
non-clinical areas, and the MRC has been unable or unwilling to resolve the 
long-standing issue of its relationship to the strategic efforts of the DST (and 
cabinet) to strengthen R&D in the country. The fact is that no programme 
exists that is designed to boost high-quality activity in clinical research as one 
of the country’s most important intellectual spheres, specifically one which 
also promotes better designed and delivered health care, enhances foreign 
direct investment, and has been a traditional strength in the national system 
of innovation. 
Another demonstration of the ‘giving up’ culture pervading clinical research 
is the inexplicable neglect of an issue that has for years been the ‘elephant 
in the room’ in terms of the organisational/operational context of the 
discipline. With academic hospitals regarding research activity as outside 
their mandate, mission and brief, with the National Health Laboratory Service 
(NHLS) considering clinical research activity as a market like any other, and 
with the MRC intimating to clinical researchers that because of funding 
limitations it is unable to fund patient-related costs of otherwise supported 
projects, a huge gap appeared that no policy-making has addressed and no 
stakeholder or participant has clearly and publicly recognised and decried. 
The pharmaceutical industry has simply had to fill that gap by default (see 
other sections of this report). The public service ethos of this research domain 
has quietly declined, and curiosity-driven investigation has diminished. 
The above situation is not compatible with the previously listed six core 
components of a productive, self-perpetuating national culture of high-
quality clinical research. These components are inter-dependent, and 
operationalising them will require concerted and cooperative actions by many 
of the stakeholders in central and provincial government. The revitalisation 
and repositioning of clinical research in South Africa can help to develop 
new or more effective treatments for the health problems affecting our 
population. Creating a solid and efficient infrastructure for clinical research in 
South Africa can help to attract foreign direct investment for local economic 
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development, and developing and nurturing local clinical researchers can 
help to grow our human capital and reposition South Africa as a knowledge-
based economy. 
AN AGENDA FOR REVITALISING CLINICAL RESEARCH
The agents that determine the sectoral ‘culture’ in which clinical research can 
flourish through the above drivers are clearly multiple, interactively related 
and require joint action by direct and indirect funders of research (funding 
agencies and the National Treasury), by trainers and educators in the broad 
health domain (through career development approaches, curricula and 
coordinated planning), by hospital managers (in respect of cost containment), 
by external partners such as the NHLS through discounted fees, and by the 
policy-making environment (especially in the national Department of Health 
and the provincial health departments). 
An expanded and adequately funded public sector involvement in clinical 
research, specifically in clinical trials, should meet the following expectations: (i) 
it would need to draw on the collective expertise and available competence, 
which is considerable; (ii) it should meet the national need in the public sector, 
including HIV/AIDS, tuberculosis, especially the drug-resistant forms, cancer, 
diabetes mellitus, diarrhoeal diseases and meningitis, among others; (iii) it 
should be non-profit in the sense that all or most profits would be ploughed 
back into research; and (iv) all activities would be contracted and pursued 
in a spirit of scientific excellence. The focus would be on what can be done 
uniquely, generally to avoid involvement in what others are capable of doing 
well and wish to do, which should be left to them.
Nonetheless, even with the above constraints, there is potential to work to be 
done in Phases I to IV clinical trials and in post-marketing surveillance, which 
has become increasingly important and has expanded beyond the strict 
confines of medicines and vaccines safety. The work may deal with special 
issues, including traditional medicines and pharmaco-economics (the latter is 
an especially important and neglected area in South Africa). Training would 
be at the heart of clinical research. 
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Much of the rest of this report expands on the high-level positions the Panel has 
taken on the narrow-focus, sectoral aspects of a national culture, “in which 
clinical research is seen as essential, and clinical trials are widely accepted 
and promoted as the most reliable basis for establishing the efficacy and 
safety of new therapies and approaches.” 
NATIONAL CULTURE
First, we need to develop a national culture supportive of clinical research. 
The achievement of a strong ‘public service and benefit’ ethos is an absolute 
requirement for a sustainably excellent clinical research community. This does 
not exclude the recognition of fine personal or team contributions, nor of 
the recruitment of private-sector funding and partnership, nor of sponsored 
conferences and helpful equipment grants, etc. The explicit primary values of 
public service and benefit should simply pervasively and effectively inform the 
basic system of how clinical research is initiated, regulated, funded, reported 
and translated into improved health care of individuals and populations. Doing 
this would in itself provide regulatory mechanisms to harness the goodwill and 
resources of all the necessary partners in the enterprise. 
Although general science promotion has been well funded, there are no 
government programmes currently promoting clinical research; greater 
attention has been paid to the basic sciences than the clinical sciences. 
There is no professional body or journal solely dedicated to the promotion 
of clinical research, and more local clinical researchers are publishing in 
specialist international journals. Campaigns to improve public engagement 
with science tend not to include clinical medicine. 
The application of realistic risk management to clinical research will require 
critical analyses which can probe this topic in comparative terms throughout 
society, which can properly calculate and record risks against likely benefits, 
and, most important, which can train researchers to include such features in 
their proposals and to clarify aspects of the ethical design of their protocols. 
Linking this to efforts to improve the public understanding of, and engagement 
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with, clinical science will be most valuable. The research community itself 
must be responsible for enhancing the translational aspect of their project 
designs, in concert with appropriately modified guidelines for funding and 
partnerships that will bring the necessary skills into play.
Developing a national culture supportive of clinical research includes getting 
more public support for and participation in research. Public concerns about 
clinical research may impede recruitment to research, affect adherence 
to interventions and even threaten the continuation of research projects 
(Geissler, 2005; Molyneux, et al. 2005; Pool and Geissler, 2005; Fairhead et al., 
2006; Nchito, et al. 2003; Singh and Mills, 2005; Molyneux et al., 2004). Such 
concerns may also affect recruitment to clinical research careers. Geissler 
and Pool (2006) suggest that rumours about clinical researchers engaging in 
blood and organ trafficking, deliberate spreading of disease and surreptitious 
birth control are widespread across Africa and pose a potential threat to 
public support of and participation in clinical research. Too little attention has 
been paid to understanding and improving public understanding of clinical 
research in South Africa. To do this we have to understand the legacy of the 
historically close relationship between clinical research agendas, the needs 
of industry and the colonial and apartheid state.
REGULATION 
Second, there is a need for better capacitation of the ethics and regulatory 
bodies for clinical research. South Africa has a well-established ethics 
governance and regulatory environment, but this is currently decentralised, 
understaffed and underfunded, resulting in delays in the approval of clinical 
research protocols and a shortage of ongoing monitoring activities to ensure 
compliance with approved protocols. There has been an increase in overall 
workload, but a decline in industry-related clinical trials reviewed by research 
ethics committees (RECs) at South African academic institutions in recent 
years (Cleaton-Jones and Voster, 2008; Dhai, 2005). This illustrates the shift of 
clinical trials from academic institutions to the private sector, where trials are 
often less well regulated. Successful implementation of the new Intellectual 
Property Rights Act will require optimal alignment between this and the ethics-
regulatory systems (see Chapters 5 and 9). 
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PUBLISHING
Third, concerted government and professional attention needs to be paid to the 
development of scientific publishing in clinical research and the development 
of an interdisciplinary local scientific community. Although South African 
researchers historically performed well on the international stage, there has 
been a decline in the number of ISI-listed journal articles in clinical medicine: 
from 1 063 publications in 1987 to 736 in 2001. This has represented a decline 
in South Africa’s world share of publications in clinical medicine - for example, 
South Africa’s share of the world’s ISI-listed publications in clinical medicine 
declined by 18% from 0.59% (1990-1994) to 0.46% (1996–2000) (Pouris, 2003). 
It has also represented a decline in the proportion of local research in the 
field of clinical medicine from a 22 to 20% share of overall production (South 
African Department of Science and Technology, 2005). This problem is likely to 
increase as the proportion of older authors has been rising. For the period 2001 
to 2006, 13% of all South African authors publishing in clinical science journals 
were over the age of 60. The ageing of authors in clinical research testifies to 
the shrinking of the health research workforce (see Chapter 6). 
EDUCATION
Fourth, research institutions need to be supported in educating researchers and 
encouraging research outputs. Research experience and knowledge must 
be infused into undergraduate clinical education and training for this to be a 
basis of life-long learning and effective practice and service. At postgraduate 
level, this is the case to an even greater extent, yet opportunities for research 
and exposure to clinical researchers have diminished progressively over 
recent years in the face of huge service challenges and cutbacks in staffing 
and resources. A growing division of focus and responsibilities between health 
service organisations, on the one hand, and academic institutions and funding 
agencies, on the other, has largely severed the critical connection between 
research/scholarship and education/training. Prospective clinical researchers 
in South Africa have few focused training programmes and career paths, little 
in the way of appropriate facilities, and once qualified, lack a supportive 
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infrastructure to undertake patient-orientated clinical research or a career 
structure to support their progress as clinical scientists.
Specific measures need to be taken to ensure equity in research development. 
South Africa has not fully reversed the historical legacy of race and gender 
discrimination in clinical medicine or the institutional and regional imbalances 
in research capacity inherited from the past. Although more female and black 
authors have been publishing in the clinical medicine field than before, we 
have not yet reached race or gender equity in terms of publication outputs 
and clinician-researcher demographics. Most publications still come out of a 
few major South African universities which have developed a strong scientific 
base over the last century. A handful of researchers from a few main centres 
also conduct most clinical trials (see Chapter 7). 
FUNDING
Fifth, there is need for better and more efficient funding of clinical research. 
Clinical research is currently being hampered by inadequate, uncoordinated 
funding, inadequate support from government health authorities, and lack 
of centralised research policy and management. Clinical research has 
experienced significant disinvestment since the 1980s because of the shift 
towards funding delivery of public health services in provincial hospitals, the 
loss of research subsidies from the NHLS and the lack of dedicated funding for 
clinical research. The MRC has failed to step up funding for clinical research 
in the face of withdrawal of funding by the provincial departments of health 
and the NHLS. Until now, despite its mandate to support all scientific research, 
the NRF has not directly funded clinical research. It has recently indicated a 
willingness to consider doing so. Much of the clinical and epidemiological 
research now being performed in South Africa is funded by foreign, non-
private foundations and government bodies and not by private companies 
(see Chapter 8). 
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COORDINATION
Sixth, there is need for a concerted and coordinated effort by government, 
industry and research institutions to promote and develop clinical sciences. 
Creating an attractive environment to conduct clinical trials in this country 
requires better coordination and integration of different components of the 
system. In particular, there is a need for better coordination of government 
departments responsible for aspects of the revitalisation of clinical research. 
The DTI has an interest in attracting foreign direct investment by maximising 
and optimising the opportunities for multi-national research investment. At the 
same time, they wish to promote the growth of an indigenous biotechnology 
industry which has the capacity to create new therapies and to test them 
through appropriate clinical trials. The South African Government has identified 
the pharmaceutical industry as a priority industry to fuel economic growth 
under AsgiSA. Research is essential for growth in any industry, and clinical 
research is the lifeblood of a research-based pharmaceutical industry. The 
clinical trials industry is growing worldwide, and is seeking new locations for 
trials, so we compete for clinical trials with many other countries. 
Science, technology and innovation are a key component of the NEPAD 
strategy for addressing the Millennium Development Goals (NEPAD, 2006), and 
research universities are being set up across Africa to promote postgraduate 
science. In 1996, the then South African Deputy President Thabo Mbeki 
envisaged a key role for science and technology in aiding the intellectual 
and spiritual renewal of Africa – the African Renaissance. The DST’s Ten-Year 
Innovation Plan (2008) sets out to develop a knowledge-based economy in 
which the production and dissemination of knowledge leads to economic 
benefits and enriches all fields of human endeavour. It has to promote 
research and innovation in this highly inter-dependent and complex system, 
but this is dependent on the development of a skills base. Yet of the 72 NRF 
Research Chairs awarded to date, the majority of the (few) chairs awarded in 
the health sciences have supported basic rather than clinical sciences (NRF: 
http://www.nrf.ac.za/sarchi/index.htm).
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The Department of Education (DoE - now the Department of Higher Education 
and Training, DoHET) has to make sure that the skills and capacities of health 
care personnel are developed to the highest degree possible, through the 
huge system of public higher education. Yet much of the teaching and 
research actually takes place problematically on the terrain of another 
ministry/department, namely that of Health, channelled just as problematically 
through provincial funding and responsibility. The DoH wishes to oversee 
an effective system of safety testing and approval of medicines and other 
therapies, and to ensure that these are affordable, safe and widely available; 
this requires that a research ethics and regulatory environment be created 
that is efficient and rational, capable of balancing interests, and trusted by all 
participants. Finally, the National Treasury has a deep interest in more efficient 
funding of health care, while providing for the education and training needs 
upon which health care delivery is critically dependent. Yet, as discussed 
above, there has effectively been massive disinvestment in clinical research 
since the 1980s.
There is a need for strategic servicing of clinical trials, and for expertise in 
their planning and budget, information technology support for trials, global 
biometrics, serious adverse event monitoring and reporting, training and 
retraining and perhaps certification, document management, and clinical 
study management. There would be opportunity to concentrate on niche 
areas such as Good Clinical Practice (GCP), biostatistics, data management 
support and the development of systems. New opportunities might be 
sought for collaboration between the private and public sectors, and for 
comprehensively addressing Good Laboratory Practice (GLP), GCP and quality 
assurance. In Malaysia at the University of Kuala Lumpur there is an institute for 
biochemistry and biometrics which serves as a national reference centre. One 
can take work there, offload work or data for processing, commission studies, 
and develop educational models and children’s educational games. It is part 
of the national plan to promote mathematics, science and technology. It is 
open and used 24 hours, seven days a week. This is what should be done in 
South Africa in the area of public sector clinical studies.
REVITALISING CLINICAL RESEARCH IN SOUTH AFRICA63
A STUDY ON CLINICAL RESEARCH AND RELATED TRAINING IN SOUTH AFRICA
There are problems, however, and there will be no success unless they 
are confronted. Activities must be confined to true science and clinical 
research; promotional studies must be avoided; there should be enlightened 
approaches to budgeting and costing; there will be ownership issues, 
including intellectual property of communities; there are limits to clinical trial 
capacity in the country; excellent systems of data management need to 
be put in place; this work can only be managed with reform of the national 
medicines regulatory process; there is a need for assessment tools for clinical 
trials capacity; insurance of patients has to be put in place, including no-fault 
liability; policies are needed regarding institutional overheads; and a business 
and funding plan is necessary. 
If we are able to meet these challenges and plan strategically to revitalise 
clinical research, this is likely to benefit the African continent at large as well 
as South Africa. 
FINDINGS
A national culture supporting clinical research will: 
1. Accept the value of clinical research, based on the principle that ‘the 
proper study of humankind is humans themselves’;
2. Understand that sustainable health care systems require guidance by 
a critical mass of research-experienced clinicians and the continuous 
training of new generations of research-informed clinical caregivers;
3. Recognise the importance of investment in clinical research, due to its 
complex and multi-dimensional nature;
4. Enable an appropriate balance between risks and benefits in clinical 
research, ensuring ethical practice; 
5. Enable an appropriate balance between curiosity-driven and problem-
directed research in addressing key health risks in society; 
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6. Place clear emphasis on public service and public benefit in the conduct 
of clinical research, promoting public trust in and understanding of the role 
and contribution of research in society. 
RECOmmENDATIONS
Develop a national culture supportive of clinical research by:
1. Raising the status of clinical research both within the broader domain of 
scientific research and within government programmes funding science;
2. Creating a strong public service and benefit ethos, based on better 
programmes promoting public engagement with clinical science, and 
better risk-benefit analyses that inform prioritisation for clinical research in 
the country;
3. Capacitating local ethics and regulatory bodies for clinical research;
4. Developing an interdisciplinary local scientific community through scientific 
publishing and coordinated promotion activities, while encouraging links 
between laboratory-based and clinical research;
5. Enhancing specialist knowledge and competence that is internationally 
visible, without reducing interdisciplinary communication among clinical 
researchers within South Africa;
6. Creating targeted educational programmes, funding, career-pathing and 
institutional support for the development of new clinical researchers in the 
country; 
7. Increasing and better coordinating the funding of clinical research;
8. Working towards a concerted and coordinated effort by government, 
industry and research institutions to promote and develop clinical research 
capacity at the highest level possible.
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C H A P T E R  4 :
HOW TO FOSTER GREATER PUBLIC ENGAGEMENT WITH 
CLINICAL SCIENCE
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in this chapter, we engage with the following questions:
1. How can fostering better public engagement with science in general 
promote a national culture supporting clinical research?
2. What do we know about public opinion of clinical research in South 
Africa?
3. What can we do to improve public understanding of and trust in clinical 
research?
INTRODUCTION
As discussed in Chapters 2 and 3, public understanding of medical research, 
and science in general, has been negatively affected by our history of 
colonialism, ‘Bantu’ education and the continuing inadequacies of our 
science education system. Unfortunately, medical researchers have been 
slow to engage with South African communities to build public trust in clinical 
research, and where this engagement has happened it has been difficult 
and often unsuccessful. Fostering better public engagement with science 
can promote a national culture supporting clinical research. Fostering more 
effective interaction between scientists and the public about the aims, 
methods and findings of clinical research may also help to make clinical 
research more relevant, and more sensitive to the needs and perceptions 
of participant communities. Fostering better public understanding of and 
trust in the benefits of clinical research for society may improve willingness to 
participate in research, to recruit more young researchers to clinical research 
careers, and to support state funding of research.
Developing a national culture of support for clinical research depends not 
only on providing information to improve the public’s general knowledge 
about science but also on increased mutual knowledge and trust between 
scientists and the public. public trust in medical science can be hampered by 
ignorance about science ‘from the inside’ (how science works) and, perhaps 
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more seriously, by misunderstandings between scientists and the public about 
‘science from the outside’. Understanding ‘science from the outside’ includes 
understanding the role and value of scientific research, how it generates value 
for others and how it relates to other forms of knowledge: its place within the 
broader political economy of power, money and knowledge. Public mistrust 
of science may be associated with cultural and historical factors as well as 
the lack of specific scientific knowledge. Developing better communication 
and trust between scientists and the public should thus be based on a better 
understanding of how the public feel about science already.
PUBLIC UNDERSTANDING AND OPINION OF mEDICAL 
RESEARCH
Public perceptions of medical research and science in general will affect 
their participation in, and support of, clinical trials and clinical research. public 
confidence in expressing opinions contrary to scientific views has strengthened 
in recent years. Disputes over scientific research in the public domain have 
become more frequent, for example on the question of scientific research 
on the human remains of indigenous people. The public has challenged the 
removal and ‘ownership’ of these remains by scientists, for example in the case 
of the Mapungubwe remains at Pretoria University and the Prestwich Place 
graveyard in Cape Town (Legassick, 2000; Shepherd, 2007). The media has 
also begun to play a greater role in influencing public perceptions of clinical 
trials. For example, in 2007 there was public outrage after an HIV microbicide 
trial was stopped in KwaZulu-Natal, “heightened by sensational media 
coverage depicting the women as ‘guinea pigs’, alleging that participants 
in microbicide trials were encouraged to visit bars and other similar places of 
entertainment, and engage in unprotected sex” (www.plusnews.org/Report.
aspx?ReportId). The trial had passed all the relevant ethics approvals but had 
failed to achieve a sufficient level of public consultation and trust to deal with 
such a setback.
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PUBLIC UNDERSTANDING OF SCIENCE
In spite of growing interest in the promotion of science, biotechnology research 
and community intellectual property protection, there has been too little 
research on the public understanding of science or on public perceptions of 
clinical trials in South Africa. The little research that has been done has been 
trapped to some extent in the ‘knowledge deficit’ tradition, focusing on how 
little knowledge the public has about science. Instead of simply investigating 
public knowledge about science ‘from the inside’ (how science works to 
produce knowledge) we need to start investigating how people understand 
the purpose and politics of scientific research and how it affects them. 
Current research understands poor public engagement with science in South 
Africa mainly as a problem of poor communication that can be addressed 
by telling people more about science, developing indigenous-language 
terminology, or phrasing sexual behaviour messages in a more culturally 
appropriate way. The problem could also, however, be seen as a broader 
socio-political issue, linked to a history of popular experience of science in 
South Africa, as elsewhere in Africa, that has resulted in a mismatch between 
popular and scientific understanding of the role and value of science in 
society. 
In 1999, a survey was conducted by the HSRC to determine the level of 
public understanding of science in the country using modified international 
survey instruments (Blankley and Arnold, 2001). The data from the sample of 
2 207 randomly selected adults were weighted to match the demographics 
of the national adult population. The data showed that 30% of respondents 
had never studied mathematics at school, 50% had never studied biological 
science and 55% had never studied physical or chemical science. Only about 
20% had a pass in mathematics on leaving school and only 3% to 4% of the 
sample had ever studied mathematics or science at tertiary level. Race, 
age, gender and income level were correlated with levels of science or 
mathematics education: poorer, older black women were worst off. 
Although the South African respondents showed interest in science (83% were 
interested in new discoveries in medicine), the study found that science was 
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a low-salience issue for most of them prior to the survey. Although 60% of the 
respondents believed that the positive benefits of science had outweighed 
any harmful effects, perhaps mirroring government statements on the 
usefulness of science, 68% felt that “science makes our way of life change too 
fast”, and 48% felt that “we depend too much on science and not enough 
on faith”. Analysis of the data suggested that there are some problems in 
applying a survey developed for wealthy western countries directly to South 
Africa: people who were most optimistic about its benefits also showed the 
most reservations about science, in contrast to US data. The authors of the 
study suggest this may have been a result of random or unconsidered survey 
responses, but it may be that different applications of science may present 
reasons for concern or optimism. 
The HSRC study thus recommended more investment in science education 
especially for certain groups, and the use of radio programmes for science 
education among the general population (Blankley and Arnold, 2001). Public 
education could also be achieved through revision of school curricula, 
systematic use of popular science magazines and science centres for 
information dissemination, a National Health Research week and other 
initiatives discussed below. As the British experience has shown, however, 
simply disseminating knowledge about science will not necessarily foster 
trust in science or address all the concerns that the public might have 
about science and more specifically about clinical research. Blankley and 
Arnold (2001) warned that “Given current low levels of understanding [about 
science], there is the danger that public debates on issues such as HIV/AIDS, 
nuclear power or genetically modified organisms are likely to be guided, even 
swayed, by those with special interests or agendas.”
Studies of school performance in science indicate that the percentage of 
final-year school passes in mathematics and physical science higher grade 
have declined slightly in the period 1997–2000, while passes in the standard 
grade in these subjects have risen somewhat. The performance of African 
learners in these subjects has been particularly poor: in 2001, between 11% 
and 40% of candidates passed mathematics on SG or HG in the various 
provinces (an outlier being the 75% pass rate for Limpopo with 78 learners) 
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(Mouton et al., 2002). Numbers of both master’s and doctoral graduates have 
increased between 1989 and 2000, but the majority of graduates are still in 
the humanities rather than the sciences (Bunting, 2002 and Cloete et al., 2002, 
cited in Mouton et al., 2002).
A preliminary scoping study on the uptake of research in social development 
was recently commissioned by the Research and Development Uptake in 
South Africa (RADUSA) Forum, comprised of the NRF, the Southern African 
Research and Innovation Management Association (SARIMA), the CSIR, 
the Association of Commonwealth Universities (ACU) and Metalab. The 
report of this investigation, produced by the CSIR (Funke et al., 2008), may 
have limited value in measuring efforts to disseminate medical research 
information because it did not incorporate specific interviews with the MRC. 
People from a number of other science councils, government departments, 
higher education institutions and communities were sampled, but there were 
a few comments made about public views on science, specifically health 
information. Information about water quality or sexual behaviour provided by 
government agencies in the rural area sampled was not always acceptable 
to or trusted by community members. Information about healthy eating 
was not always relevant when people struggled to find enough to eat. The 
report concluded that “Government agencies and research organisations 
should be aware that cultural and linguistic barriers exist when they attempt 
to disseminate research and development findings to communities in need. 
These issues need to be addressed on a project-specific basis, and might also 
make for important areas for future research” (Funke et al., 2008).
PUBLIC PARTICIPATION IN CLINICAL TRIALS
One of the measures of public trust in medical research could be participation 
in clinical trials. Recruitment to clinical trials in Europe has been dropping, 
making it difficult to achieve full enrolment, even as people have become 
more educated about science (Smith, 2000; Williams et al., 2008). One of the 
reasons why South Africa is advertised as an attractive location for clinical 
trials is that the country has a good clinical infrastructure, and a large urban 
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population who are apparently treatment-naïve and willing to participate 
(Scholtz and Pretorius 2005). Recruitment for clinical trials has been easier in 
South Africa in an environment of high unemployment and difficulty accessing 
expensive drugs, and perhaps also in an environment in which people have 
limited scientific literacy. 
Buckley (2008) suggests several factors may have adversely “affected the 
public’s relationship with health care research in Europe and the US: increased 
data protection legislation and the resultant consent requirements; access 
to unforeseen levels of both information and misinformation through the 
mass media; and a growing culture of personal choice which may have 
eroded the perceived importance of activities whose benefits are societal 
rather than personal”. But in general there is little research on patients’ views 
about participation in clinical research (Lecouturier et al., 2008). In the US, 
black participants and other minorities are under-represented in clinical trials. 
Some commentators have ascribed this to popular memory of the unethical 
Tuskegee syphilis trials (which were only stopped in 1972). However, others say 
that public concern about Tuskegee is simply presented an excuse for laziness 
in recruitment efforts by researchers among African Americans. Such efforts 
would involve public education to reduce broader distrust about the purpose 
of the research, especially if it involves genetic testing of black doctors in the 
study, making arrangements for travel and child care and so on (Editorial, 
1997). 
South Africa does not seem to have had high-profile ethical trial disasters 
like Tuskegee in the US, but there have been examples of unethical medical 
research in the country. These are, however, relatively poorly documented 
(The Guardian newspaper, 1998; Cohen, 1997; Smith and Nicodemus, 1999; 
Schoofs, 2001, cited in Barsdorf and Wassenaar, 2005). As has been mentioned 
in Chapter 3, the long history of state support for medical research, the 
historically mainly white and male composition of medical doctors and the 
often adversarial relationship between medicine and indigenous healing 
traditions must have influenced experiences and perceptions of medical 
research and willingness to participate in clinical trials (Baldwin-Ragaven, 
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De Gruchy and London, 1999). Lurie and Wolfe (1997) pointed out that some 
HIV trials in developing countries such as South Africa have been unethical 
because they offer a different standard of care to developing and developed 
country participants, but these kinds of inequalities may not be evident to 
local trial participants. 
There has been an assumption that providing more information to communities 
about clinical trials, such as the AIDS vaccine trials, will promote faith in science 
and recruitment to clinical trials in South Africa. Swartz and Kagee (2006) suggest 
that empowering people to know more about the costs and benefits of trial 
participation may make them less likely to decide to participate in the trials. 
Greater knowledge of science may not by itself promote altruistic involvement 
in clinical research, or indeed trust in anonymous testing procedures. Quite 
apart from the ethical requirements for informed consent, better-informed 
participants may also be more likely to stay on a trial. Other factors such as 
perceived risk can also play a role in willingness to participate. In the HSRC/
Nelson Mandela HIV survey for 2005, male, Indian or white respondents were 
in fact more likely to refuse participation and testing than women, coloured or 
African respondents (30% of those interviewed refused HIV testing, but refusals 
were not evenly distributed across the sample). Those at higher risk of HIV 
infection were more likely to agree to being tested (Shisana et al., 2005). In 
some situations, rural black communities have shown good knowledge of, 
and positive attitudes to, biomedical interventions such as vaccination, and 
a generally positive attitude to HIV vaccines and vaccine trials (Lindegger et 
al., 2007).
Barsdorf and Wassenaar (2005) indicate that there are racial differences in 
public perceptions of voluntariness of trial participation. African Americans 
are less likely to participate in clinical research than white in the US (Fairchild 
and Bayer, 1999; Bull, 2003, cited in Barsdorf and Wassenaar, 2005), and 
recruitment of black participants in South African vaccine trials has also been 
problematic. In a sample of 111 employees from two urban communities in 
South Africa, Barsdorf and Wassenaar (2005) found that black respondents 
perceived participation in medical research to be less voluntary than white 
and Indian respondents, independent of educational level, knowledge of 
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medical research procedures and close or personal experience of medical 
research. Lower perceptions of voluntariness among black trial participants 
may be due to South Africa’s racist past, and possibly to awareness of abuses 
of medical research which are often more frequent in research conducted 
on disadvantaged groups. It is not clear how perceived lack of voluntariness 
would necessarily lead to decreased participation, however – it may increase 
participation of vulnerable groups. 
public ambivalence towards trial participation is expressed in different ways 
depending on the cultural, historical and political context, but there are some 
broad commonalities across Africa. There are widespread bioethics discussions 
within the scientific community about ‘guinea-pig’ trials which do not benefit 
locals, and about lax ethical controls in Africa, for example (Humphreys, 
2006; Bosch, 2004), but in the popular imagination these concerns are often 
expressed in the form of rumours about blood and organ trafficking, deliberate 
spreading of disease and surreptitious birth control (Geissler and Pool, 2006). 
Geissler and Pool suggest that such rumours are widespread across Africa. They 
impede recruitment to research, affect adherence to interventions and even 
threaten the continuation of whole research projects while more commonly 
providing a background noise without direct impact (Geissler, 2005; Fairhead 
et al., 2006b; Nchito et al., 2003; Singh and Mills, 2005: 975; Molyneux et al., 
2004). Similar patterns of public concern about western medicine surface in 
South Africa and affect clinical trials. In the 1960s, heart surgeons at Groote 
Schuur Hospital were thought to be harvesting organs from black people for 
use in white people (especially after Barnard failed to obtain permission from 
one donor’s family before using the heart) (Digby, 2006: 368). Such rumours 
were common in the northern parts of South Africa in the early 1990s, linking 
popular fears about organs being stolen for muti medicine or witchcraft to 
fears of a new transplant market for organs in public hospitals (Niehaus, 1993; 
Campion-Vincent, 2002; Comaroff and Comaroff, 1999). As Scheper-Hughes 
(1996) points out, rumours about organ stealing have some metaphorical 
or actual truth, especially when the full extent of ‘dirty tricks’ campaigns in 
times of political oppression become known, where poor people’s bodies are 
treated without much respect in public hospitals, where ‘presumed consent’ 
is common practice in organ harvesting from corpses, and the illegal market 
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in blood and organs. While rumours take the form of urban legends, they are 
not simply the product of ignorance or resistance, but “local interpretations 
of medical research ethics – especially relating to the problem of resource 
transfers and flows of value” (Geissler and Pool, 2006). 
Public understanding of trials and their benefits is also informed by the fact 
that the pharmaceutical industry consists mainly of large companies whose 
head offices are located in wealthy Western countries, and that the benefits 
of trial participation do not always filter down to the communities involved. 
As Alfred Chandler (2005) says in his magisterial history of the American and 
European chemical and pharmaceutical industries, their emergence in the 
second phase of the industrial revolution from the 1880s was made possible by 
the development of infrastructure enabling mass production and distribution – 
the railroad and steamship, the telegraph and cable. Conditions in the newly 
unified Germany and the growth of heavy industry along the Rhine gave 
pharmaceutical companies there and in Switzerland particular advantages, 
which helped them to retain market dominance into the 20th century, while 
yielding a bit of ground to American pharmaceutical companies in terms of 
innovation after they entered the market in the 1920s and 1930s. The product-
related embedded organisational knowledge base generated by these 
early American and European pharmaceutical and chemical companies 
effectively defined the industry and constituted a significant barrier to new 
entrants, even from countries like Japan. The pharmaceutical industry 
expanded after World War II with the development of antibiotics. In the 1970s, 
new areas of scientific investigation such as microbiology, enzymology, genetic 
engineering and genomics were taken up and exploited by the industry’s 
leaders. With the emergence of the biotechnology industry in the late 20th 
century, significant shifts in the industry occurred and reduced some barriers 
to entry for biotechnology start-ups, but it has been difficult for companies in 
South Africa to override barriers to entry in the arena of mass drug production 
and therefore in the financing of clinical trials required for drug registration 
and approval. 
Although clinical trials are essential in testing and approving new drugs, and 
have brought increased research income into South Africa especially in 
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recent years after regulations governing the location of trials were liberalised, 
the specific political and economic features of the pharmaceutical industry 
has raised valid questions about research capacity development, the 
development and monitoring of local ethical guidelines, data access and the 
relevance of research to the local context. Most of the leading scientists on 
clinical trials are located in wealthy countries. New drugs are often designed 
for developed-country markets, and may be too expensive or inappropriate 
for the developing countries in which they have been tested (Benatar, 
2002). This means that by participating in such trials, local researchers can 
lose opportunities to develop locally relevant research (Mayosi, 2008). Tucker 
and Makgoba (2008) have suggested that more non-Africans than Africans 
still occupy decision-making positions in many public-private partnerships 
regulating what HIV/AIDS, malaria and TB trials will be conducted in Africa: this, 
they say, constitutes a continuation of the pattern of scientific imperialism that 
historically characterised the sector (Tucker and Makgoba, 2008). Much of 
the intellectual property (ip) and research experience generated by clinical 
trials is thus located outside of developing countries such as South Africa, and 
local access to drugs still under patent is limited by their greater cost. 
CURRENT INITIATIVES TO PROmOTE CLINICAL SCIENCE IN 
SOUTH AFRICA
The state in South Africa has come to be viewed by a wide range of academics 
and policy-makers as a developmental state – one that actively intervenes in 
the economy to harness resources for economic development, especially in 
poor communities. It is often assumed that South Africa’s transformation into 
a knowledge-based economy, as in Asia, will “largely be dependent on the 
existence of a developmental state that promotes technological innovation 
and takes measures to enhance the human capabilities of its people” 
(Edigheji, 2008). In 1996, the then Deputy President, Thabo Mbeki, envisaged 
a key role for science and technology in aiding the intellectual and spiritual 
renewal of Africa – the African Renaissance. As stated in Chapter 7, science, 
technology and innovation are a key component of the NEPAD strategy for 
addressing the Millennium development goals (NEPAD, 2006) and research 
universities are being set up across Africa to promote postgraduate science. 
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It is critical to develop a national culture in which both doctors and patients 
are able and willing to consider the results of clinical research in deciding 
on health care solutions. In South Africa, the NRF is already promoting public 
engagement with science. The South african agency for Science and 
technology advancement (SaaSta), an agency of the NRF, aims to advance 
public awareness, appreciation and engagement of science, engineering 
and technology in South Africa. It was formerly known as the Foundation for 
Education, Science and Technology (FEST), but changed its name when it was 
incorporated into the NRF in December 2002. Its scope of activities includes:
1. Building the quantity and quality of mathematics and science outputs 
at school level (developing science education and training (SET) human 
capital);
2. Raising the general interest in, engagement and appreciation of the 
public (and especially poorer communities) for the benefit of science 
(strengthening the SET culture);
3. Communicating science to the South African citizenry (bringing science 
and scientists closer to civil society) (http://www.saasta.ac.za/aboutus/
background.shtml).
SAASTA hosted the first African Science Communication Conference in 
2006, and through this facilitated the development of the African Science 
Communication Network and the Southern African Science Communication 
Network (SASCON) (http://www.saasta.ac.za/aboutus/background.shtml. They 
are members of the International Network on Public Communication of Science 
and Technology (PCST). South African initiatives such as National Science Week, 
managed by SAASTA, and Scifest Africa have sought to promote science 
among the general public, especially the youth. 
The focus of SAASTA’s initiatives has been influenced by Africa’s Science and 
Technology Consolidated Plan of Action (African Union and NEPAD, 2006) 
which consolidated the science and technology programmes of the African 
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Union (AU) Commission and NEPAD. The plan is administered by the African 
Ministerial Council on Science and Technology (AMCOST). One of the aims of 
the plan is to build “a strong political and civil society constituency for science 
and technology in Africa” (African Union and NEPAD, 2006:10). But public 
engagement with science or medicine is not included in the proposed NEPAD 
indicators for African science, technology and innovation (NEPAD, 2006). 
To guide its focus from 2006 to 2010, the plan identified six flagship research 
and development clusters. These include: 
1. Biodiversity, Biotechnology and Indigenous Knowledge;
2. Energy, Water and Desertification;
3. Materials Sciences, Manufacturing, Laser and Post-Harvest Technologies;
4. Information, Communication and Space Science Technologies;
5. Improving Policy Conditions and Building Innovation Mechanisms;
6. Implementation, Funding and Governance.
Yet only one of the flagship areas, biodiversity, biotechnology and indigenous 
knowledge, relates to medical research, in spite of the enormous contribution 
medical research can and does make to social and economic development 
on the continent. The plan is committed to promoting science and tech- 
nology in the achievement of the Millennium Development Goals (MDGs), 
and three of the eight goals are health-related (child health, maternal 
mortality, HIV/AIDS, malaria and other diseases) (African Union and NEPAD, 
2006). Clinical research has thus not been sufficiently prioritised in government 
strategies to promote science and technology.
In the development of new drugs based on indigenous knowledge of local 
plants, South Africa already has a number of initiatives that can be used 
to increase access to essential generic drugs that are still under patent 
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protection, and to protect the intellectual property of communities whose 
knowledge about the use of plants for medicinal purposes is used to create 
new drugs. The DTI has made a number of modifications in South African 
law to protect community-based intellectual property (IP), the Department 
of the Environment and Tourism has gazetted bio-prospecting regulations, 
and the DST has set up an Indigenous Knowledge Systems unit to manage 
the development of benefit-sharing agreements between communities 
and companies wishing to use their IP (Department of Environmental Affairs 
and Tourism, 2007; Department of Science and Technology, 2004; Patent 
Amendment Act 2005; Intellectual Property Laws Amendment Bill [Draft] 
2009). The Department of Health and the MRC have funded collaborations 
between indigenous medical practitioners and scientists to test the efficacy 
of indigenous remedies in laboratories. The tRaMEd (traditional medicine) 
project associated with the MRC programme is mainly concerned with 
testing traditional medicines in clinical settings and has already compiled a 
plant database (http://databases.mrc.ac.za/Tramed3), and the University of 
the Western Cape Pharmacopoeia monograph project has further data on 
traditional medicinal plant use (http://www.sahealthinfo.org/traditionalmeds/
monographs.htm). 
One of the examples of benefit-sharing agreements has been the development 
of an obesity drug from the plant Hoodia gordonii, used traditionally by the 
San to reduce hunger. However, in this case the benefit-sharing agreement 
refers to a patent on the use of a molecule rather than on the use of the plant 
itself. It is difficult, although not impossible, to patent the rare and unusual use 
of a natural plant. Many producers are thus bypassing the Hoodia patent and 
thus earning profits which do not benefit the community concerned (Business 
Day newspaper, 12 July 2006).
As discussed in Chapter 3, much of the intellectual property and research 
experience generated by clinical trials is located outside of developing 
countries such as South Africa, and local access to drugs still under patent 
is limited by their greater cost. Increased African involvement in setting 
clinical research agendas and improved intellectual property protections 
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for communities will help to build trust in clinical research, and ensure that 
benefits important to participant communities accrue from clinical trials. 
Stabilising research capacity locally requires investment in local opportunities 
for existing researchers by, for example, locating key research institutions in 
countries such as South Africa.
Some of these concerns have begun to be addressed by funding clinical trials 
on locally relevant drugs and local research capacity building, increasing 
access to early clinical trials data, and developing locally appropriate ethical 
protocols (Humphreys, 2006; Bosch, 2004; Benatar, 2002). One particularly 
interesting initiative is the European and developing countries clinical trials 
partnership (Edctp) initiative, which was created in 2003 as a response to 
the global health crisis caused by the three main poverty-related diseases 
of HIV/AIDS, malaria and TB. The idea behind the partnership is to help EU 
member states to integrate and coordinate their own national research and 
development programmes and form partnerships with their sub-Saharan 
African counterparts. The EDCTP “aims to accelerate the development of 
new or improved drugs, vaccines and microbicides against HIV/AIDS, malaria 
and tuberculosis, with a focus on phase II and III clinical trials in sub-Saharan 
Africa.” African scientists are well represented on EDCTP’s decision-making 
governance structures (http://www.edctp.org/Home.162.0.html). 
In conclusion, there is an agency within SAASTA that is specifically mandated 
to promote public understanding of science, and a broader African Plan of 
Action (2006–2010) promoting science and technology, but the basic sciences 
have received more attention than clinical research. There has to date been 
too little research on how the public responds to science, and specifically to 
clinical research, and few initiatives to improve this engagement. However, 
a number of initiatives have been put in place to protect community-held 
intellectual property over indigenous medical knowledge and to redress the 
imbalance between local and international scientists in decision-making 
about clinical trials.
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WHAT STILL NEEDS TO BE DONE
Developing a national culture supporting clinical research requires interventions 
by the clinical research community and by the state. The state can support 
clinical research through awareness-raising activities, coordinated funding 
for education of researchers, the activities of research institutions and clinical 
researchers. Local and regional science and technology-promotion activities 
need to be integrated and expanded to focus more on clinical research. 
The clinical research community and other promoters of clinical research 
need to engage more with the public about the aims, processes and results 
of research to improve public trust and participation in research, but also to 
improve their own understanding of community needs, to improve community 
access to the benefits accruing from research and to inform research ethics 
models. It is critically important for the science fraternity to start to engage in 
open debates with other stakeholders about the nature and role of science, 
and how to use science and other sources of knowledge to address issues 
of public concern. In an environment where science is not necessarily 
trusted on its own terms, rumours are a vehicle through which the public can 
debate feelings of ambivalence about “the advantages (free treatment) 
and disadvantages (giving blood) of participation in research, and issues of 
inequality and the fair distribution of benefits.” In medical research in Africa 
the issue of inequality and fairness has to be something researchers negotiate 
with research participants rather than simply impose on them (Geissler 
and Pool, 2006). Dialogues between scientists and the public about these 
misunderstandings thus have to happen “if medical research in resource-poor 
settings is to continue to be sustainable and politically legitimate” (Fairhead 
et al., 2006b).
In the UK a new Sciencewise funding scheme funds public engagement with 
science in the context of developing public policy on new technologies. The 
project uses public engagement to achieve three main aims (http://www.
sciencewise-erc.org.uk/cms):
1. to inform and strengthen policy recommendations, provide legitimacy to 
decisions and lead ultimately to better legislation that benefits all society;
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2. to provide opportunity for exchanges between scientists and the public, 
not only to provide and debate scientific information but also information 
about the social context and moral environment in which science policy 
decisions must work; 
3. to develop public trust in the use of science and new technologies in driving 
the country’s development, and to make their views on acceptability of 
new technologies heard. 
One of the associated initiatives, the UK Clinical Research Collaboration 
(UKCRC), is “a partnership of organisations working to establish the UK as a world 
leader in clinical research, by harnessing the power of the NHS.” Part of this 
programme includes setting up Patient and Public Involvement programmes 
and Public Awareness groups (UK Clinical Research Collaboration, 2008-2011). 
A number of projects were initially developed and delivered, including the 
recruitment of patient/public members to key UKCRC Boards and Advisory 
Groups; materials aimed at raising public awareness and understanding 
of clinical research; and People in Research, a web-based resource which 
helps patients and members of the public make contact with organisations 
that have opportunities for patient and public involvement (http://www.
peopleinresearch.org). The Social Issues Research Centre (with the Royal 
Society) and the Royal Institution of Great Britain have published guidelines 
on science and health communication (http://www.sirc.org). The Patient and 
Public Involvement Strategic Plan 2008 – 2011 seeks to increase patient and 
public involvement in clinical research at a strategic level, improve public 
understanding of and confidence in clinical research, and develop the 
sustainability of patient and public involvement in the UK (http://www.ukcrc.
org). A recent survey of public attitudes to science in the UK follows similar 
surveys in 2000 and 2005 (http://www.sirc.org). 
A number of other projects have emerged internationally from increasing 
interest in improving the engagement between science and the public. Not 
all of these projects are government initiatives. Observa – Science in Society 
(http://www.observa.it)- is, for example, a ‘non-profit cultural association’ of 
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academics in a number of European institutions, affiliated with no private or 
public organisations, which aims at “promoting the study and the discussion 
of the interaction between science and society, stimulating dialogue among 
researchers, policy-makers and citizens.” Observa focuses on three main areas: 
Science Communication; Research and Innovation Policy; and Science, 
Citizens and Technology (http://www.observa.it). In the US, the Clinical 
Research Forum was established in 1996 and refocused in 2005 to “provide 
leadership to the national clinical and translational research enterprise and 
to promote understanding and support for clinical research and its impact on 
health and health care” (http://www.clinicalresearchforum.org). It promotes 
public understanding and participation in clinical research. The National 
Science Board in the US has given annual public service awards since 1996 
to key people (not just scientists) who have promoted public understanding 
of science and science literacy in various science fields, including medicine, 
and engineering (National Science Foundation, http://www.nsf.gov; http://
www.nsf.gov/nsb/awards/public_recipients.jsp). The Royal Society in the UK 
offers the Kohn Award for excellence in engaging the public with science, 
and the Michael Faraday award for science communication (http://www.
royalsociety.org).
Other kinds of initiatives include the Edinburgh International Science Festival 
and the London Summer Science Exhibition, the Australian Science Festival 
(from 1988) and the World Science Festival in New York. Many countries 
celebrate science weeks and research weeks – Brazil has a National Week of 
Science and Technology in which scientists speak to schoolchildren (http://
www.rnp.br/en/news); television is also a key part of the Brazilian public strategy 
to develop interest and knowledge about science (Barata and Jorge, 2008). 
The Philippines started an Annual National Health Research System (PNHRS) 
Week in 2007, based on a partnership between the Department of Science 
and Technology and the Department of Health to which the Commission on 
Higher Education (CHED) and University of the Philippines - National Institutes 
of Health (UP-NIH) have been added. The week has a theme (the theme for 
2008 was strengthening networking and convergence within the PNHRS), and 
includes training sessions on research article writing, writing policy briefs and 
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proposal development in accessing research funds from the Department of 
Science and Technology (DST), CHED and the University of the Philippines – 
National Institutes of Health (UP-NIH). Conferences associated with the event 
include scientific sessions focusing on priority areas identified in the ASEAN 
Plan of Action on Science and Technology (APAST) such as functional food, 
open source technology, alternative energy, and disaster mitigation. There 
will be separate sessions on capacity building and intellectual property to 
cover topics on human resource development, intellectual property rights, 
technology transfer mechanisms, and strategies adopted by ASEAN member 
countries to develop science and technology capability (Asmolo, 2008).
academic interest in public understanding of science has also increased. 
The London School of Economics (http://www.lse.ac.uk) has a research 
programme called STEPS: Science, Technology and the Public Sphere. 
Various university chairs, courses and departments specialising in this area 
have been established. A Chair for the Public Understanding of Science at 
Oxford University in the UK was founded in 1995 (Charles Simonyi Professorship 
in the Public Understanding of Science, Oxford University, http://www.admin.
ox.ac.uk/fp/wd9-018.shtml). The aim of the professorship is to communicate 
science to the public outside the University, including non-specialists and 
also those in opinion-forming positions without, in doing so, ‘dumbing-down’ 
the science. The Chair is expected to play a role in developing the science 
outreach activities of the University and its museums (http://www.admin.
ox.ac.uk). In Australia, the Centre for the Public Awareness of Science (CPAS) 
(http://en.wikipedia.org/wiki/CPAS) was established at the Australian National 
University (ANU) in 1996. Foreshadowing the conclusion reached by the British 
House of Lords more than ten years later, CPAS adopted the philosophy of 
‘Public Awareness’. Its thrust was not directed solely at increasing public 
understanding of science. Rather, it was concerned with increasing public 
awareness of science, fostering in the community a ‘need to know’, and 
encouraging the community to take possession of science and orchestrate 
its own learning. CPAS offers graduate education in science communication, 
including master’s and PhD programmes, which have proved very popular 
(http://www.en.wikipedia.org). It has also funded various initiatives for 
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promoting science in South Africa (see also http://en.wikipedia.org/wiki/
Science_communication#cite_note-15).
The UK-based James Lind Alliance is an initiative that aims to include the 
public in identifying and confronting uncertainties about the effects of 
treatments considered important by both patients and clinicians (http://
www.lindalliance.org). Funded by the British Medical Research Council and 
the UK Department of Health, the Alliance promotes two principles: first, that 
addressing uncertainties about the effects of treatments should become 
accepted as a much more routine part of clinical practice; and second, 
that patients and clinicians should work together to agree which, among 
those uncertainties, matter most and thus deserve priority attention. Meetings 
between the general public and clinicians are organised to prioritise research 
areas and a database, the database of uncertainties about the Effects of 
treatments (duEts), has been established. DUETS aims to identify and publish 
uncertainties reflected in patients’ and clinicians’ questions about the effects 
of treatments which cannot be answered by referring to up-to-date systematic 
reviews of existing research evidence. DUETs is being used to inform priorities 
for new research, in particular those identified through working partnerships 
of patients and clinicians.
In the developing world, the basic concept of democratic engagement 
on difficult issues remains relevant, although programmes promoting public 
engagement with science would need to focus on development policy 
goals such as science education and health. These public debates need to 
be carefully prepared, but should also aim at starting productive mutually 
respectful dialogue on solving a common problem, rather than being staged 
to ‘produce’ a positive view of science. Debate could be fostered both 
within clinical trial contexts and outside of them, as a way of understanding 
public views and addressing public concerns about clinical research. The 
proposed National Health Research week could integrate well with existing 
projects such as National Science Week and Scifest Africa, and provide a 
focus for open discussions about the role of research and the relationship 
between Western science and indigenous medicine. Churches, activist 
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groups, traditional healers and community leaders could play a role in such 
discussions. A National clinical Research Society or Network could, together 
with ASSAf, promote research and projects to improve public engagement 
with clinical research as part of a broader agenda promoting excellence and 
relevance in clinical research.
The roles of health and science journalists and the media in general also need 
to be addressed in relation to the theme of this chapter. Clinical researchers 
are often antagonistic to what they perceive as excessive sensationalism 
and inaccurate reporting; this does not help them, as the antagonism is 
often exacerbated by off-handedness and evasion. Suffice it to say that no 
approach to the public understanding of clinical science will succeed if it 
does not take into account the importance of the media.  
More attention also needs to be paid to developing a bottom-up approach 
to ethics in clinical trials: understanding community fears and needs, 
encouraging more community involvement in assessing the ethical conduct of 
medical research and negotiating what benefits will accrue to trial participants 
(Geissler and Pool, 2006; Buchanan et al., 2008). Researchers need to try and 
understand how the public perceives them and their research institutions, not 
just as producers of important knowledge, but as players within the local socio-
economic context (Fairhead et al., 2006b). As we have pointed out above, 
simply providing scientific facts and dismissing public views as ignorance and 
rumour is not productive in addressing misperceptions. Researchers need to 
justify their research to participants in terms of concrete outcomes. Forums 
for identifying mutual interests and concerns among researchers, activists 
and participants, based on principles of reciprocity and transparency, can 
be used to identify early public concerns about trial participation (Singh and 
Mills, 2005). Trying to understand rumours about blood and organ trafficking, 
deliberate spreading of disease, and surreptitious birth control could “enrich 
medical research ethics debates and improve relations between medical 
researchers and study communities” (Geissler and Pool, 2006). Other 
mechanisms to improve researcher-community relationships in trials could 
include the appointment of community liaison officers, the use of prior fact-
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finding missions on operational issues, confidence-building measures (such as 
the inclusion of activist groups in community advisory boards), engaging the 
media, and education (e.g. on therapeutic misconception, compensation 
for study-related injuries, and post-trial benefits) (Singh and Mills, 2005). This 
can improve mutual understanding about what clinical trial participants 
and researchers believe they are exchanging with each other in the trial 
context, and reduce misunderstandings about their respective roles. Where 
there is direct benefit in terms of drug access, better feedback can improve 
adherence or take-up of new therapies. Ultimately, making a more direct link 
between research and fair benefit to participants (from their own viewpoint) 
will be the best way of fostering trust in scientific research and encouraging 
participation in future trials. 
Building a broader public culture supportive of clinical research requires that 
the benefits, biases and challenges of the clinical trials industry are debated 
and addressed. South Africa already has a number of initiatives to address 
such challenges. These initiatives should be more widely publicised and better 
integrated.
FINDINGS
1. There has been too little research on the public understanding of science 
or on public perceptions of clinical trials in South Africa. 
2. There is a legacy of distrust and ignorance in the relationship between 
research participants and clinical researchers because of the history of 
South Africa. Mutually beneficial engagement between the public and 
clinical researchers has not been extensive enough in the past. 
3. South Africa is an attractive location for clinical trials, inter alia because it has 
a good clinical infrastructure, low levels of litigation, a credible regulatory 
environment, and a full spectrum of health problems. Recruitment for 
clinical trials has been relatively easy in South Africa due to a large 
treatment-naïve urban population, who experience high unemployment 
and difficulty accessing expensive drugs. 
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RECOmmENDATIONS
1. Raise the profile of clinical research on the continent: for example, in 
the African Science Communication Network and the Southern African 
Science Communication Network (SASCON), and include clinical research 
as a further flagship research and development cluster for the 2011–2015 
African Science and Technology Plan of Action. 
2. Raise the profile of clinical research within South Africa: for example, 
broaden National Science Week to incorporate a National Health Research 
week; establish an ASSAf award for Promoting Public Engagement with 
Clinical Science. 
3. Improve public engagement with science: for example, fund qualitative 
and quantitative research about the public understanding of science in 
southern Africa within universities and research institutions; motivate for an 
NRF Research Chair in Public engagement with Science and ensure there 
are clinical candidates; include public engagement with science in the 
NEPAD Indicators for African science, technology and innovation.
4. Review the new curriculum statements in schools: refer specifically to 
therapeutic/clinical concepts based on an historical (longitudinal) 
approach in order to make useful connections between chemistry, human 
physiology (e.g. endocrinology as an internal ‘drug-administering system’), 
mathematics literacy, ethics and economics.
5. Ensure a more democratic engagement between the public and 
researchers, and help to ensure that they share a common understanding 
about the operation and purpose of clinical research, for example by:
a. developing locally appropriate public communication guidelines and 
ethical protocols for researchers;
b. engaging with public views about clinical research, including geopolitical 
issues as part of research preparation activities;
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c. promoting rights access and education for trial participants.
6. Promote health and science journalism and effective interfaces between 
the media and the clinical research community.
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ENHANCING ETHICAL OVERSIGHT OF CLINICAL RESEARCH 
TO PROTECT INDIVIDUALS AND COMMUNITIES
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in this chapter, we engage with the following questions:
1. What are the current mechanisms for ethical oversight for clinical research 
in South Africa?
2. How well are these mechanisms functioning?
3. How do ethical oversight mechanisms for clinical research function 
elsewhere?
4. How can we improve ethical oversight for clinical research in South 
Africa?
5. How can ethical publication practices be ensured? 
INTRODUCTION
The fundamental role of clinical research in the provision of high-quality care is 
well documented (Moerman et al., 2007). Biomedical research is yielding new 
diagnostic and therapeutic methods at an accelerating rate (Patenaude 
et al., 2007) and this provides health care professionals with information on 
optimal strategies for the prevention, diagnosis and treatment of health 
conditions (Moerman et al., 2007). About 100 000 clinical trials are carried out 
around the world each year, with 10% being done in developing countries 
(Watson, 2007). In 2000, South Africa was reported to be handling 0.6% of 
global trials, although it had the capacity to conduct 2.5% of the world’s 
clinical research contracts (Baird and Niekerk, 2004). The global clinical trials 
business was worth an estimated US$50 billion in 2008, with a rate of growth 
of 10% (Global Clinical Trials Business Report & Analysis, 2008-2018). In South 
Africa, clinical research was worth approximately US$1.5 billion in 2006 (http://
www.crc-sa.com) and there was a 40% growth between 1997 and 1998 in the 
clinical research industry, mainly as a result of the ability of researchers being 
able consistently to meet patient recruitment timelines and targets (Dhai, 
2005). There has recently been a decline in industry-related clinical trials at 
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academic institutions, however, as evidenced by a 16% reduction in clinical 
trials applications to the University of Witwatersrand’s Human Research Ethics 
Committee (HREC) between 2003 and 2007 (Cleaton-Jones and Vorster, 2008). 
A similar trend was reported at the Biomedical Research Ethics Committee of 
the University of KwaZulu-Natal, where there was a 36% decline in industry-
related applications between 2000 and 2004 (Dhai, 2005). This decline in 
industry-related clinical studies at academic institutions has been confirmed 
by the Medicines Control Council of South Africa (MCC). The impact of clinical 
research on the health and economy of any country emphasises the need to 
keep the research enterprise afloat. Various initiatives such as the European 
roadmap for initiative research have been recommended as measures to 
identify and train best researchers in universities, laboratories, industry and 
health care settings (Groves, 2008). 
Identifying barriers to the successful conduct of research plays an important 
role in promoting and safeguarding the clinical research enterprise. Addressing 
challenges that present at different levels in research in South Africa would 
assist in driving clinical research to flourish. This must be done in a manner that 
also respects human rights and dignity. Ethical principles and values, such 
as respect for persons, beneficence, non-maleficence, justice and respect 
for human dignity must underscore all health research activities. Obtaining 
informed consent from prospective research participants is a vital requirement 
if research is to be conducted ethically. Barriers to the informed consent process 
in South Africa are language, culture and vulnerabilities associated with 
poverty and massive socio-economic disparities. Benefits to participants and 
communities who are involved in research should outweigh potential harms 
and risks. Moreover, benefits and risks of the research should be distributed 
equitably in society, both locally and globally. If research is to be carried out 
in South Africa, research participants and communities should have access 
to interventions that are proven to be efficacious. Standards of care should 
be equal for all during research, thereby demonstrating equal respect for 
research participants’ dignity. In addition, research participants should not be 
expected to bear the costs of trial participation, i.e. management of trial-related 
injuries should be the researcher’s and not the participant’s responsibility. A 
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requirement of justice is that the trial should leave the participant better off, 
or at least no worse off. 
In this chapter, we look at (i) the law governing the conduct of research, 
(ii) ethics governance, i.e. RECs: their composition, functions, workloads 
and funding, and (iii) existing instruments and processes for the facilitation 
and promotion of research. We make recommendations to facilitate the 
promotion of ethical clinical trials research.
THE SOUTH AFRICAN LAW GOVERNING CLINICAL 
RESEARCH
Regulations governing clinical research serve the purpose of providing ethical 
and scientific quality standards for designing, conducting, recording and 
reporting trials that involve participation of human participants (International 
Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use – Good Clinical Practice [ICH-GCP]). Failure of 
the research enterprise might be a reflection of the relative failure of national 
regulations to have a downstream effect on the practices of research staff 
(Rab et al., 2008). In South Africa, Chapter 9 of the National health act, Act 61 
of 2003, makes the conduct of ethical health research a legal requirement. 
Health research is defined in the National Health Act as any research that 
contributes to knowledge of:
1. The biological, clinical, psychological or social processes in human 
beings;
2. Improved methods for the provision of health services;
3. Human pathology;
4. The causes of disease;
5. The effects of the environment on the human body;
REVITALISING CLINICAL RESEARCH IN SOUTH AFRICA99
A STUDY ON CLINICAL RESEARCH AND RELATED TRAINING IN SOUTH AFRICA
6. The development or new applications of pharmaceuticals, medicines and 
related substances;
7. The development of new applications of health technology.
The rapid proliferation of clinical trials, where clinical trials are defined as a 
systemic study involving human subjects that aims to answer specific questions 
about the safety or efficacy of a medicine or method of treatment (section 
72(7) of the National Health Act), and the increasingly complex regulations 
governing research (Chaddah, 2008) have had a negative impact on the 
continued growth of research. While some concerns have been raised that 
the protection of research participants is often assumed to be inadequate in 
the formulation of policy or legislation, other concerns exist that protection 
programmes result in overregulation, increasing the time and expense devoted 
to activities of marginal utility in protecting human research participants (Fost 
and Levine, 2007: 2196).
South Africa has a well-established regulatory process based on guidelines 
for clinical studies (Scholtz and Pretorius, 2005). Section 12 of the Bill of Rights 
of the constitution of South africa, Act 108 of 1996, affirms that no one will be 
involved in medical experimentation without providing informed consent. The 
National Health Act stipulates the basic ethical requirements in the conduct of 
research. The principles emphasised in the Act include confidentiality (section 
16) when using medical records for research purposes, respect for persons, 
and autonomy by allowing self-determination in the requirement for written 
informed consent form (section 71). These principles are also found elsewhere in 
the regulations governing research in South Africa, including the South african 
good clinical practice guidelines, 2nd Edition 2006, and the Department 
of Health’s Research Ethics guidelines, 2004. Enshrined in Chapter 9 of the 
National Health Act is section 69 which provides for the establishment of a 
National health Research committee. This committee is mandated in terms 
of the Act to identify research priorities of the nation (section 70). Realisation 
of distributive justice is enhanced through this provision as this section serves 
to eliminate research that is biased towards an elite group while disregarding 
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the needs of the poorer communities. Inadequate protection of research 
participants could have deleterious effects on research, as participants 
might be less willing to engage in research (Campbell, 2004). Section 72 of 
the National Health Act provides for the establishment of a National Health 
Research Ethics Council (NHREC). This Council, which was established 
in October 2006, has been directed by the Act to establish Research 
Ethics committees (REcs) accredited with it and to register and accredit 
existing RECs. Flawed implementation of regulations by local RECs or in the 
governing regulations themselves where investigators perceive problems 
could stifle research activities (Whitney et al., 2008: 71). The former is likely 
to be minimised through the accreditation process when it is implemented, 
however, as the NHREC will monitor and investigate the policy standards and 
standard operating procedures, training and capacity building, appeals and 
subcommittees of local RECs (Article 3.2, Ethics Guidelines, 2004).
The statutory functions of the NhREc include:
a) determining guidelines for the functioning of health research ethics 
committees;
b) Registering and auditing health research ethics committees;
c) Setting norms and standards for conducting research on humans and 
animals, including norms and standards for conducting clinical trials;
d) adjudicating complaints about the functioning of health research ethics 
committees;
e) hearing any complaint by a researcher who believes he or she has been 
discriminated against by a health research ethics committee;
f) Referring to the relevant statutory health professional council matters 
involving the violation or potential violation of an ethical or professional 
rule by a health care provider;
g) instituting such disciplinary action as may be prescribed against any 
person found to be in contravention of any norms, standards or guidelines 
set for the conducting of research in terms of the National health act;
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h) advising the national and provincial departments on any ethical issues 
concerning research.
The NHREC therefore has obligations to both researchers and research 
participants to ensure the creation of an enabling environment for the conduct 
of ethical clinical research. It is imperative that the NHREC is supported by 
the national Department of Health in implementing its mandate. It is also 
imperative that implementation is carried out efficiently and without delay 
and that members of this very important Council have the necessary 
competence to allow for the optimal functioning of this body. In addition, 
both researchers and health research ethics committees need to be aware 
of the NHREC, its mandate and any pertinent ethics guideline documents 
emanating from it to allow for informed decisions on the ethical aspect of 
studies. Functional knowledge and understanding of ethics in research on 
the part of health research ethics committee members would also serve to 
facilitate the research process rather than stifle it as is currently the common 
perception. Stifling of research due to a lack of awareness of national and 
international guidelines by REC members, as reported by Ikungura et al. (2007) 
for Tanzania (>50%), could be minimised through the accreditation process.  
In terms of section 73 of the National Health Act, every institution, health 
agency and health establishment at which health research is conducted, 
must establish or have access to a health research ethics committee, which 
is registered with the National Health Research Ethics Council. The provision 
further outlines the functions of the RECs, including review of research 
proposals. Within the South African regulatory framework, limitations are 
placed on RECs with regard to the type of proposals that they are allowed to 
review based on their accreditation level. Article 3.3.2 of the Ethics Guidelines 
(2004) articulates that RECs would be accredited as either level 1 or level 
2, depending on the capacity of the committee. Level 1 committees would 
assess straightforward research designs that involve minimal risk to human 
participants or low budget research (less that R250 000). Level 2 committees 
would review all types of health research proposals. This division of committee 
functioning could help to expedite review of minimal-risk research. It has been 
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stated, however, that the danger with this division is that it could encourage 
the diversion of resources from areas of greater need to minimal or no-risk 
research (Gunsalus, 2006; Boronstein, 2007) because of the perception that 
there would be less stringent review. Other concerns include the fact that 
the accreditation systems could reduce the number of operating RECs and 
discriminate against historically disadvantaged institutions (Moodley and 
Myer, 2007). 
ETHICS GOVERNANCE: REC COMPOSITION, FUNCTIONS, 
WORKLOADS AND FUNDING
composition of REcs
The quality and efficiency of protocol review by an REC is fundamentally a 
function of its aggregate expertise. It is possible that difficulties could emerge 
if an REC examines a research protocol where it lacks expertise within its 
membership in the respective fields of inquiry (Boronstein, 2007). Many 
countries have developed formal regulations governing the composition 
of ethics committees to ensure that specific expertise is present, such as 
biomedical and biometrical expertise, ethical and legal competence and 
expertise on issues regarding patients (Moerman et al., 2007). The European 
Union (EU) directive (Article 2.1k) states that ethics committees should be 
independent bodies in each member state, consisting of both health care 
professionals and non-medical members (Hedgecoe, 2006). The same is 
provided in a regulation of the FDA which articulates that “the IRB shall be 
sufficiently qualified through experience and expertise of its members, and 
diversity of its members” (Moodley and Myer, 2007).
The South African National Ethics Guidelines of 2004, in section 4, affirm that the 
primary role of REcs is to protect the rights and welfare of research participants. 
The primary role of each committee member is to decide, independently, 
whether in his or her opinion, the conduct of the proposed research will protect 
the participants. Section 4 goes on to place an obligation on institutions where 
health research is undertaken to ensure that there are adequate resources to 
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establish and maintain a REC in accordance with national and international 
norms and standards. A further obligation placed on institutions is that they 
accept legal responsibility for the decisions and advice received from the 
REC, and that they also indemnify the REC members. 
A REC should thus consist of members who collectively have the qualifications 
and experience to review and evaluate the science, health aspects and 
ethics of proposed human-subject research, and should be independent, 
multidisciplinary, competent and pluralistic. The REC must be representative 
of the communities it serves and, increasingly, reflect the demographic profile 
of the population of South Africa, and must include:
1. Members of both genders, although not more than 70% should be either 
male or female;
2. At least nine members, with 60% constituting a quorum;
3. At least two lay persons who have no affiliation to the institution, are not 
currently involved in medical, scientific or legal work and are preferably 
from the community in which the research is taking place;
4. At least one member with knowledge of, and current experience in, 
areas of research that are likely to be regularly considered by the ethics 
committee;
5. At least one member with knowledge of, and current experience in, the 
professional care, counselling or treatment of people. Such a member 
might be, for example, a medical practitioner, psychologist, social worker 
or nurse;
6. At least one member who has professional training in both qualitative and 
quantitative research methodologies;
7. At least one member who is legally trained.
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Most of the RECs in the country that are affiliated to health sciences 
institutions have organised, or are currently in the process of organising, their 
membership and standard operating procedures to be in line with these 
guidelines and the National Health Act. At most institutions, however, support 
for, and commitment to, these processes lag far behind. Furthermore, REC 
workloads are also increased as a result of the breadth of the definition of 
health research, resulting in an ever-larger number of studies being submitted 
for ethics review and approval. Local REC members undertake their work in 
nearly all cases as volunteers, over and above their daily professional activities 
(Cleaton-Jones, 2007). REC members are usually faculty staff who struggle to 
combine their busy service commitments with REC activities. 
The size of REcs in Africa ranges from nine to 31 members, with the majority 
of members being clinicians and physicians (Kass et al., 2007). RECs in South 
Africa typically comprise seven to 29 individuals, with a median of 16 members 
(Moodley and Myer, 2007) of which 46–82% are men and 18–54% are women. 
None of the RECs in Africa require gender balance, although all consciously 
include women (Kass et al., 2007), save for South Africa which has regulations 
stating that not more than 70% should be of the same sex (Article 4.1, Ethics 
Guidelines, 2004). The majority of REC members in South Africa are health 
scientists/clinicians who make up 61% of membership, compared with 49% 
in the US (Moodley and Myer, 2007), with ethicists being under-represented 
(Milford et al., 2006). There is usually a provision for at least 25% lay member 
representation to prevent intimidation of lay members during REC deliberations. 
While regulations require that lay members should be part of the community 
being researched, Moodley and Myer (2007) showed that this is not always 
the case. Most RECs have at least one full-time administrative staff member. 
The skewed composition of RECs results in a lack of expertise on RECs in many 
African countries, which impedes research (Ikungura et al., 2007). In South 
Africa, lack of diversity of expertise within RECs is attributable to the nature of 
the faculty community where most of these committees are housed (Moodley 
and Myer, 2007). It is questionable whether RECs have adequate capacity for 
effective assessment of ‘non-biomedical’ protocols (Boronstein, 2007). Lack 
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of diversity on the RECs, which are typically made up of researchers and 
physicians, leads to bias towards quantitative research (Green et al., 2006:215; 
Milford et al., 2006), and a tendency to engage mainly with technical issues 
that fall outside the expertise of non-scientists (Schuppli and Fraser, 2007). 
Lack of expertise, accountability and open dialogue is also prominent in 
self-appointed private commercial and non-commercial RECs (Milford et al., 
2006). Some private RECs have full-time members and review protocols more 
frequently (Moodley and Myer, 2007). 
How members are appointed onto the RECs determines the expertise that 
exists in these committees. The Portuguese government nominates all 34 
members of a central ethics committee in Portugal – the Ethics Committee 
for Clinical Investigation (CEIC) (Hedgecoe, 2006). The appointment of 
members of both the central ethics committee and local ethics committees 
in Sweden is by the Swedish Government (Hedgecoe, 2006). In Canada, 
university administrators, such as the vice-president of research, are formally 
responsible for appointing members, but the committees themselves tend to 
forward names (Schuppli and Fraser, 2007). The UK’s central ethics committee, 
the UK Ethics Committee Authority (UKECA), comprises the Secretary of State 
for Health and representatives from the National Assembly of Wales, the 
Scottish Ministers and the Department of Health (Hedgecoe, 2006) who are 
politicians. In South Africa, members of the NHREC are ministerial appointees 
(section 72, National Health Act). Membership of local RECs is determined by 
the respective institutions according to their individual policies. 
The political appointment of members to an REc poses some challenges 
which could effect its integrity, independence and efficiency. It could also 
negate the multidisciplinary and multi-sector framework that is vital for good 
REC functioning (Van Bogaert and Tangwa, 2007). Politically sensitive research 
could in effect be censored because of the REC review process (Hamburger, 
2004: Boronstein, 2007) as the committees would be vulnerable to political 
manipulation. Abuse of power in selectively choosing which research should 
be approved, coupled with a shortage of avenues for appeals against an 
REC decision, could stifle research (Boronstein, 2007).
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In the case of some RECs, recruiting of members is by word of mouth (Schuppli 
and Fraser, 2007). This means that membership is open to people with various 
motives other than promoting the mandate of the REC (Schuppli and Fraser, 
2007). Most REC members do not have a stipulated tenure. Low turnover of 
membership may stifle the introduction of new ideas, limit the possibility of new 
volunteer membership, and increase the risk of indoctrination (Schuppli and 
Fraser, 2007). Some senior faculty within institutions avoid serving on RECs as 
they feel constrained in exercising their autonomy because of the bureaucratic 
requirements of regulations governing RECs, which they perceive as focusing 
on unimportant minutiae (Fost and Levine, 2006).
FUNCTIONS OF RECS, APPLICATION AND APPEAL 
PROCESSES
The primary function of RECs is participant protection (Moodley and Myer, 
2007; Kass et al., 2007). This is derived from various rights accorded to humans, 
such as the right to freedom to participate or not in research, the right not to 
be harmed, deceived, or exploited, and the right to be treated with dignity 
and fairness, which are enshrined as basic tenets of biomedical research 
ethics (Van Bogaert and Tangwa, 2007). Besides participant protection, RECs 
are vital in demystifying health research by defining what is ethical for each 
application (Dixon-Woods et al., 2007) and providing a public forum for the 
accountability of the researcher (Ikungura et al., 2007). They serve as a third 
party which has the mandate to review and minimise conflict of interests (Kass 
et al., 2007). Through what they say and what they do not say, the RECs act 
as a moral authority to structure the research environment (Dixon-Woods et 
al., 2007). The SA Ethics Guidelines, 2004, propose that the functions of RECs 
include:
a. Review research proposals and protocols to ensure that research will be 
conducted in the spirit of endeavouring to promote health, and to prevent 
or cure disability and disease;
b. Ensuring that humans involved in research are treated with dignity and 
that their well-being is not compromised;
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c. Ensuring that informed consent is obtained when enrolling a participant in 
the research; 
d. granting approval where research proposals meet ethical standards.
Different applications are treated differently, as the work of the REC is 
explicitly judgment and discretion. This differs from rule-based judgments, in 
which there is an appeal to a codified standard (Dixon-Woods et al., 2007). 
In fact, if RECs bureaucratically and inflexibly apply regulations to all projects, 
their efforts could be corrosive to research and actually harm human subjects 
(Boronstein, 2007; Green et al., 2006), because of a focus on minutiae at 
the expense of more important, substantive issues (Fost and Levine, 2007). 
Flexibility in application and interpretation of guidelines and standards could 
explain the occurrence of instances where a proposal is rejected by one 
REC and accepted by another, while apparently using the same guidelines 
(Cleaton-Jones, 2007). This flexibility in the application of regulations across 
RECs has been ascribed to differing conceptions of risk (Boronstein, 2007). 
This issue becomes highly problematic when multi-centre research proposals 
are considered. In Finland, variable practices of local ethics committees 
that caused extra work, delays and confusion to the applicants and made 
processes inefficient were reported as a disincentive to pharmaceutical 
companies who wished to carry out clinical studies (Keinonen et al., 2003). 
Barriers to initiating clinical trials are in any case not uniform for all trials, as the 
steps involved in developing investigator-initiated, industry-sponsored, and 
cooperative group trials are all different (Govindarajan et al., 2007).
Some challenges inherent in REc functioning include dissipation of resources, 
conflict of interests and delays, in addition to lack of experience and expertise 
(Pentz, 2004; Green et al., 2006; Ghersi, 2004). Multi-centre research projects 
face additional problems which include multiple review processes, and 
additional costs and delays associated with administrative errors (Green et 
al., 2006). Such difficulties, and the reported substantial variability of revisions 
requested by multiple RECs for a single research protocol, could present 
potential barriers to much-needed multi-institutional research (Dyrbye et al., 
2007).
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A study on multi-centre research by Green et al. (2006) reported that the time 
for REc approval ranged from 52 days to 798 days, with a median time of 286 
days at 43 sites for a full protocol review, and 127 to 546 days for an expedited 
review. In South Africa, the time from protocol submission to response was 
five weeks with a range of 10 days to 10 weeks (Moodley and Myer, 2007). 
The protocols reviewed included clinical and academic research. Clinical 
researchers feel that the long time frames for REC review processes for multi-
centre research are prohibitive (Ghersi, 2004). Others also feel that the REC 
review process might restructure research through multiple revisions in such a 
way that the nature of the inquiry is changed (Boronstein, 2007). The existence 
of cross-cultural issues in international inquiries could compound the delays 
that frequently occur with multi-centre research (Ghersi, 2004). Bureaucracy 
poses further problems for developing nations where official meetings typically 
start late and deadlines are often ignored (Macpherson, 2004). Absenteeism 
from meetings by some REC members further adds to the delays, as some 
committees’ decisions are influenced by variable attendance (Schuppli and 
Frazer, 2006). These hurdles raise fears among clinical researchers of diversion 
of their resources from patient care to research through futile REC applications 
(Macpherson, 2004). Some researchers have devised strategies to overcome 
persistent rejections by RECs, including several that may actually undermine 
their work (Lincoln and Tierney, 2004; Boronstein, 2007). Even if it may not be 
the intention of RECs to obstruct research, self-censorship by researchers in 
research avenues where obtaining approval is exceedingly difficult could 
have dire consequences, as important and much-needed research with 
policy implications may not be conducted (Boronstein, 2007).
The creation of a central REc to overcome multiple obstacles encountered by 
researchers seems reasonable. A centralised REC, through a versatile combi- 
nation of centralisation, specialisation, and management, could expedite 
multi-centre research, lessen the workload involved for the submitter and also 
serve to coordinate study start-up at multiple sites across regions (Chaddah, 
2008). On the other hand, yet another level of bureaucracy due to a centralised 
system of review may increase the burden on researchers and RECs (Ghersi, 
2004). A way of overcoming problems encountered by researchers would be 
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to adopt a system of expedited review like the one in Australia. There are three 
levels of review in the Australian system: there is no need for independent 
review of minimal-risk quality assurance; expedited review of low-risk quality 
assurance and other research; and full ethics committee review of higher 
risk research (Cave and Nichols, 2007). The drawback of this system lies is its 
dependency on the ability of the researcher or the REC to discern the mode 
of review suitable for the proposed research in each case. This may result in 
inadequate protection of research participants in a way that could jeopardise 
the future of clinical research, as participants may be less willing to engage in 
research processes (Campbell, 2004).
Funding of REcs
As medical research funding can yield a return of up to six-fold on investment 
through a healthier population that creates more wealth (Groves, 2008), 
funding of REcs is important to ensure greater returns from biomedical research 
while upholding public health and rights. In developing countries, research 
is often financed by well-resourced developed countries and conducted in 
vulnerable host communities with diverse cultural backgrounds (Milford et al., 
2006). Some RECs in Africa have no operating funds whatsoever, whereas 
others derive funding solely from either the government, foreign agencies, 
levying fees for reviews (Kass et al., 2007), an affiliated university or institution, 
and/or pharmaceutical companies (Milford et al., 2006: 2). Some RECs obtain 
their funding from a combination of these sources. 
Although financial considerations should not take precedence over the 
mandate of protecting human subjects, the costs associated with reviewing 
protocols can be fairly significant (Hyman, 2007: Sugarman et al., 2005; 
Boronstein, 2007). While recent legislative changes mandate ethical rigor, 
there are huge financial challenges to implementation, which is true even 
for resource-rich regions. Deficiencies in Institutional Review Board procedures 
have led to the suspension of several clinical trails programmes in the US, but 
strengthening the processes concerned has increased their operational costs 
substantially (Dhai, 2005). 
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In South Africa, funding of RECs is a constant problem at most institutions mostly 
because they are viewed as low-priority committees within the institutions 
(Moodley and Myer, 2007). Institutions provide varying levels of logistic 
support for their RECs (Cleaton-Jones, 2007) and it is fairly unlikely that any 
institution has sufficient resources available to meet the demand of having 
its RECs inspect comprehensively every form of research that involves human 
subjects. Fees levied for protocol review (only for sponsored protocols), are 
used to fund training in most of the RECs in South Africa (Moodley and Myer, 
2007). Although adequate administrative support must be provided for the 
support, management and training of REC members (Ashcroft et al., 2005), 
this is not a high priority for governments in developing countries which are 
struggling to provide health care and education services (Macpherson, 2004). 
Underfunding and/or understaffing of committees, or confining its members 
to poor systems and facilities could seriously undermine the credibility of RECs 
and their members (Van Bogaert and Tangwa, 2007) by making it difficult to 
attract the new members required to ensure fair representation from a wide 
range of professions and relevant community perspectives (Cleaton-Jones, 
2007). Furthermore, the ability of RECs effectively to review protocols and to 
monitor approved research is compromised (Milford et al., 2006). Research 
activity is quickly stifled through infrequent and indecisive REC meetings, which 
lead to delays in the initiation of projects. Inadequate monitoring of projects 
in turn undermines participant protections, which can be catastrophic for 
future research. Many funders (both governmental and private) from the US, 
Europe and Canada have stringent research ethics requirements, and lack of 
firm affirmation locally for research ethics through adequate support for and 
development of RECs may impact negatively on the ability of investigators to 
conduct internationally funded research (Rab et al., 2008).
Various suggestions have been made to reduce the number of RECs, some of 
which meet too infrequently to be useful, and to have some RECs members 
serving as paid, full-time staff, for example retired senior clinicians (Aschcroft 
et al., 2005). This is the case with the UK’s National Research Ethics Advisors 
who operate on a continuous full-time basis so that straightforward studies 
can be approved without delay (Cave and Nichols, 2007). 
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REc workloads
The low current turnover of research proposals reviewed by local RECs has 
been attributed partly to increased workloads for the voluntary reviewers 
serving on these committees. Moodley and Myer (2007) found that between 
four and 30 protocols were reviewed per meeting. Cleaton-Jones and Vorster 
(2008) reported a 26% increase in total applications from 439 in 2003 to 553 in 
2007 at the HREC of the University of the Witwatersrand, but there was a 16% 
reduction in industry-related clinical trial applications over the same period. 
Applications at the University of KwaZulu-Natal increased by almost 60% from 
2000 to 2004 (Dhai, 2005). As in the case of other academic institutions, there 
was a 36% decline in the industry-related clinical research, while investigator-
driven research increased by 72% over the same period. Similar trends have 
been observed in the UK, where applications doubled over a five-year period 
from 1991 to 1995. This increase in the workload has not, however, been 
paralleled by a similar increase in the membership and support of RECs, 
resulting in huge delays in review processes. This kind of situation has impacted 
negatively on researchers who try to meet publications deadlines, to earn 
tenure, or to conduct research that has strict time limits (Boronstein, 2007). 
Monitoring and Oversight by REcs
The primary role of monitoring and evaluation of the ethics of clinical research 
is to champion the mandate of RECs, that is, to protect research participants. 
There are, however, other purposes achieved through this activity. Weijer 
(1995) held that the ultimate goal of any institution’s commitment to monitoring 
research must be the education of its research staff and not to police 
researchers; this is a move towards evidence-based ethics, since a monitoring 
system is not an end in itself. Quality assessment and system improvement are 
achieved by the use of information generated from the monitoring exercise, 
and by determining whether guidance provided by RECs to researchers 
is actually being followed (Coleman and Bouësseau, 2008). Deviations by 
investigators from approved protocols can have grave consequences, both 
in terms of the safety of research participants and in public trust in the research 
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enterprise (Lavery et al., 2004). The erosion of public trust may result in the 
reluctance of many patients to participate in clinical trials and in decreased 
funding for medical research generally (Wiejer et al., 1995). Ethical oversight of 
research therefore serves as a public affirmation by RECs of their commitment 
to the ethical conduct of experimentation involving humans (Coleman and 
Bouësseau, 2008). 
Despite the existence of regulations mandating RECs to monitor the research 
that they approve and the importance of continuing review, few RECs are in 
a position to honour this obligation (Weijer, 2001; Tuech et al., 2005). Most RECs 
get assurance from the investigators’ written reports that studies are being 
conducted in an ethical manner (Jamrozik, 2000). Only 18% of RECs were found 
to be performing ‘ongoing reviews or audits’ of research in a study conducted 
by the National Council on Ethics in Human Research in Canada (Weijer, 2001); 
53% indicated that they required only an annual report from investigators. 
Another survey in ten Latin American countries revealed that 68% of the 25 
RECs surveyed did not require progress reports from investigators, while 59% 
had no follow-up mechanisms in place (Rivera and Ezcurra, 2001). A survey 
of Australian RECs indicated that 44% ‘always’ or ‘usually’ undertook post-
approval review and that, in almost all (99%) cases, this involved only annual 
reporting (Weijer et al., 1995). Clinical trials by pharmaceutical companies in 
South Africa are closely monitored as part of good clinical practice, with the 
local RECs requiring the submission of six-monthly progress reports (Cleaton-
Jones, 2002). RECs in South Africa do not perform active on-site monitoring 
of ethics, however, e.g. of the actual informed-consent processes. Much 
reliance is placed on the good faith and integrity of the researchers. It can be 
concluded that RECs in South Africa currently do not have enough support 
and capacity to comprehensively honour their post-approval responsibilities. 
There are several guidelines for those aspects of research that require 
monitoring. These include: (i) continuing (annual or six-monthly) review; (ii) 
monitoring of the consent process; (iii) monitoring for adherence to protocol; 
and (iv) monitoring of data integrity (Article 8.9, SA-GCP, 2006; Article 4.7, 
Research Ethics Guidelines, 2004). The aim of monitoring includes quality 
REVITALISING CLINICAL RESEARCH IN SOUTH AFRICA113
A STUDY ON CLINICAL RESEARCH AND RELATED TRAINING IN SOUTH AFRICA
assurance in research (Lavery et al., 2004). A study on monitoring clinical 
research at St Mary’s Hospital Centre, Montreal, revealed flaws in the consent 
process: 3.8% of the consent forms used were different from the one approved, 
and there was a discrepancy between the age of participants and the age 
criteria specified in the protocol in 1.3% (McCuster, 2001). Deviation from the 
original research protocol without the approval of the RECs was reported in 
research by Weijer et al. (1995). It is obviously imperative that the ethics of 
research be monitored to safeguard both the participants and the clinical 
research enterprise itself. The enormous workload associated with monitoring 
as many as 1 500 projects per year, as is the case with the HREC of the 
University of the Witwatersrand (Cleaton-Jones and Vorster, 2008), remains a 
considerable challenge. 
Recent amendments to the Helsinki Declaration leave little room to 
manoeuvre on the use of placebos in clinical trials. It states that “a new 
intervention must be tested against the best current proven intervention.” A 
placebo is acceptable “where no current proven intervention exists” or where 
its use is necessary to determine an intervention’s efficacy (Normile, 2008). 
The stringent stipulations of the Helsinki Declaration have resulted in the FDA 
allowing applicants for new drug approvals to bypass the Helsinki Declaration, 
and instead to comply with the ICH-CGP when conducting trials outside the 
US (Normile, 2008). This lack of universal uniformity in review standards creates 
inconsistencies in review processes that could harm the research enterprise. 
While the FDA’s approach is less rigorous and more flexible and hence could 
facilitate research, there is a concern that this may be happening at the cost 
of compromising ethics. 
ETHICAL PUBLICATION
There has recently been a serious re-examination of the ethics of publishing 
in the area of clinical trials, particularly in the US where a high incidence 
of ‘sponsor control’ over authors has been uncovered, often extending to 
the unacknowledged drafting of manuscripts, or parts of manuscripts, by 
company staff. Failure to acknowledge sponsorships is another apparently 
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serious problem. Much attention is accordingly being given to signed ‘conflict 
of interest‘ statements required of all authors before publication.
While this has not yet been an issue in South Africa, careful attention needs to 
be given to the ethics of publishing, both within institutions and by regulatory 
bodies. 
CONCLUDING REmARKS
Because clinical research is a social contract, ethical oversight is imperative 
as it is a public affirmation by RECs of their commitment to the ethical conduct 
of experimentation involving humans. Identifying and overcoming barriers 
to the successful conduct of research plays an important role in promoting 
and safeguarding the clinical research enterprise. Addressing the challenges 
at different levels in research in South Africa would assist in allowing clinical 
research to flourish. 
Establishing new or strengthening existing programmes on research methods 
and ethics would be invaluable in promoting clinical research both at 
undergraduate and postgraduate levels. Incorporating ethics into research 
methodology would also be a major objective of any such programme.
Institutions and the Department of Health must support REC functioning both 
from an administrative and review perspective. RECs cannot continue to be 
viewed as committees with simple administrative functions. Where necessary, 
RECs should be able to carry out consultations with experts. Post-approval 
responsibilities, including passive and active monitoring of approved research 
by RECs, must also be adequately supported. Perhaps the time has also 
arrived for RECs to employ full-time, salaried reviewers, possibly drawn from 
the growing pool of retired experts. 
Understanding and correctly implementing national and international 
regulations and guidelines by REC members serves to facilitate rather than 
hinder clinical research. Focused, ongoing educational programs for REC 
members on ethics protocol review, current and past ethics research discourse 
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and debate and ethics regulation are necessary to ensure competent, 
high-quality review, which should itself be subject to quality assurance at 
predetermined intervals. 
Empirical research on REC functioning and the ‘life-cycle’ of clinical studies, 
from application for ethics review and clearance up to publication, is much 
needed, as is research and evaluation of ethics training curricula with regard 
to impact and implementation, at both researcher and REC levels.
Creation of a central REC to overcome multiple obstacles encountered 
by researchers in multi-centre projects is recommended. A centralised 
REC, through a versatile combination of centralisation, specialisation and 
management, could expedite multi-centre research, lessen the workloads of 
submitters and enable better coordination of study start-ups at multiple sites 
across regions (Chaddah, 2008). The role of the local RECs would then merely 
be to ensure that the research takes into consideration local nuances specific 
to the local context. 
Adopting a system of expedited review for minimal-risk research could result 
in a significant reduction in the turn-around time for relatively innocuous 
studies.
FINDINGS
1. Research should be viewed as a social enterprise, i.e. a contract with 
society whereby ethically conducted research will serve to assure society 
that individuals will not be harmed.
2. The primary function of Research Ethics Committees (RECs) is thus the 
protection of research participants, including adequate scientific review 
for excellence and relevance. 
3. The laws governing the conduct of research in South Africa are generally 
adequate, as are the institutional provisions for ethics governance and 
regulation. The National Health Act has set the standards for ethics 
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in research, but implementation of these standards is far from being 
realised.
4. While legislative changes have resulted in increasing numbers of research 
projects requiring ethics review and approval, there has not been a parallel 
increase of support for REC functioning, resulting in often unnecessary 
delays (this is particularly problematic regarding multi-centre studies).
5. Very few RECs are in a position to honour their obligations to monitor and 
provide oversight for the research they approve, despite the fact that the 
majority of REC members in South Africa are health scientists and clinicians 
and that RECs operate largely within university environments.
6. The shift of clinical trial commissioning from academic institutions to the 
private sector weakens the access of academic institutions to funding and 
their ability to develop research capacity.
7. Only a handful of core researchers are doing trials, and those that do 
conduct too many trials concurrently.
RECOmmENDATIONS
1. Institutions and the Department of Health must support RECs both from an 
administrative and review perspective. 
2. This includes post-approval responsibilities, including passive and active 
monitoring of approved research; the monitoring and evaluation of REC 
functioning; and making information about clinical research more widely 
available. 
3. The operational independence of the National Health Research Ethics 
Council should be maximised, while emphasising its overall accountability 
to government and society. 
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4. The National Health Research Ethics Council should register and accredit 
RECs and expedite their ability to process applications.
5. A system of expedited review for minimal risk research could result in a 
significant reduction in the overall turn-around time of study proposals.
6. Institutions and RECs should collaborate to reduce duplication in ethics 
review in South Africa and thus facilitate multi-centre studies.
7. Focused, ongoing educational programmes for existing and potential 
REC members on ethics protocol review, current and past ethics research 
discourse and debate, and ethics regulation are required to ensure 
competent, high-quality review, which should itself be subject to quality 
assurance at predetermined intervals. 
8. Editors of journals publishing clinical research should maintain strict 
surveillance of conflicts of interest and inappropriate interference with 
publishing by sponsors.
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C H A P T E R  6 :
SCHOLARLY PUBLISHING AS A MEANS OF MEASURING AND 
PROMOTING CLINICAL RESEARCH
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in this chapter, we engage with the following questions:
1. What key problems with South African clinical research can be identified 
by an analysis of published outputs? 
2. What specific interventions will best promote the overall productivity of 
clinical research in terms of both quality and quantity?
INTRODUCTION
clinical research in a developing country has more than one purpose. It seeks 
to contribute to health care at all levels by identifying the causes of health 
problems, facilitating diagnosis, improving the efficiency and effectiveness 
of care, and promoting good policy-making. It supports the training of 
health professionals of all kinds, and contributes to global knowledge 
about the prevention and treatment disease. Scholarly publication and the 
accompanying targeted dissemination of new information is a key process 
in achieving these multiple functions, and is simultaneously an important, 
measurable indicator of its success in doing so (Gevers et al., 2006). It 
must be remembered, however, that different functions require the use of 
available indicators in different, even if sometimes interdependent ways, and 
misleading impressions can be created if one publication indicator is applied 
to the exclusion of others.
Considerable importance is currently attached to international publication of 
local research. International publication has come to mean the placement of 
original articles in the relatively small number of journals selected to be indexed 
in international periodical databases. The most well-known and frequently 
analysed of these is the Thomson Reuters Institute of Scientific Information (ISI) 
database. With the enormous recent growth of publications (most of it in the 
developed countries), specialisation within the main clinical sub-disciplines, 
not to mention sub-sub-disciplines, has spawned in each of them a limited 
set of (mostly US and European) journals regarded as the most desirable and 
rewarding targets of researchers in that area. Thus, publishing ‘internationally’ 
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has come to mean publishing in the (usually voluminous) leading journals 
of each sub-discipline or sub-sub-discipline, achieving connectivity and 
reputation within the global community of other researchers working in a 
focused field, and satisfying the demands of funders and local policy-making 
for ‘significant research outputs of high impact’ (see below). 
With this kind of publication, specialisation has given rise to a general migration 
of attention from the few remaining, still highly competitive multidisciplinary 
clinical journals to the many more and consequently larger-capacity specialty 
journals in the international indexes. If one considers the fabled categorisation 
of scholars into ‘foxes’ and ‘hedgehogs’ (the former constantly moving from 
one field to another, and the latter burrowing ever more deeply into one 
topic), the system has become much more friendly to hedgehogs than to 
foxes.
It is clear that the ability of researchers to publish articles arising from their 
clinical research in leading international speciality journals generally reflects 
high standards of design and execution of research projects, and promotes 
international collaborations, facilitates the acquisition of international grants 
and provides solid evidence for a variety of rewards in career development. 
It is generally considered that such publishing is a kind of visible iceberg or 
proxy of general bottom-up excellence in research groups, centres and 
institutions, in which in-house and local conferences provide opportunities 
for pre-publication presentation and concomitant peer review of productive 
work, apprentice-type development of younger staff and postgraduate 
students, and enhancement by collaboration (Mode 2 research) (Gibbons et 
al., 1994). But the following questions can reasonably be asked: Are there are 
down sides to the prevailing system of formal publication almost exclusively 
in international speciality journals in a developing country such as South 
Africa? Do high-quality local journals, successfully completed postgraduate 
studies, effective research-based teaching and training, innovation in drug 
development, etc., also have specific roles and functions, other than being 
poorly visible components of the metaphoric ‘iceberg of excellence’ indicated 
by international publications? Is the scientific community too fragmented 
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to foster cross-field insights and collaboration? Can our young researchers 
develop into the leaders of tomorrow when they are located in isolated 
groups whose main scientific contacts and focus are outside the country? 
Can the core values of clinical research be acquired without community of 
purpose and enquiry? 
We will accordingly examine whether and how the worldwide trend of 
international specialty publishing is reflected in South African clinical research, 
and how this affects the fact that clinical research has many important 
functions besides achieving recognition in the ways described above. We will 
look at the question of how analysis of published outputs helps us to assess 
whether and how the different functions are being met in an optimal and 
balanced manner. Specifically, we will endeavour to answer the question of 
how a health sector can be built that sees research as an essential element 
of improved health care. We will also address the question of how research 
communities can best be created, as part of a vibrant culture of clinical 
research, both for established practitioners and for new entrants to the field. 
Finally, this will connect to the matter of public engagement with clinical 
research.
While much of the information presented will be drawn from a commissioned 
study done for the Panel by the Centre for Research in Science and Technology 
(CREST) at Stellenbosch University (covering the ten-year period from 1996 to 
2005), other published sources will also be extensively used.
mEASURING RESEARCH OUTPUTS
As already stated above, published research outputs in the form of peer-
reviewed scholarly journal articles represent a powerful but not exclusive 
proxy for the performance of a research sector such as the clinical research 
sector in this country. Books and book chapters, conference proceedings, 
patents and other published outputs need, however, also to be considered, 
as disciplines vary in their use of these modalities. Published journal articles 
carry unique weight and simultaneously fulfil the five objectives of scholarly 
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publication in a consistent way: registering, certifying, making aware, 
archiving and rewarding (Roosendaal and Geurts, 1997).
Contributions to the training and growth of young scholars, and to the nature 
and quality of health care service provision (including safer and better drugs 
or therapies) are other potentially highly significant and valuable measures in 
the case of a sector such as clinical research (this topic is covered in other 
sections of the report).
SOUTH AFRICA’S PUBLICATION RECORD IN CLINICAL 
mEDICINE
South Africa is part of a ‘long tail’ of developing and least-developed countries 
that produce only a tiny fraction of the world’s health-research literature 
(Paraje et al., 2005). Despite this, the country is comparatively a giant in sub-
Saharan africa, and was for some time particularly productive, in world terms, 
in clinical medicine. In fact, health-related research has been responsible 
since the 1960s for the largest single contribution from South African addresses 
in the indexed thomson Reuters iSi system. Tijssen’s (2007) exhaustive study 
of African research articles included in Thomson Reuters’ ISI indexes showed 
that 50% of all articles were in the medical and life sciences (the analogous 
figure for Africa overall was no less than 61%). In addition, an ISI-based citation 
assessment has revealed that no fewer than six South African universities 
exceeded a threshold set at 1% of all citations in ‘clinical medicine’ over the 
period 1995–2005, the only scientific field in which this was the case (Pouris, 
2006). In 1995, it was reported in Science that Groote Schuur Hospital alone 
had achieved a greater number of the most cited 1% of the papers in the 
ISI system over the period 1981–1991 than all but two of South Africa’s higher 
education institutions (Clery, 1995). 
The above indicators of activity become more complex when newer 
analyses are taken into account. One study showed that the share of total 
iSi-indexed papers from South Africa in clinical medicine fell by 18%, from 
0.59 to 0.48, between the periods 1990–1994 and 1996–2000, mostly caused 
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by growth in the size of the system with which it was not keeping up (Pouris, 
2003). A more recent paper on the ISI databases found a slight fall in the 
absolute numbers of papers in this area published between 1996–2005 (7 342) 
and 1995–2004 (7 440), while the citations to South African clinical medicine 
papers increased from 50 462 (6.8 cites per article) to 55 500 (7.6 cites per 
article) (Jeenah and Pouris, 2008). The citation rates of South African papers 
in the field outperformed those of both India and Brazil, which are far bigger 
contributors in numbers of indexed papers. In terms of total indexed papers 
worldwide, however, South Africa ranked number 30 in clinical medicine, but 
number 20 in the geosciences (where only 2 594 papers were published that 
were indexed in the ISI system). 
The data clearly show that the majority of the South African ISI-indexed 
papers in clinical medicine have in fact appeared in international (overseas) 
speciality journals, while the number of papers in this field in local journals, 
ISI-indexed or not, is small and has dramatically decreased in recent times. 
For example, the number of controlled randomised trials reported in the local 
flagship journal, the ISI-indexed South African Medical Journal, between 1976 
and 1987 was 195, but fell to 92 between 1988 and 1997 (Pienaar et al., 2003). 
Such trials are a crucial contributor to effective translational research, which 
has been promoted as a key priority by local policy-makers. (Much more 
information on clinical research publishing from and in South Africa is given 
below, arising from a study commissioned by the Panel.) 
The composite picture of South African publications in clinical medicine/
research is thus one of continuing productivity in the widely recognised 
publishing domain recorded in the international indexed ISI system, ranked 
second among the country’s own broad scientific fields, but only thirtieth 
amongst all countries in this specific field. Since the average citation rates 
per article in clinical medicine exceed those of the principal emerging 
nations of the South, however, one could say the quality of South African 
papers according to this criterion has been higher and the quantity lower in a 
comparison with developing nations. In this sense, South Africa has performed 
like a small developed country, with a heavy focus on international journals 
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in the sub-disciplines or specialities, and very little attention to local and/or 
traditional multidisciplinary publishing, for which the decline of clinical research 
publications in the South African Medical Journal is the best indication. 
Politically, the picture mirrors the still-continuing functioning of South African 
knowledge production as a (small) well-developed component co-existing 
within a much larger developing country. It must be emphasised that while 
there is no a priori reason why this should not be a satisfactory basis on which 
to build a future system of clinical research and its publication for the whole 
nation/society (see the above arguments in relation to the ‘iceberg’ model 
of proxy indicators of the all-round functionality of the research system), any 
recommendations for the future must be based on a careful examination of how 
the workings of such a (possibly declining) system will affect the development 
of the next generation of clinical researchers, and the achievement of a 
vibrant national research culture in an engaged society. 
The above considerations induced the Panel to commission a detailed 
comparative study of all South African publications, in all health areas, that 
were accredited by the Department of Education (DoE) (ISI-indexed or not) 
over the ten-year period 1996 to 2005 (see below). This information permits a 
detailed review of recent patterns of research article publication within and 
from South Africa in bibliometric terms, in all ISI-indexed and non-indexed 
publications which were DoE accredited, with a view to discerning messages 
for a better future system. Outputs in the form of books and book chapters 
have also been reviewed in order to assess their nature and quality. Together, 
the findings can assist in the development of recommendations for enhancing 
multiple outputs and contributions of clinical research in South Africa in the 
future, as part of a general stimulation of the sector.
RESEARCH OUTPUTS IN THE FORm OF JOURNAL ARTICLES
As described in the 2006 ASSAf Report on journal-based scholarly publishing 
in South Africa (Gevers et al., 2006), quality assurance takes effect at two 
levels. The first is the adoption of best practice in editorial discretion and peer 
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review when new articles are submitted to a journal; this limited and private 
assessment leads to acceptance or rejection decisions, improvements 
mandated by peer reviewers and/or editors, and copy editing to publication 
standard. The second takes place after publication, namely ‘universal peer 
review in public’, through multiple citation in other published articles in the 
literature, especially by authors completely independent of the original 
authors or groups (i.e. not self-citation) (Garfield, 1955). citation indexing 
is by no means a perfect science, but it forms an important and valid part 
of bibliometric methodology provided its limitations are appreciated and 
necessary refinements applied when possible (e.g. field or journal-based 
normalisation to render comparisons more meaningful) (Moed, 2005). 
The first ‘either-in-or-out’ stage confers entry of a research paper into the 
literature in a more-or-less standardised way; the second post-publication 
stage positions it in a general hierarchy of noteworthiness, which is a measure 
of its contribution to progress in a field being made by the vast community of 
scholars. The first measure is broadly one of quantity both as a total output and 
as a stratified one in terms of the kind of authorships involved (for example, 
inter-institutional or international collaborations, gender, race and age); the 
second measure is one of quality, and can also be refined, for example in 
terms of the pattern of appearance of citations over time. It is dangerous, 
however, to regard both measures as anything other than (significant) proxies 
for a more comprehensive evaluation of the productivity of a research 
system. 
One must be aware of the changing international background to the 
research outputs of any one country. The continued rapid growth of the 
publishing system as a whole; the recent emergence of countries such as 
India, China, South Korea and Brazil as steadily increasing contributors; the 
continued skewing of the system in favour of English-language articles and 
journals published in Northern, wealthy countries; and the phenomenal 
intrusion of internet-based open access into a previously print-based model, 
have all taken place in the same time-frame as the present analysis. For this 
reason, evaluative approaches that diminish the impact of system change 
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(such as determining the percentage of articles produced in a given period 
by a country as part of world production for that period) provide information 
that is just as significant as are absolute criteria (such as the number of papers 
produced by authors from a specific country in a given period). In any case, 
single parameter comparisons are highly suspect against a background of 
multiple contexts and a changing global system. 
A COmmISSIONED STUDY
The Panel requested the centre for Research in Science and technology 
(cRESt) at Stellenbosch University to carry out a study of research articles in 
the clinical and other health sciences published in journals both in South Africa 
and in other countries, over the period 1996 to 2005. The report prepared by 
CREST was received in February 2008, and has been adapted and extended 
in this section of the chapter; the data have been supplemented, where 
appropriate, with some derived from other sources.
The selection of appropriate methodology is crucial to the assessment of 
journal articles in a system; no single approach is adequate. CREST used 
its extensive ‘Sa Knowledgebase’ to produce a data set of peer-reviewed 
articles in the health sciences for the period concerned. SA Knowledgebase 
(SAK) is by far the largest database of research output in South Africa; it aims 
to deliver comprehensive, accurate and up-to-date information about article 
output from 1990 onwards. The database collects bibliographic information 
(excluding citations) on articles with South African author addresses which 
have appeared in journals accredited by the DoE. Information on the article 
title, article keywords, authorships, journal title, journal publishing detail and 
journal field in SAK is captured from two bibliographic indexes – the index of 
South african periodicals (iSap) in Sabinet, and Thomson Reuter’s iSi (usually 
now called the web of Science). SAK includes all articles with a South African 
address appearing in the Web of Science and in, the case of ISAP/Sabinet, 
only articles appearing in a journal that has been accredited by the DoE.
Although the focus of SAK is on DoE-accredited journals, SAK is not limited 
to articles produced by the South African higher education sector. It also 
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includes, amongst others, articles produced by the science councils, national 
research facilities and government-based research institutions. The database 
also provides author-specific information by disaggregating the article output 
in terms of selected demographic variables (gender, race, year of birth, 
highest qualification and institutional affiliation). 
At present SAK contains more than 115 000 journal articles published by 90 600 
authors, of which about 63 000 are South African authors. What makes SAK 
unique is that it includes biographic details about article authors, specifically 
their gender, race and age at time of publication (derived from birth year).
Fields and categories
For the purposes of this study, the CREST team extracted from SAK all articles 
published between 1996 and 2005 in journals that are classified within any 
of the 54 health-related journal field categories of ISI. These categories were 
re-classified by CREST into three broad fields: clinical health sciences, basic 
health sciences and public/community health sciences. Moreover, 35 journal 
field categories were classified within clinical health sciences, 12 within basic 
health sciences, and seven within public and community health sciences. 
Not all journals were uniquely classified within a broad health field because 
multiple journal categories per journal applied. For instance, a journal could 
be classified by ISI as covering both toxicology and genetics/heredity, which 
would result in this journal being placed within both clinical health sciences 
and basic health sciences. (For this reason, the number of articles produced 
within the three broad fields cannot be added to produce the total number 
of articles in the sphere of health.)
The CREST dataset contained a total of 16 365 articles in health-related areas 
produced by South African authors between 1996 and 2005. Table 6.1 gives 
the breakdown of articles per year.
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table 6.1: total number of health articles (cRESt 2008)
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Articles 1 208 1 415 1 447 1 574 1 877 1 778 1 758 1 864 1 790 1 654
article production in the health sciences in South africa
The overall output in all health science fields increased from 7519 papers in the 
period 1996 to 2000, to 8 843 in the period 2001 to 2005. Although the number 
of papers in clinical fields increased between 1996 and 2002, the production 
of journal articles in clinical fields declined after 2003. The number of articles in 
basic health sciences and public/community health sciences remained more 
or less stable over the whole ten-year period (Table 6.2; Figure 6.1). In terms 
of the share of articles, by broad field that respectively appeared in overseas 
ISI journals (ISI & non-SA), local ISI journals (ISI & SA) and local journals not in ISI 
(Non-ISI & SA), only 38.5% of articles were published in South African journals 
(Table 6.3).
Table 6.2: Share of health articles produced by broad field,  
1996–2000 and 2001–2005 compared
Fields
Number of articles
1996–2000 % of total of 7 519 2001–2005
% of total of 8 
843
Clinical health 
sciences
5 679 75.5 6 313 71.4
Basic health 
sciences
1 795 23.9 2 307 26.1
Public/community 
health sciences
1 258 16.7 1 434 16.2
total 7 519 -- 8 843 --
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Figure 6.1: trends in publication outputs in medicine, 1996–2005 
Local research in the basic health sciences was published almost exclusively 
in overseas ISI journals (100% in 1996–2000 and 97% in 2001–2005). The 3% of 
publications in local non-ISI journals in 2001–2005 all appeared in Current 
Allergy and Clinical Immunology, a journal of the Allergy Society of South 
Africa (ALLSA).
The share of articles in overseas ISI journals in the clinical health sciences has 
been growing. This was happening partially at the expense of articles in local 
ISI journals (falling from 20% to only 18% between 1996–2000 and 2001–2005) 
but more at the expense of articles in local non-ISI journals (falling from 24% 
to 20%).
In public/community health sciences, the share of articles in foreign ISI 
journals has also been increasing (from 41% in 1996–2000 to 56% in 2001–2005). 
Concomitantly, there was a decrease in the share of articles in local non-ISI 
journals between these two time periods.
The breakdown in terms of journal ‘index’ category for each of the 54 journal 
field categories (hereafter called sub-fields) revealed the following trends:
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Only in the fields of general & internal medicine and surgery did significant 
numbers of articles appear in local iSi journals (especially the South African 
Medical Journal and the South African Journal of Surgery) The shares of 
publications in these two journals remained constant between the two year-
periods being compared (55% versus 56%, and 17% versus 19%).
Six sub-fields were characterised by a relatively large share of publications 
(>40%) in local non-ISI journals (according to figures for 2001–2005). Three 
of these were clinical disciplines: dentistry (72%), cardiac & cardiovascular 
systems (46%) and ophthalmology (43%). The others were classified as public 
and community health disciplines: health care sciences & services (72%), 
rehabilitation (70%) and nursing (69%).
In terms of the average share of foreign and South african authors, each by 
broad field and individual sub-field, the field of basic health sciences had the 
largest average share of foreign co-authors (29% in 2001–2005), while clinical 
health sciences had a share of 17% (see Table 6.3). There was an increase in 
foreign co-authorships in all three categories between the first and second 
five-year periods. 
The following clinical fields reflected above-average foreign co-authorship: 
rheumatology (39%), haematology (38%), gastroenterology & hepatology 
(36%), oncology (33%), infectious diseases (32%), dermatology & venereal 
diseases (31%), peripheral vascular disease (30%), geriatrics & gerontology 
(29%), respiratory system (28%), emergency medicine (27%), allergy (26%), 
tropical medicine (26%), urology & nephrology (26%), medical informatics 
(26%), transplantation (25%), pharmacology & pharmacy (22%), psychiatry 
(21%), clinical neurology (21%), endocrinology & metabolism (21%) and 
obstetrics & gynaecology (19%).
Examination of the share of article authors who were female for the periods 
1996–2000 and 2001-2005 reveals that progress has been best in the public/
community health sciences (Table 6.3). In the public/community health 
sciences, 43% of the pool of researchers who published in 1996–2000 were 
female, and the figure increased to 48% during the period 2001–2005. The 
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share of female authors was somewhat lower in the clinical health sciences 
and the basic health sciences (33-36%), however.
Female authorship in all three main fields increased from 1996–2000 to 2001–
2005 but the percentage point increases were on average between 3 and 5 
points only.
The share of female authors in 2001–2005 was highest in three sub-fields of 
rehabilitation (75%), nursing (72%) and dermatology & venereal diseases 
(62%).
table 6.3: percentage of South african article authors who were 
female, by broad field – 1996-2000 and 2001–2005 
compared
Fields
1996–2000 2001–2005
total Sa 
authors 
of known 
gender
% female 
authors
total Sa 
authors 
of known 
gender
% female 
authors
Clinical health 
sciences 2 429 33.2 2 454 35.9
Basic health sciences 1 227 34.8 1 388 36.7
Public/community 
health sciences 824 43.0 857 48.4
total 3 056 35.7 3 253 38.5
Note: Tota ls  do not  add up because of  mul t ip le c lass i f icat ions of  journals 
in to journal  f ie ld.
In terms of the share of ‘black’ authors, by broad field and sub-field, the 
following observations were made (‘Black’ was taken here to include Africans, 
‘coloureds’ and persons with Indian origins) (Table 6.4):
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table 6.4: percentage of South african article authors who were 
‘black’, by broad field – 1996-2000 and 2001–2005 
compared
Fields
1996–2000 2001–2005
total Sa authors 
of known race
% ‘black’ 
authors
total Sa 
authors of 
known race
% ‘black’ 
authors
Clinical health 
sciences 2 097 14.8 2 171 17.5
Basic health 
sciences 1 094 14.2 1 286 17.9
Public/community 
health sciences 722 14.4 783 20.8
total 2 672 14.9 2 914 18.4
Note: Tota ls  do not  add up because of  mul t ip le c lass i f icat ions of  journals 
in to journal  f ie ld categor ies.
During the period 1996–2000 14% of all authors in all three broad fields were 
‘black’. ‘Black’ representation increased in all fields over the next five years, 
although more so in public/community health sciences (from 14% to 21%) 
than in clinical or basic health sciences (an increase from around 14% to 18%). 
The average of 18% across all health science fields was significantly higher 
than the average of about 10% for all sciences in South Africa during the 
same period.
The three sub-fields with the largest percentages of ‘black’ authors during the 
period 2001–2005 were rheumatology (42%), anatomy & morphology (35%) 
and integrative & complementary medicine (31%).
In the case of the preceding gender and race analyses, each author 
appeared only once in the pool of researchers during any year-period 
because a person’s gender and race status was taken to be ‘fixed’ – i.e. 
it could not change over time. In the case of an age analysis, however, a 
person’s age category could vary within the same year-period (e.g. someone 
could be both 38 and 41 during 1996–2000, thus falling in both the 30–39 and 
40–49 age categories in this period). Hence a different analysis was required 
to present the results in terms of the age of authors, that is, the share of article 
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equivalents (i.e. article fractions) produced by a particular age category over 
the two periods of comparison. 
There was thus clear evidence of an ageing publication workforce in all 
fields examined. For the period 2001–2006, a substantial 13% of all authors in 
clinical science fields were over the age of 60. Two fields in particular – neuro-
imaging (78% of authors in 2001–2005 older than 60%) and gastroenterology 
& hepatology (46% of authors in 2001–2005 older than 60%) – appear to 
be facing the biggest challenge in this area. Other fields in which more 
than 15% of the authors were older than 60 were: cardiac & cardiovascular 
systems, clinical neurology, dentistry, oral surgery & medicine, dermatology & 
venereal diseases, haematology, oncology, paediatrics, peripheral vascular 
disease, radiology, nuclear medicine & medical imaging, rheumatology and 
toxicology.
citation analysis of health research published in, and from,  
South africa
A number of bibliometric indicators of article output and citation impact were 
produced for this analysis by the centre for Science and technology Studies 
(cwtS) at the University of Leiden in Holland. It is important to emphasise that 
this analysis was done on all papers authored by at least one author with a 
South African address which appeared in one of the ISI citation indexes. This 
explains why the number of papers produced per field is not identical to the 
figures presented in Section 2 which also includes papers produced in South 
African (non-ISI) journals.
The overall production of ISI papers per field has increased: the number of 
papers in the vast majority of fields (33 fields) increased from the first period 
(1997–2001) to the second (2002–2006). The number of papers remained 
relatively stable in eight fields, whereas there was a decline in absolute 
number of papers in 13 fields.
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Journal and field-normalised citation scores
We now turn to the two most robust and useful indicators produced by 
the CWTS analysis. The so-called ‘crown’ indicator that the CWTS at Leiden 
University produces – the field-normalised citation rate, signifies that the 
papers in a particular field have generated above-average recognition and 
visibility compared to all articles published in that field in a particular period. 
The following 18 fields (exactly one third of the 54 fields analysed) recorded 
above-average field-normalised citation rates for the period 2002–2006 (in 
descending order):
Table 6.5: Above-average field-normalised citation rates for the 
period 2002–2006 (in descending order)
Sub-field Number of papers Field-normalised citation rates, 2002–2006
Allergy 17 2.66
Orthopaedics 31 1.84
Anaesthesiology 64 1.62
Oncology 144 1.61
Infectious diseases 331 1.29
Psychiatry 128 1.20
Medical informatics 3 1.20
Integrative & complementary 
medicine 19 1.19
Tropical medicine 81 1.15
Paediatrics 191 1.11
Respiratory system 145 1.11
Critical care medicine 47 1.11
Cardiac & cardiovascular 
systems 90 1.10
Rheumatology 55 1.07
Health care sciences & 
services 35 1.07
Health policy & services 28 1.12
Immunology 243 1.04
Haematology 70 1.02
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This is a very significant result, as in many of these cases these fields also 
improved their international visibility. Significantly, two of these fields are from 
public and community health, while none are from the basic health sciences 
and the remaining majority (16) are from the clinical health sciences. 
Although some of these fields are extremely small (measured by number of 
papers), fields which produced more than 100 papers with an above-average 
field-normalised citation rate can be regarded as fairly robust and very visible 
sub-fields. These are oncology, infectious diseases, psychiatry, paediatrics, 
pulmonology and immunology.
With regard to journal-normalised citation rates, some fields showed an 
improvement between the two citation windows. These 23 fields were (again 
in descending order):
table 6.6: Journal-normalised citation rates
Sub-field Journal-normalised citation rates, 2002–2006
Allergy 2.04
Oncology 2.08
Orthopaedics 1.67
Anaesthesiology 1.62
Geriatrics & gerontology 1.46
Health care sciences & services 1.35
Health policy & services 1.35
Respiratory system 1.34
Medical informatics 1.34
Immunology 1.29
Paediatrics 1.29
Haematology 1.22
Critical care medicine 1.21
Rheumatology 1.19
Obstetrics & gynaecology 1.16
Infectious diseases 1.15
Tropical medicine 1.14
Medicine, general & internal 1.11
Medical laboratory technology 1.10
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Sub-field Journal-normalised citation rates, 2002–2006
Integrative & complementary medicine 1.08
Dermatology & venereal diseases 1.06
Virology 1.06
Otorhinolaryngology 1.04
The results for the journal-normalised citation rates, although not as revealing 
as the profiles of the field-normalised rate, are still valuable as they signify that 
nearly half of the fields in clinical research have recorded above-average 
journal-normalised citation rates for the period 2002 to 2006, and improved 
their international visibility in this process.
CONCLUSION: CREATING A VIBRANT LOCAL CULTURE OF 
CLINICAL RESEARCH
The above investigation of publication patterns in clinical and related health 
science fields has confirmed the increasing tendency of South African 
clinical researchers to publish their best work in ‘international’ journals, and 
particularly in a wide variety of specialty journals. The total number of ‘clinical 
health sciences’ articles published worldwide from South Africa every year 
has recently begun to decline, and much of the authorship is provided by an 
ageing cohort of established researchers. The few remaining health sciences 
journals have understandably migrated to a varying mix of first-submission 
original articles, summarised ‘lectures’ relating to continuing professional 
education, popular reviews, practitioner-directed features, house journal 
functions, a plethora of advertising, and articles repeatedly refused elsewhere. 
First-submission reports of good clinical research do not fit into this design, and 
so the country’s productive clinical researchers live vicariously in the heavily 
North-oriented global system. what this says about the local culture is that it 
is fragmented by specialisation and is heavily overseas-orientated. Such a 
system is poorly positioned to inspire a new generation of younger clinical 
scientists unless the previously described ‘iceberg’ effect, reflecting a well-
functioning domain of intensive seminars, interdisciplinary collaboration, well-
organised local conferences and exciting graduate programmes is actually 
abridged  Clinical Research  Report 2009  | South africa
ACADEmY OF SCIENCE OF SOUTH AFRICA140
C H A P T E R  6
S C H O L A R LY  P U B L I S H I N G  A S  A  M E A N S  O F  M E A S U R I N G  A N D  P R O M O T I N G 
C L I N I C A L  R E S E A R C H
operative. This kind of infrastructural health is unlikely given the well-recorded 
pressures on clinical researchers caused by increases in service pressures, 
administrative burdens and teaching responsibilities (partly due to the shrinking 
participation of part-time specialists as bedside tutors). 
This report recommends elsewhere measures to address the optimisation of 
research training, development, multi-sector support and systemic policy 
change. In this section, only the topical issue of one or more local journals 
reporting original clinical research of high quality is raised.
We contend that a sufficiently large number of clinical research papers is 
produced every year to permit the operation of a local (or regional) journal 
dedicated to clinical research, if it is properly established, edited, supported 
and marketed, and is placed at the core of a reinvigorated clinical research 
community. 
The South African Medical Journal (SAMJ) has an outstanding record as 
an internationally recognised, high-impact, general medical journal. It has, 
however, deliberately re-positioned itself in recent years as a mixed-content 
journal in which peer-reviewed articles constitute only about 20–25% of the 
total contents, and these are restricted editorially to articles which directly 
address health problems or are practically useful to general medical or public 
health practitioners. This approach has retained the interest of its readership. 
The infrequently appearing ‘specialist daughter’ journal titles of the SAMJ do 
not feature anything like the cream of the country’s clinical research articles 
in their pages. 
The 2006 ASSAf Report on A Strategic Approach to Research Publishing in 
South Africa made a strong general case for the publication of indigenous, 
high-quality journals, showcasing local activity and contributions, fostering 
coherence of the local research community, supporting the training of a new 
generation of high-quality researchers, and providing ample opportunities for 
intellectual growth of local scholars as editors, peer reviewers and contributors 
(Gevers et al., 2006). Examples of successful (mostly open-access) journals in 
the clinical sciences can be found in India (e.g. Indian Journal of Medical 
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Research, MEDNOW), Brazil (Brazilian Journal of Medical and Biological 
Research), Mexico and China. 
It is thus possible that enhancement of clinical research in South Africa will 
not be possible without a ‘flagship journal’ published locally to the highest 
standards, promoting the coherence of the field, and visibly incentivising 
young researchers to develop to their fullest potential. The proposed journal 
could also sponsor annual research conferences, and be aligned with a 
national society for clinical research. The journal would need to seek indexing 
in the same international databases in which the SAMJ currently appears. 
In this way it would rapidly become an ‘international journal’ in the sense 
of promoting the reputations, rewards and funding opportunities of its 
published authors, while simultaneously enriching and enhancing the local 
clinical research community, especially its young members. Accreditation by 
the Department of Education in terms of its research outputs policy would 
automatically follow. 
It is therefore reasonable to propose that the South African Medical Association 
(SAMA) be urgently requested to explore the possibility of publishing a new, 
open-access journal/daughter journal dedicated to high-quality clinical 
research, across the sub-disciplines in the field (South African Journal of Clinical 
Research). Alternatively, such a journal could be started independently 
through a joint initiative of interested stakeholders.
Such a journal should appear at least bi-monthly, and be edited by a 
competitively appointed, part-time, contract Editor-in-Chief, assisted by an 
appointed team of part-time, contract Associate Editors (including foreign-
based clinical researchers of high standing), each responsible for particular 
selected sub-topic areas. The journal should maintain the highest possible 
standards, market itself energetically and professionally for article submissions 
and readership throughout Africa and the rest of the world, and contain 
added-value features such as editorial comment on key articles, authoritative 
reviews, scholarly correspondence, as well as accessible summaries and 
(English-language) formal abstracts of each article. Indexing in Thomson 
Reuters ISI, Medline and Google Scholar should be sought, and permission to 
authors to deposit their articles in institutional repositories granted.
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The leading role of multidisciplinary clinical journals such as the New England 
Journal of Medicine, The Lancet and the British Medical Journal show that 
readers and contributors active in sub-specialties are ready to share their 
best work in high-quality periodicals, and, in turn, it is these which enrich their 
perspectives, generate fruitful collaborations and inspire young entrants to 
the otherwise daunting, uphill world of clinical research. 
Multidisciplinary cohesion and synergy in the execution and reporting of 
high-quality research are also well-characterised features of successful 
departments and research units/centres/institutes. Extending this to larger 
contexts, in regional and even national concentrations of researchers, can 
be a highly effective way of increasing the productivity and impact of local 
teams, and of fostering a new generation of motivated and well-trained 
scholars. A modern journal that reflects the best thinking of the best clinical 
researchers, that is well-edited with sparkling enhancement features, and that 
becomes a regional flagship, is a prerequisite for such a vision.
FINDINGS
1. While South African scientific publishing represents a small fraction of world 
output, it comprises a large proportion of scientific research on the African 
continent. 
2. Clinical research has formed an important part of South Africa’s scientific 
output in terms of quality and quantity. 
3. Although the number of clinical medicine journal articles has declined 
since 2003, nearly half of the fields in clinical research have recorded 
above-average field-normalised and journal-normalised citation rates for 
the period 2002 to 2006. 
4. The trend has been towards increased publication of clinical medicine 
journal articles in international journals, and particularly in a wide variety of 
specialty journals.  
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4. Although more female and black authors have been publishing than 
before, progress has been slow and the proportion of older authors has 
been rising. 
RECOmmENDATIONS
1. Promote publication of high-quality clinical research in local, especially 
multidisciplinary journals.
2. Change institutional cultures to promote local publication, for example 
by recognising and rewarding publication in both local and international 
journals of high quality. 
3. Increase opportunities for local publication, for example through estab-
lishing vibrant supplements to existing journals and/or establishing a new, 
open-access, multidisciplinary journal for clinical research, possibly as a 
‘daughter’ of the existing flagship, the South African Medical Journal.
4. Create a national society for clinical research.
REFERENCES FOR CHAPTER 6
Clery, D. 1995. Elite science in a poor country. Science. 268: 1282-1286.
Garfield, E. 1955. Citation indexes to science: A new dimension in documentation through association 
of ideas. Science. 122: 108-111.
Gevers, W., Mati, X., Pouris, A., Page-Shipp, R. and Hammes, M. 2006. A Strategic Approach to 
Research Publishing in South Africa. Pretoria: Academy of Science of South Africa.
Gibbons, M., Limoges, C., Nowotny, H. et al. 1994. The New Production of Knowledge: The Dynamics 
of Science and Research in Contemporary Societies. London: Sage.
Jeenah, M. and Pouris, A. 2008. South African research in the context of Africa and globally. South 
African Journal of Science. 104: 351-354.
Moed, H. 2005. Citation analysis of scientific journals and journal impact measures. Current Science, 
89: 1990-1996.
Paraje, G., Sadana, R. and Karam, G. 2005. Increasing international gaps in health-related 
publications. Science. 308: 959-960.
abridged  Clinical Research  Report 2009  | South africa
ACADEmY OF SCIENCE OF SOUTH AFRICA144
C H A P T E R  6
S C H O L A R LY  P U B L I S H I N G  A S  A  M E A N S  O F  M E A S U R I N G  A N D  P R O M O T I N G 
C L I N I C A L  R E S E A R C H
Pienaar, E. D., Volmink, J., Zwarenstein, M. and Swingler, G. H. 2003. Randomised trials in the South 
African Medical Journal 1948-1997. South African Medical Journal. 92: 901-903.
Pouris, A. 2003. South Africa’s research publication record: The last ten years. South African Journal 
of Science. 99: 425-428.
Pouris, A. 2006. The international performance of the South African academic institutions: A citation 
assessment. Higher Education. 54: 501-509.
Roosendaal, H. and Geurts, P. 1997. Forces and functions in scientific communication: An analysis of 
their interplay. Paper presented at the Conference on Cooperative Research Information Systems 
in Physics, 31 August — 4 September 1997, Oldenburg, Germany. Available at: http://www.physik.
uni-oldenburg.de/conferences/crisp97/roosendaal.html. 
Tijssen, J. W. 2007. Africa’s contribution to the worldwide research literature: New analytical 
perspectives, trends, and performance indicators. Scientometrics. 71: 303-327.
C H A P T E R  7 :
EDUCATION AND SkILLS DEVELOPMENT – EQUIPPING 
CLINICIANS- IN-TRAINING TO EMBRACE CLINICAL RESEARCH
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in this chapter, we engage with the following questions:
1. How do we address the declining size and increasing age of the workforce 
actively engaged in clinical research?
2. How do we address the paucity of effective training programmes and 
unattractive career-pathing in the clinical research sector?
WHAT IS THE PROBLEm? DECLINING qUANTITY AND 
qUALITY OF RESEARCH OUTPUTS IN CLINICAL mEDICINE
An analysis of South African research outputs in clinical areas is presented in 
Chapter 6. What is directly relevant to this chapter is that there has been a 
decline in the contribution of the medical and health sciences from a 22% 
to a 20% share of overall South African production of ISI-indexed research 
articles (Department of Science and Technology, 2005), and an absolute fall 
in the number of papers in clinical medicine from 1 063 publications in 1987 to 
736 in 2001. South Africa’s share of the world’s ISI-listed publications in clinical 
medicine declined by 22 from 0.59% (1990–1994) to 0.46% (1996–2000) (Pouris, 
2003).
There are several factors that may be responsible for the falling number of 
outputs in clinical publications from South Africa. The two that are discussed 
below are (1) the shrinking size of the health-research workforce, and (2), 
the absence of effective training programmes and suitable career paths for 
clinical researchers in South africa.
SHRINKING SIZE AND AGEING OF THE SCIENCE RESEARCH 
WORKFORCE
Research and development surveys of the DST have shown that the size of 
the public research and development workforce has been declining steadily 
since the early 1990s; a decline in full-time equivalent researchers of more 
than 40% (from nearly 6 000 to 3 424) between 1990/91 and 2001/2, has been 
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documented, affecting both the higher education sector and the science 
councils (Department of Science and Technology, 2005). Furthermore, the 
phenomenon of ageing of publishing scientists in South Africa continues 
unabated: whereas 18% of all articles by South African scientists in 1990 were 
published by authors over the age of 50 years, this percentage increased to 
48% in 2002. Further analysis shows that these trends are not identical across 
scientific fields, but that the situation is worse for the medical and health 
sciences, possibly accounting for the reason for the decline in output (see 
Chapter 6).
ABSENCE OF A NATIONAL PLAN FOR THE EDUCATION, 
TRAINING AND EmPLOYmENT OF CLINICAL RESEARCHERS
There is no national plan for the education and training of clinical researchers 
in South Africa, despite its importance not only for the promotion of health 
in the South African public but also as a necessary catalyst of economic 
activity in one of the major missions of the government, the ‘farmer to pharma’ 
programme of developing the potential of indigenous remedies for worldwide 
application, and becoming a major globally important centre of clinical trials 
activity. 
The justifiably high priority given to primary health care in the national public 
health system has been allowed, inexplicably, to result in the weakening of 
academic hospitals and tertiary facilities in the public sector. This means small 
complements of professionals in specialist clinics, high service workloads, and 
poorly equipped facilities for diagnosis and treatment. At the same time, the 
withdrawal of any kind of support for research (as opposed to service) by 
provincial health administrations, the refusal of the National health laboratory 
Service (NhlS) to discount fees for research projects, and the under-funding 
of the MRc in respect of its resulting ‘sole mandate’ for research support in 
the clinical area, have amounted to a massive disinvestment by the state in 
clinical research activity. 
The above situation has been addressed in part by the recent decision to 
provide significant funds to health science faculties via the Department of 
Education (DoE) for clinical training at both undergraduate and postgraduate 
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levels (I. A. Bunting, DoE, Personal communication, 2008). In the 2007/08 to 
2009/10 national budgets, the National Treasury allocated funds for the first 
time to the DoE for the clinical training of health sciences professionals. The 
amounts involved were: 2007/08: R8 million to fund a review of clinical training 
in the health sciences; 2008/09: R200 million to support clinical training in 
universities; and 2009/10: R300 million to support clinical training in universities. 
In March 2007, the Director-General of the then Department of Education 
established a committee to undertake the review referred to above. This review 
committee had as chair the Deputy Director-General: Higher Education, and 
as members officials from the Departments of Education, Finance and Health, 
and representatives from the Health Sciences Professional Council and from 
Higher Education. The review committee was set four broad tasks: 
(1) to examine the current financial arrangements which hold between 
provincial health departments and higher education institutions;
(2) to investigate the clinical training needs of higher education institutions;
(3) to examine the current student-carrying capacity of health sciences 
faculties, and consider ways in which this capacity could be increased;
(4) to determine how the 2008/09 and 2009/10 allocations for clinical training 
should be distributed between universities.
The uses to which these allocations could be put included the appointment 
of additional clinical training staff and other staff to support the delivery of 
clinical training services, support of partnership agreements with public and/
or private providers of clinical training services, meeting operating costs of 
clinical training service delivery, and improving the infrastructure needed 
for clinical training, including equipment, building refurbishment, and the 
construction of new clinical training facilities. Allocations were provided when 
detailed spending plans had been submitted and approved. Progress reports 
were required.
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The mechanism distribution of the clinical training funds (R500 million in 
2008/09 and 2009/10) proposed by the official working group was based on 
a simple formula. All programmes which had clinical training requirements 
were included, mainly undergraduate degree programmes in medicine, 
dentistry,physiotherapy, occupational therapy, pharmacy, speech pathology, 
audiology, dietetics, dental therapy, as well as master’s-level specialist training 
programmes in medicine, surgery and dentistry. These degree programmes 
were assigned, for each year of study, a weighting which represented the 
proportion of the curriculum for that year devoted to clinical training. These 
weightings were applied to the 2006 head count student enrolment in the 
programmes which qualify for clinical training funding. (These head count 
enrolment totals had to be supported by a certificate from each institution’s 
external auditors). The weighted totals of undergraduate and postgraduate 
clinical training students were aggregated into a total for each institution, and 
ultimately a weighted national total. The allocation each institution received 
was then determined as:  
(institutional weighted total/national weighted total)*funds available.
It is evident that this highly significant intervention in clinical training, approved 
and funded in 2008, interfaces directly with the subject of clinical research 
training, and presents a model which could produce massive improvements 
in the quality and quantity of South African clinical research as advocated in 
this report. There is already a possibility that the funding of research/research 
training in the case of MMed candidates could be funded under the scheme 
as it is currently set up. 
DEGREE STRUCTURES PROmOTING RESEARCH TRAINING 
AND DEVELOPmENT
intercalated BSc degrees in medical sciences are available in most South 
African medical schools, and in the past have served to induct promising 
individuals into the research in this area. They have, however, been seen by 
most faculties as minor programmes for the gratification of the personal interest 
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of a small number of gifted students, and as rather costly, and certainly not 
as deliberately planned pathways to develop a new generation of research-
active clinicians (but see international example below). 
The BScMed honours programmes offered in various special directions by 
most health science faculties are generally open to medically qualified 
students, but the take-up has been very low in recent years, associated with 
the extensions of compulsory community service, high student indebtedness, 
and the lack of adequate bursaries at the level concerned. 
The Master of Medicine (MMed) degree is offered by the eight South African 
universities with programmes leading to the MB ChB degree and related 
postgraduate programmes. It is one of the pathways to registration as a 
specialist in South Africa, but serves mainly as a professional qualification – its 
relatively minor research component generally does not result in the initiation 
or production of high-quality research, nor is there frequently significant 
continuation of research activity after registration. In fact, several universities 
for many years tacitly registered students for the MMed degree only to allow 
them to complete their College examinations and default on completing 
the master’s degree (registered by the Department of Education as ‘drop 
outs’). The Health Professions Council of South Africa (HPCSA), the authority 
that sets the standards of training and requirements for registration of doctors, 
is proposing to make the completion of a research component a condition 
for registration of specialists in South Africa. This initiative offers an opportunity 
to turn the research component of the MMed degree into programmes to 
develop properly equipped clinical researchers, for example by combining 
them with honours work offered by the same institution and faculty. 
There is little incentive for clinicians to train in doctoral programmes, resulting 
in a very small number of the clinical professoriate having doctoral degrees. 
No equivalent of the MD/PhD programme which is so active in the US has yet 
been developed in South Africa into analogous MB ChB/PhD programmes (see 
below), where purist interpretations of both the standardised undergraduate 
curriculum and the ‘very senior’ PhD degree have conspired to make the 
pursuit of doctoral degrees specially ambitious and rare. Financial support 
packages at this level are also not readily available. 
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While the above situation in respect of formal postgraduate studies in clinical 
research provides many reasons for declining numbers of clinical researchers 
and declining outputs, it is likely that the problem begins much earlier, in the 
approach to the undergraduate phase of development.
STATUS OF CLINICAL TEACHING AT UNDERGRADUATE 
LEVEL 
Medical research is an integral part of medical education (Deo, 2008), 
hence the need to promote a research culture at undergraduate level. 
Universities in the US admit only postgraduates to clinical study, thus ensuring 
that a wide range of majors already completed serve as the foundation of 
a research system able to capitalise on the same diversity of developed 
skills (in this country, only the University of the Witwatersrand offers this kind of 
curricular organisation). Most South African universities offer undergraduate 
medical programmes that in recent years have been significantly modified 
and broadened in line with the premises of ‘primary health care’. This has 
had both good and bad effects, seen from the point of view specifically of 
clinical research capacity – on the one hand, the student-centredness of the 
curriculum has fostered independent thought and personal development, 
on the other, grounding in formal ‘preclinical’ scientific disciplines has been 
diluted and weakened.
Despite these changes in undergraduate curricula, most faculties have 
programmes that sensitise undergraduate students to the concept of 
evidence-based medicine and research. As an example, at one university, 
medical students in their third and fourth years are exposed to various aspects 
of research through lectures and theme sessions, looking at different types 
of studies, research methods, study designs, systematic reviews and meta-
analysis, during a total of 15 two-hour sessions and 11 two-hour sessions, 
respectively. The students also undergo formal teaching in research protocols, 
methodology, questionnaire design, statistics and data analysis in their fifth 
year, with a contact time of over eight hours. There are also research days (a 
total of five complete days per year) where students in groups draft a protocol 
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and carry out empirical research after its approval. The research project 
contributes to 35% of the year mark for the students’ integrated block.
At the University of Cape Town, there is a compulsory four-week long supervised 
special study module (SSM). During this period, students choose from about 
100 research topics provided by the Department of Medicine. They have no 
other course commitments during this time, hence the four weeks are devoted 
to various research activities including literature reviews, actual conduct of a 
study and audits. It is mandatory that students are successful (pass) in this 
component prior to progressing to the next semester. 
At the University of Pretoria, ethics training forms part of the ‘Golden Threads’ 
of the curriculum, and is addressed in all of the six years of study, culminating 
in an ‘Ethics Breakaway’ in the final year, with mandatory attendance. 
Clinical research is promoted in all years, and even in Year 2 students do small 
collaborative research projects to be presented to the class. Clinical trials are 
addressed in all clinical blocks as ‘Evidence-Based Medicine’ (another ‘Golden 
Thread’ of the curriculum). Drug trials are mentioned but less thoroughly 
addressed. Specific matters, including scientific misconduct, are addressed 
during many blocks and in particular during a special activity comprising six to 
10 teaching hours in the block called ‘Evidence-Based Medicine’.
At the University of the Witwatersrand, medical students in the third and fourth 
years of study are exposed to various aspects of research through lectures 
and theme sessions. During these guided sessions, they review published 
articles, and look at different types of studies, research methods, study 
designs, systematic reviews and meta-analyses. In 2008, third-year students 
had a total of 15 two-hour sessions and fourth-year students had a total of 
11 two-hour sessions specific to research. These students further underwent 
formal teaching in research protocols, methodology, questionnaire design, 
statistics and data analysis in their fifth year of study. In 2008, the total contact 
time for the fifth-year students was 8,5 hours. Furthermore, there are research 
days (a total of five complete days per year) where students in groups draft 
a protocol to conduct an empirical research project after approval of the 
protocol. This research project contributes to 35% of the year mark for the 
students’ integrated block.
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SUPPORT STRUCTURES FOR RESEARCH WITHIN INSTITUTIONS
Research flourishes in an environment that is conducive for research. 
Inspirational visions and missions aid in fostering a culture among students that 
reflects the ethos identified in the visions and missions. Research management 
at institutions of higher learning has an impact on the volume and quality 
of research output. Early-career researchers (young researchers) need a 
nurturing environment and a system of support in the early stages of their 
career. 
A web-based survey of South african universities with medical schools was 
conducted to identify components that foster a rich research environment, 
and structures that promote and support research at these institutions. 
Special attention was given to (i) whether research was mentioned in their 
mission and vision statements, (ii) the existence of a research strategic plan, 
(ii) existence of a research office that offers various services such as research 
grants facilitation, monitoring and assisting young researchers, and (iv) the 
existence of information on research that is easily accessible to researchers, 
e.g. research links on the websites. 
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Research 
mentioned in the 
vision statement
Research 
mentioned  
in the mission 
statement
Existence of 
a research 
strategic  
plan
Existence of 
a research 
office
Research 
website  
link
Free State 
university
Research  
not mentioned 
in the vision 
statement
“The pursuit of 
scholarship as 
embodied in 
the creation, 
integration, 
application and 
transmission of 
knowledge by 
promoting the 
following within the  
ambit of financial 
sustainability: 
Pure and applied 
research”
A Strategic 
Framework for 
the Develop- 
ment of 
Research at 
the University 
of the Free  
State (2003) 
Exists as: 
Research 
Develop-
ment 
Directorate
Available 
at: http://
www uovs.
ac.za
Medunsa 
university
Not available on 
the website
“A world-class 
African university 
which responds 
to education, 
research and 
community 
development 
needs through 
partnerships 
and knowledge 
generation – 
continuing the long 
tradition  
of empowerment”
Not available 
on the 
website
Exists: 
Research 
Admin-
istration 
Office
Available 
at: http://
www.
medunsa.
ac.za/
research/
welcome.
htm
Stellenbosch 
university
“In a spirit of 
academic 
freedom and 
of the universal 
quest for truth 
and knowledge, 
the University as 
an academic 
institution sets 
itself the aim, 
through critical 
and rational 
thought, 
of gaining 
national and 
international 
standing by 
means of 
its research 
outputs”
Research not 
mentioned in the 
mission statement
Research 
strategy 
contained 
in the 
university’s 
Strategic 
Framework for 
the Turn of the 
Century and 
Beyond (2000)
Research 
Develop-
ment and 
Support 
Division
Available 
at: http://
www.sun.
ac.za
table 7.1: website survey of research support structures in South 
african universities with medical schools
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Research 
mentioned in the 
vision statement
Research 
mentioned  
in the mission 
statement
Existence of 
a research 
strategic  
plan
Existence of 
a research 
office
Research 
website  
link
university of 
cape town
Research not 
mentioned 
in the vision 
statement
“Our mission is to 
be an outstanding 
teaching and 
research university, 
educating for life 
and addressing the 
challenges facing 
our society.
Educating for 
life means that 
our educational 
process must 
provide: research-
based teaching 
and learning”
University of 
Cape Town 
Research 
Strategy
Research 
office exists 
under The 
Department 
of Research 
and 
Innovation
Available 
at: http://
www.
uct.ac.za/
research/
libraries
university 
of KwaZulu-
Natal
Research not 
mentioned in 
the university’s 
vision statement 
but mentioned 
in the faculty of 
health sciences 
vision statement 
(Strategic Plan 
2008)
“A truly 
South African 
university that is 
academically 
excellent, 
innovative in 
research, critically 
engaged with 
society and 
demographically 
representative, 
redressing the 
disadvantages, 
inequities and 
imbalances of the 
past”
Research 
Policy II: 
Developing, 
Retaining and 
Rewarding 
Researchers 
(2008) and 
Strategic 
Plan - Faculty 
of Health 
Sciences 
(2008)
Exists: 
Research 
Office
Available 
at: http://
www.
research.
ukzn.ac.za
university of 
pretoria
Research not 
mentioned 
in the vision 
statement
“The mission of 
the University of 
Pretoria is to be 
an internationally 
recognised South 
African teaching 
and research 
university and a 
member of the 
international 
community of 
scholarly institutions 
that: encourages 
academically 
rigorous and 
socially meaningful 
research, 
particularly in 
fields relevant 
to emerging 
economies”
Exists as one 
of the thrust 
areas in the 
Innovation 
Generation: 
Creating the 
Future, 2007-
2011 Strategic 
Plan
Research 
Office in the 
Department 
of Research 
Support
Available 
at: http://
www.web.
up.ac.za
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Research 
mentioned in the 
vision statement
Research 
mentioned  
in the mission 
statement
Existence of 
a research 
strategic  
plan
Existence of 
a research 
office
Research 
website  
link
university 
of the wit-
watersrand
“Universities 
have the 
immense 
responsibility 
of producing 
cutting edge 
research…”
“We will build 
increasingly 
close 
relationships 
with the private 
sector, and the 
public sector 
professions 
in seeking 
sponsorship 
of research 
projects, 
research 
students, joint 
appointments of 
staff, and joint 
programmes of 
research that  
contribute to 
economic  
and academic 
development.”
“Wits’ mission is 
to build on this 
foundation in a 
way that takes 
account of its 
responsibilities 
within South 
Africa today; 
and to maintain 
and enhance 
its position as a 
leading university 
in the Republic, 
in Africa, and 
in the world by 
sustaining globally 
competitive 
standards of 
excellence in 
learning, teaching 
and research.”
University of 
the Witwaters-
rand Strategic 
Research Plan 
2007 to 2011
Exists: 
Research 
Office
Available 
at: http://
www.web.
wits.ac.
za/
Academic 
/Research
walter Sisulu 
university
“Walter Sisulu 
University 
(WSU) will be a 
leading African 
comprehensive 
university 
focusing on 
innovative 
educational, 
research and 
community 
partnership 
programmes 
that are 
responsive to 
local, regional, 
national 
development 
priorities, and 
cognisant of 
continental and 
international 
imperatives.”
“In pursuit of 
its vision as a 
developmental 
university, WSU 
will: maintain the 
highest possible 
standards in 
innovative 
teaching and 
learnerships, 
basic and 
applied research, 
community 
development 
partnerships in 
cooperation with 
development 
agencies, the 
public and private 
sectors …”
Not available 
on the 
website
Not 
mentioned 
on the 
website
Not 
available 
on the 
website
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While research is mentioned in only three of the vision statements of eight 
universities, it has been identified as an important mission in all but one of the 
universities. Six of the eight universities either had a strategic plan specifically 
for research, or research was enshrined in the strategic plan available on their 
respective websites. 
RESEARCH ETHICS TRAINING IN SOUTH AFRICA
There are a number of institutional research ethics training programmes in the 
country for both researchers and research ethics committee members.
South Africa has two Fogarty-funded programmes: International Research 
Ethics Network for Southern Africa (IRENSA) based in Cape Town and the 
South African Research Ethics Initiative (SARETI), a collaboration between the 
Universities of Pretoria and KwaZulu-Natal. The University of the Witwatersrand 
runs a master’s programme in Bioethics and Health Law, which includes an 
elective unit in research ethics. Several institutions conduct short workshop-
style courses in ethics in research. In addition, the University of Stellenbosch 
has recently developed an online programme for advanced Good Clinical 
Practice (GCP) training in research.
These programmes and courses contribute significantly to capacity building in 
ethics in research in the country, and multidisciplinary expertise and leadership 
in research ethics and bioethics is being developed. An objective of most 
programmes is the building of capacity for ethical review of health research 
and strengthening of institutional training capacity necessary to achieve this. 
INTERNATIONAL POLICY AND PLANNING INITIATIVES THAT 
SEEK TO ADDRESS THE PROBLEm 
Two examples of programmes in clinical medicine in other countries that are 
designed to produce clinical researchers as their major outcome are worth 
considering at this point: (a) intercalated degrees in the UK system, and (b) 
the MD/PhD programmes in many US universities.
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intercalated degrees in the uK medical schools
As opposed to the tiny proportion of South African medical students who choose 
this option, about one third of medical students in the UK add an additional 
year to the basic five-year undergraduate course and intercalate a degree in 
medical science (a BSc or BMedSci) (McManus et al., 1999). The UK Medical 
Research Council has concluded that the intercalated degree is extremely 
valuable in introducing future clinicians to research, and in providing a cadre 
of graduates who are likely to become attracted to, and excel in, a career in 
academic medicine (Smith, 1986). A longitudinal study of final-year medical 
students who had taken intercalated degrees has provided evidence that 
they were more interested in medical research than their comparators, and 
had better ‘deep and strategic style’ scores. The effects of the intercalated 
degree were greatest in medical schools where a relatively small proportion 
of students took the degree; differences between medical schools are most 
easily explained by resource dilution (McManus et al., 1999). 
The barriers to expansion of intercalated years in the South African situation 
are financial (additional costs to both funders/sponsors and families), social 
(cohort cohesion), and academic (extra costs of intense supervision in scientific 
disciplines). These barriers could obviously be lowered if prioritised plans were 
carefully developed and adapted to local conditions. For example, exemption 
from one year of compulsory community service on successful completion of 
an intercalated degree would have little effect on national health person 
power but a big effect on research capacity development.
Among the systemic enablers of researcher development, two deserve special 
mention. The first, discussed in Chapter 6 with a firm proposal for remediation, 
is the existence of a high-quality local journal for clinical research which is 
multidisciplinary and so designed that it encourages broad reading and ‘lateral’ 
learning amongst most or all people who are active in research in the country, 
young or established. The second is concentration on local conferences to 
make them hothouses for presentation skills, networking, collaborations and 
generally ‘getting the hang of it’. Again, multidisciplinary conferences are 
important even though ‘deep-focused’ workshops and conferences can also 
be valuable when participative attendance is encouraged and skill-enabling 
objectives are built into the design of their programmes. 
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Md/phd programmes in uS and uK universities – a high-powered 
model for the development of a medical research workforce
Joint Md/phd programmes are offered at nearly every US medical school in a 
wide range of fields. Many MD/PhD programmes receive institutional support 
through the Medical Scientist Training Program (MSTP) of the National Institute 
for General Medical Sciences of the National Institutes of Health (NIH). The 
primary intent of these joint MD/PhD degree programmes is to produce highly 
trained physician-scientists who will engage in biomedical science research 
careers. 
A report of the MSTP cohorts enrolled between 1970 and 1990 revealed that 
MSTP graduates were more likely than other medical school graduates to 
receive postdoctoral fellowships, to hold academic appointments, to receive 
external research funds, to apply for NIH grants, and to have published more 
than their MD counterparts (Rosenberg, 2008).
It is worth noting that Cambridge and other universities in the UK now also 
offer the equivalent degree of MB/PhD, which may be more suited to our 
medical curriculum which is based on the British model. The Cambridge 
website describes the degree as follows:
The MB/PhD Programme leads to the MB, BChir  and PhD degrees and is 
des igned for medical  s tudents who are in teres ted in academic or research 
careers by enabl ing them to in tegrate a three -year per iod of research wi th 
thei r  c l in ical  educat ion.
The c l in ical  component  of  the cur r icu lum is  des igned to equip s tudents 
for  a l i fe t ime of medical  pract ice in a changing wor ld wi th emphasis on 
the acquis i t ion of  c l in ical  sk i l l s  by di rec t  pat ien t  contact .  At  the s tar t  o f 
the programme, s tudents fo l low the Standard Course Stage 1 cur r icu lum 
up to and inc luding the Stage 1 s tudent - se lec ted component.  Fo l lowing 
a c l in ical  academic module and subjec t  to sat i s fac tor y progress,  th is  i s 
fo l lowed by a three -year per iod of fu l l - t ime research combined wi th th ree 
hours a week of  c l in ical  educat ion. I t  concludes wi th s tudents re join ing 
the c l in ical  course to comple te thei r  s tudies wi th e i ther the Standard or 
Cambridge Graduate courses, depending upon the t ime of comple t ion of 
the PhD.
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As in the case of intercalated degrees, a national MB chB/phd programme 
would have to be adequately resourced and adapted to local conditions. The 
many BScMed honours programmes already available could readily become 
‘qualifying courses’ for concurrent and subsequent hands-on research leading 
to PhD degrees – this effectively spreads the load of development work 
between non-clinical and clinical staff, and establishes sustained networks of 
personal support and encouragement amongst both ex-students and their 
teachers. 
Experience in certain countries, notably the UK, has indicated that concurrent 
MB ChB and PhD/M studies can cause some students to ‘fall between 
two stools’, and it is probably necessary in each instance to ensure that 
mentoring takes place to avoid such situations. A flexible approach to career 
development is absolutely necessary in relation to the challenging issues 
confronting individual students/trainees.
LOCAL POLICY AND PLANNING INITIATIVES THAT SEEK TO 
ADDRESS THE PROBLEm
department of health: the National human Resources plan for health 
of 2006
The National Human Resources Plan for Health that was launched by the 
National Department of Health in 2006 recognises the general shortage of 
health professionals in South Africa, and has identified a number of priority 
areas for implementation. The plan calls for the establishment of a Health 
Sciences Academic Development Programme that is spearheaded at the 
national level and implemented at the institutional level to:
1. Develop health sciences educators; 
2. Recruit and increase the pool of health sciences academics;
3. Promote research;
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4. Bring about demographic transformation of the academic leadership 
cadre and specialists in the country. 
The next step in this process is intended to be the development of a strategy 
and associated implementation process, which may be assisted by the 
present report.
the colleges of Medicine of South africa project – 2007
The Colleges of Medicine of South Africa (CMSA) convened a policy Forum 
on tertiary academic Medicine and Specialist training on 24–25 October 
2007 and again on 1–2 December 2008. The aim of the Forum was to bring 
together leaders, policy-makers, decision makers and stakeholders to discuss 
strategic issues with regard to tertiary academic medicine and specialist 
training in South Africa. The output from the event was an agreement to 
continue to create a forum for discussion and debate on issues relevant to 
academic medicine and specialist training; a memorandum was sent to 
relevant government departments informing them of the CMSA initiative to 
improve specialist and sub-specialist training. 
department of Science and technology’s ten-year innovation plan – 
2008
The purpose of the dSt’s ten-Year innovation plan, which was published in 
2008, is to develop a knowledge-based economy in which the production 
and dissemination of knowledge leads to economic benefits and enriches all 
fields of human endeavour. The Plan identifies four pillars for progress: 
1. Human capital development; 
2. Knowledge generation and exploitation (R&D); 
3. Knowledge infrastructure; 
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4. Enablers to address the ‘innovation chasm’ between research results and 
socioeconomic outcomes. 
One of the five grand challenges to act as the substrate for research and 
development is the ‘Farmer to pharma’ value chain to strengthen the bio-
economy. Over the next decade, South Africa is urged to become a world 
leader in biotechnology and pharmaceuticals, based on the country’s 
unique indigenous resources. To succeed in this area, South Africa will need 
to produce an expanded pool of appropriately trained clinical researchers. 
Indeed, the ten-year plan recognises that a significant strengthening of the 
production of human capital and improvement of the institutional environment 
for knowledge generation is necessary to achieve its goals.
The targets for this human capital development programme over the next 10 
years are as follows:
1. Five hundred Research Chairs by 2018 (70 in place by 2008);
2. About 6 000 PhDs produced per year in all science, engineering and 
technology disciplines by 2018 (currently 600 per year are produced).
FINDINGS
1. The clinical research force is ageing and has also been steadily declining 
in numbers since the early 1990s.
2. The combined burden of clinical teaching and training, health service, 
and research thus falls on a shrinking and ageing pool of academics in 
health science faculties.
3. This means that there is limited capacity to increase the production 
of properly trained health care workers and to train and inspire a new 
generation of clinical researchers. 
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4. Simultaneously, the situation has brought about an inability to cope 
with the increasing demands of clinical service imposed by the colliding 
epidemics of infectious disease (TB and HIV/AIDS) and non-communicable 
disease (heart disease and stroke).
5. A national plan involving the spending over three years of half-a-billion 
rand has recently been implemented to enhance clinical training at all 
levels in South African higher education institutions
6. There is, by contrast, currently no national plan to provide coordinated 
support for the training and development of clinical researchers, and grossly 
insufficient support for research professorships and training fellowships in 
the clinical research field.
7. There is little incentive for clinicians to train in doctoral programmes, 
resulting in a very small number of the clinical professoriate having doctoral 
degrees. 
8. There are a number of institutional research ethics training programmes 
in the country for both researchers and research ethics committee 
members. 
9. The National Human Resources Plan for Health that was launched by the 
National Department of Health in 2006 recognises the general shortage of 
health professionals in South Africa, and has identified a number of priority 
areas for implementation.
10. The Colleges of Medicine of South Africa (CMSA) has a Policy Forum on 
Tertiary Academic Medicine and Specialist Training.
11. The DST’s Ten-Year Innovation Plan aims to develop a knowledge-based 
economy in which the production and dissemination of knowledge leads 
to economic benefits and enriches all fields of human endeavour.
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RECOmmENDATIONS
1. create a national plan for research capacity development in clinical 
sciences (a ‘National Clinical Scholars Programme’) for undergraduate 
and postgraduate students, and junior and senior faculty in clinical 
research, based on the idea of the PhD as the key driver for progress in 
this area, as part of the human capital generation project of the DST’s Ten-
Year National Plan for Innovation. Also create a publicly funded training 
programme for the production of a clinician research workforce from the 
top 2% of undergraduates (through student research fellowships) and 20% 
of postgraduates (through clinical research fellowships). A target should 
be set for 500 PhDs to be produced in the clinical research field over 
the next 10 years, while 30 Research Chairs should be earmarked for the 
clinical sciences. The objectives of the proposed National Clinical Scholars 
Programme may be achieved through:
a. Expansion of the intercalated research year model of selective training 
of motivated undergraduates in carefully planned curricula designed to 
establish a life-long interest in research;
b. Re-design of the MMed research component to enhance its effectiveness 
in research training and competence, and to serve as the basis for Md/
phd study;
c. Stimulating phd degrees for professional graduates through the widening 
of the necessary opportunity and support mechanisms, including the 
use of modules and learning methodologies from BScMed honours 
programmes;
d. Providing a maximum of flexibility in funding possibilities and degree 
structures, including bursaries and fellowships that are adequate to retain 
promising people on their training trajectories.
2. create a clinical academic career track in all disciplines in the academic 
health complexes under the Health Sciences Academic Development 
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Programme of the national Department of Health (SA Department of 
Health 2006). A new cadre of clinical lectureships and clinical professorships 
needs to be established in all clinical disciplines to rejuvenate and expand 
the pool of clinical research trainers and academic clinicians in general.
3. Promote training for biostatisticians and other supporting professions for 
clinical research at universities.
4. Incorporate ethics into clinical research training and education.
5. Fund learnerships for graduates in the research facilities of large multi-
national and national companies.
6. Develop and support a network of skilled mentors who can lead the 
development of young clinical researchers.
7. create a ‘National clinical Research coordinating centre’ at the MRc to link 
and coordinate clinical research centres and clinical trials programmes at 
universities and research councils, and in government and industry. Such a 
network would foster collaborative research efforts, training programmes 
and research projects aimed at strengthening patient-orientated research 
(Rosenberg, 1999). The Centre should be given a maximum degree of 
operational independence while retaining overall accountability. It 
should seek to increase the participation of foundations, pharmaceutical 
companies, health insurance firms and the managed care industry in the 
clinical training enterprise.
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C H A P T E R  8 :
FUNDING FOR LOCAL INVESTIGATOR- INITIATED CLINICAL 
RESEARCH SHOULD BE INCREASED AND BETTER 
COORDINATED
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in this chapter, we engage with the following questions:
1. How much should developing countries spend on medical, and specifically 
clinical research?
2. How much does the South African government spend on research and 
development, and of this, how much is spent on medical, and specifically 
clinical research?
3. How are funding priorities determined?
4. Through which institutions is government funding allocated?
5. What are the other sources of funding?
INTRODUCTION
The cSiR became the major systematic source of research funding at South 
African universities before handing over its role of funding medical research 
and managing its national research units to the newly established Medical 
Research council (MRc) in 1969 (Brink, 1987). The successor to the CSIR in 
funding non-medical research, the Foundation for Research Development 
(FRD), functioning by statute in purely agency mode (it had no intramural 
research programme), was generally nervous about the dividing line between 
its mandate and that of the MRC, and provided very limited support to a 
number of basic scientists in the medical schools, as well as bursary support to a 
limited number of health science postgraduates. The MRC, by contrast, set up 
a progressively increasing intramural research programme, while supporting 
medical research at universities in agency mode, through joint research units 
and centres, self-initiated research grants to individuals, and an extensive 
bursary and capacity development system. It has consistently been generally 
recognised that the MRC, partly as a result of its ‘late arrival’ in the science 
council system and partly because of difficulties in articulating itself through 
the Department of Health, remains the ‘Cinderella’ of the annual science 
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vote (this limitation has turned out to be a crucial issue in later developments 
described below). 
A good indication of the inadequacy of MRC funding levels can be obtained 
from our preliminary examination of the allocations in 2007/08 for health 
research at universities. Only about R12 million for operational costs was 
awarded to about 40 applicants/recipients for self-initiated health-related 
research throughout the country, of which only R4 million (about 30%) 
appeared to be destined for clinical research as defined in this report. The 
support for research units and centres based at universities was significantly 
greater, with the operational costs covered for about 25 such recognised 
enterprises, amounting to about R25 million. Of this, only about R5 million 
appeared to be destined for clinical research as defined in this report. The 
amounts for salaries at units and centres were approximately three times the 
operational grants, so the total investment in clinical research outside the 
MRC’s intramural programme was about R4 million plus (R5 million X 4 = R20 
million), or just under R25 million. It is not surprising that virtually all the MRC’s 
research units and centres based at universities obtained the majority of their 
funding from non-MRC sources, notably foreign foundations and government 
agencies, local and international drug manufacturers, and other South African 
funding agencies such as the NRF and the National Cancer Association of 
South Africa. 
the MRc’s intramural research programme has been extremely successful 
in tapping external contract funding, estimated at between R250 and R300 
million per annum in 2007/08 (SA Medical Research Council Annual Report, 
2008). The clinical research component appears to be quite extensive, almost 
entirely in the clinical trials area. Operational grants from the MRC to its own 
units is about R10 million, of which only about R2 million appears to be destined 
for clinical research. With salary components running at about five to ten times 
the operational grants in these intramural enterprises, the total investment in 
their clinical research by the MRC itself is about R10 to R20 million per annum. 
The total MRC awards for clinical research in 2007/08 were thus somewhere 
between R35 million and R45 million. It should be noted that additional 
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(unquantifiable) investments were made in the form of bursaries and career 
development awards, but these are unlikely to exceed R5 million. 
The MRC has no policy prohibiting awards for patient-related costs (e.g. 
hospital beds) or fee-for-service laboratory tests, but limits its awards to R130 
000 for self-initiated research projects due to a shortage of funds. We have 
ascertained that very few applications currently include budgets for patient-
related costs, as though the research community concerned has tacitly 
‘written off’ the MRC as a source of funding in this domain of their budget 
planning. Alternatively, projects involving such expenditures are avoided. 
In either case, the information confirms that the funding gap left for clinical 
research in South Africa by the structural developments to be described 
below, has not been, and presently cannot be, filled by the MRC. 
The provincial governments, during the period roughly between 1955 and 
1980, contributed significantly to the promotion of clinical research through 
their academic hospitals, but to varying extents, depending on the nature of 
their partnership agreements with local universities. An important component 
was the pathology service rendered to academic hospitals, including tests 
done for clinical research purposes. In Cape Town, the partnership centred 
on UCT, and the Cape Provincial Administration was sufficiently successful to 
establish Groote Schuur Hospital as the third-most productive South African 
institutional contributor to top-ranked international publications indexed by 
the ISI in Philadelphia (see Chapter 6), after UCT itself and the University of the 
Witwatersrand (Clery, 1995). 
A number of factors began to perturb these arrangements from the beginning 
of the 1980s. The rapidly declining economic situation of the late-apartheid 
era caused provincial health budgets to come under pressure, with the 
appearance for the first time of ‘service-only’ expenditure principles in hospital 
budgets. The MRC was unable to make up the shortfall; international funding 
sank to a very low level.
The coming of full democracy in 1994 was heralded by new health policies 
aimed at creating a system of primary health care for all, and using research 
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mainly to drive its attainment. Thus In 1994, South Africa formally adopted the 
Essential National health Research (ENhR) approach in order to focus health 
research on issues relevant to the country. In 1996, the first ENHR congress 
established a list of priority health problems and identified urgent research 
questions. Follow-up conferences were held in 2002 and 2006 to review these 
priorities. HIV/AIDS, injury, TB, infectious diarrhoea and perinatal problems were 
identified as the top five problems (Lutge et al., 2008). A formal national health 
research policy document, published in 2001, proposed that 2% of health 
expenditure should be spent on well-coordinated research (SA Department 
of Health, 2001). 
The Foundation for Research and Development (FRD), by statutory merger 
with the Centre for Research Development of the human Sciences Research 
council (hSRc), became the National Research Foundation (NRF) in 2000, with 
a broad mandate to foster and develop research capacity in South Africa. 
It has become by far the most powerful and significant research funding 
agency in the country, central to the plans of the increasingly influential dSt to 
raise government investment in R&D. the NRF has successively acted as the 
agent for the innovation Fund, the Scarce Skills Fund, a system of centres of 
Excellence, the South african Research chairs initiative, a National Equipment 
plan, national large-scale facilities of various kinds, the South african agency 
for Science and technology advancement (SaaSta), and so on (Sa National 
Research Foundation annual Report, 2008). the MRc, by contrast, has had 
little or no share in these investments, despite significant growth in its contract 
income and impressive outputs in the form of publications emanating from 
intramural research programmes (SA Medical Research Council Annual 
Report, 2008). 
A further issue in recent times has been the establishment of the National 
health laboratory Service (NhlS) as essentially a ‘nationalised’ form of the 
previous university/academic hospital pathology departments. The NHLS has 
not seen fit to offer clinical researchers any discounts for tests performed for 
research purposes, and pursues a break-even, even profit-making business 
policy instead, with surpluses held in reserve or kept in a ‘research fund’ (SA 
National Health Laboratory Service Annual Report, 2008).
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The seriousness of the twin pandemics of HIV and TB in South Africa has 
focused international attention on the need for local research activity in 
these areas, often collaboratively with outstanding centres overseas. This 
has brought with it an influx of very large grants, from agencies such as the 
NIH and the Howard Hughes Medical Institute in the US, the Wellcome Trust 
in the UK, and the European Commission in the EU. Many of these grants are 
not sustainable, some of them are administered in a mode that amounts to 
externally supervised work, and no national model for the future of clinical 
research in South Africa can be built on them. 
the aggregate and cumulative effects of the above-mentioned systemic 
developments in the health research sector have been very burdensome 
for clinical researchers, and pose a serious threat to the future of clinical 
research generally. they amount to a structural disinvestment and a failure so 
far to recognise the nature of the problem, and to design solutions that do not 
require reversal of sound policies in other areas of the health system. 
The Department of Health policy document mentioned above emphasised 
the need for research to be better coordinated and regulated, and for 
funding resources be allocated to national health priorities based on equity 
and social justice (SA Department of Health, 2001). The ENHR term was coined 
to emphasise the importance of setting national research priorities, but two 
decades later much of the vision of the Commission on Health Research 
for Development, which included the intent to invest at least 2% of national 
health expenditure in research, has yet to be fulfilled. At the November 2008 
Bamako Global Ministerial Forum on Research for Health, numerous critics 
suggested that several key African countries have done ‘very little’ to invest 
in health research since pledging to do so at a world meeting of health and 
science ministers in Mexico four years earlier (Report of Commission on Health 
Research for Development, 1990). 
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Globally and locally a number of factors were identified that have had a 
negative impact on clinical research in general. These include:
1. Lack of appropriate facilities and infrastructure to undertake patient-
orientated clinical research;
2. Lack of appropriately trained clinical scientists and career structures to 
support them;
3. Lack of coordination of research policy and management;
4. Inadequate support from governmental health authorities; 
5. Increasingly complex legal and ethical governance;
6. Inadequate funding;
7. Domination of the basic sciences over the clinical sciences.
These factors have contributed to two translational blocks, firstly the translation 
of basic science discoveries into clinical research, and secondly the translation 
of the results of clinical research into public health policy and practice. 
GOVERNMENT EXPENDITURE ON RESEARCH AND 
DEVELOPmENT
The annual OECD-type survey by the HSRC found that South Africa spent at 
least R16.5 billion, or 0.92% of its GDP, on research and development (R&D) 
over the 2006/07 financial year, an indication that the country is progressing 
towards being a knowledge-based economy (SA Department of Science 
and Technology press release, 30 May 2008). The major source of R&D funds 
was from industry (49%), followed by government (33%), other sources (10%), 
and from abroad (7%). The intensity of R&D expenditure (measured as the 
percentage of GDP spent on R&D) is a good indication of the competitiveness 
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of a country’s economy. The country with the highest R&D intensity is Sweden 
(3.73% of GDP in 2006). R&D expenditure in the US measured 2.62% of GDP 
and the average for the 27 EU member states was 1.76% in 2006. The EU has 
set a goal of achieving an average R&D expenditure of 3% of GDP by 2010. 
South Africa has set a goal of achieving R&D expenditure equivalent to 1% 
of GDP by 2008/09. In comparison with some other middle and lower-middle 
income countries, South Africa spends proportionately more on R&D than 
Argentina (0.49%) and Chile (0.67%), but less than China (1.42%) and the 
Russian Federation (1.08%) (SA Department of Science and Technology press 
release, 30 May 2008; http://www.southafrica.info/about/science).
Most South African R&D work was performed in the research field of the 
engineering sciences (20.9% of total R&D), followed by the natural sciences 
(20.3%) and the medical and health sciences (15.1%). the medical and 
health R&d expenditure in 2006/07 was equivalent to R2.5 billion or 0.14% of 
the gdp.
The Third World Academy of Sciences recommends that 2% of the GDP of 
developing countries is a necessary minimum investment in indigenous 
science and technology development, with health research receiving 10% of 
that amount (http://www.southafrica.info/about/science).
THE PUBLIC FUNDING SITUATION FOR CLINICAL RESEARCH 
IN SOUTH AFRICA
There is currently no easy way to determine exactly the amount of funding 
which has gone towards clinical research in South Africa. The information 
about the funding streams for clinical research described previously is 
confined to estimates because the MRC does not itself regularly analyse its 
expenditures according to defined categories. Thus there is little information 
regarding what areas of medical and health research are funded in South 
Africa and accurate data on actual expenditure are not available.
Currently, 10.8% of all government expenditure is on health. The actual 
proportion spent on health research is very low, however. The National 
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Health Expenditure Review in 1991/92 estimated that only 1.1% of the total 
expenditure on health in South Africa was spent on research. The situation has 
not changed much since then, although accurate figures are not available. 
The 2001 Department of Health policy document on Health Research stipulates 
that the country’s budget for health research should be raised to at least 2% 
of total public sector health expenditure and should be utilised to build and 
retain capacity and to identify, articulate and conduct priority research both 
internally and in international programmes. The country budget should also be 
utilised to promote a research culture and to strengthen research institutions. 
It was suggested that the DoH should increase the health research allocation 
from 0.5 to 1.5% of its total budget in three years. In addition, the Department 
of Arts, Culture, Science and Technology (DACST), DNE and the SANDF should 
also increase their allocations to equal 0.5% of total public health expenditure 
within two years.
FUNDING OF CLINICAL TRIALS BY PHARmACEUTICAL 
COmPANIES
The pharmaceutical industry estimates that clinical trials in South Africa 
generate approximately R2.2 billion annually; this is foreign direct investment 
which can make a major contribution to the ability of all South Africans to 
enjoy better health care and quality of life (Kirkman, 2009). Of that amount, 
one-half goes to contract research organisations for work done, while the 
pharmaceutical industry itself contributes R665 million. Only 1% of the total 
spent on clinical trials worldwide is spent in Africa, with 80% of that being 
spent in South Africa. This means that between 3–4% of the research budget 
of all pharmaceutical companies is spent on clinical trials conducted in South 
Africa. In 2000, however, South Africa was reported to be handling only 0.6% 
of the global research work, although it had a capacity to conduct 2.5% of 
the world’s clinical research contracts (Baird and Van Niekerk, 2004).
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NEW SOURCES OF FUNDING FOR CLINICAL RESEARCH IN 
SOUTH AFRICA
The role of government as a source of health research funding through the 
Science Councils, government departments and tertiary institutions has been 
described above. Partly in response to the falling level of support through 
these channels, and partly owing to other dynamics, new sources of funding 
for health research have increased substantially in recent years, mainly from 
foreign not-for-profit sectors, including agencies such the US NIH, the Wellcome 
Trust in the UK, the Bill and Melinda Gates Foundation, the EU (the European 
Developing Country Trials Partnership (EDCTP)), the Howard Hughes Medical 
Institute, and the Aeras Global TB Vaccine Foundation. While exact details 
are not available, a large proportion of the funding for clinical research now 
being conducted in South Africa comes from these sources. As an example, 
the institute of infectious diseases and Molecular Medicine at the university 
of cape town, one of the leading multidisciplinary health research institutions 
in the country, derives approximately 60% of its funding from international 
private not-for-profit organisations, including the Wellcome Trust, the EDCTP, 
the Nih in the uS and the MRc in the uK, as well as the aeras global tB Vaccine 
Foundation, while about 10% is from local non-governmental sources. South 
african government agencies contribute only between 20–30% of the research 
funding, while less than 5% of the total funding in this large enterprise is derived 
from the pharmaceutical industry. 
In other smaller and less well-resourced centres, the foreign and domestic 
pharmaceutical industry is a significant funder of clinical research, mainly 
in the context of drug trials. While there is no reliably published figures for 
pharmaceutical industry expenditure on clinical trials in the country, the 
Pharmaceutical Manufacturers Association estimates that it is about R900 
million per annum. The South African National Clinical Trials Register lists 308 
active trials by condition, without declaring their phase, whereas the NIH’s 
US database clearly identifies 172 active industry-sponsored trials in South 
Africa. Another 53 trials are mainly supported by non-industry sources. Using 
the overall figure of 55% of R&D in South Africa being funded by business, it 
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is clear that the contribution of the pharmaceutical industry to South African 
clinical research represents at least that percentage of the spending on 
clinical research as well. 
AGENDA SETTING FOR CLINICAL RESEARCH
The preceding analysis has indicated that the clinical research agenda in 
South Africa is now determined by the research needs of pharmaceutical 
companies and not-for-profit international consortia (as incidentally it also is 
in many other developing countries), simply because this is where the majority 
of the funding for clinical research in South Africa is now sourced. 
Accessible funding flows thus set the agenda and the research priorities, 
instead of these being determined by the burden of disease and the health 
needs of South Africans in a well-coordinated and responsive manner. 
Speaking at the recent Bamako Ministerial summit, Dr Timothy Evans, the 
assistant director-general of the World Health Organisation, said that work 
was under way to check whether donor policies were exerting a negative 
effect, and they were “looking at the extent to which health priorities could 
be skewed by the Global Fund to fight HIV, malaria and TB”; he nevertheless 
cautioned that the evidence that donors were altering health priorities was 
mixed (http://www.tropika.net).
PROPOSED SOLUTIONS
1.  ENhaNcEd puBlic FuNdiNg FOR cliNical RESEaRch iN  
SOuth aFRica
The public funding directed to clinical research in South Africa through the 
MRC is less than R50 million annually, or less than an eighth of the MRC’s total 
annual turnover of about R400 million after current overheads of about 17.5% 
have been deducted. That is manifestly too little. The NRF dominates the 
disposition of the recent R&D investment schemes of government such as the 
South African Research Chairs Initiative, the DST’s Centres of Excellence, the 
National Equipment scheme, etc., with little or no focus on clinical research, 
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while the MRC has no or little participation in this investment despite the 
general backlog associated with its late start as a science council. 
It is simply not appropriate that South Africa’s main residual activity in clinical 
research should be funded by donors and business investors, however 
welcome and useful this support may be.
As an example, the number of research chairs awarded to clinicians under 
the Research Chairs Initiative should be increased. Of the 72 research chairs 
awarded to date by the NRF, only one Tier 1 chair has gone to a clinician and 
two others have been awarded a Tier 2 chair (DST/NRF Research Chairs 
Initiative). Other chairs have been awarded in the health sciences but with 
a focus on the basic sciences. Representation must be made to the NRF to 
increase the number of chairs made available to clinicians in order to re-
invigorate clinical research in South Africa. These chairs could in some way 
be linked to the establishment of clinical research centres. If this cannot be 
done, a separate scheme for the health sciences should be established. It is 
possible that the present separation of reporting lines for the NRF and MRc 
may have to be reconsidered if the present imbalance cannot be otherwise 
addressed. 
2.  a single national health research coordinating body
Although funding is an important concern, efficient organisation and 
management of research is needed to make best use of scarce resources. 
A major challenge is to develop a well-organised and comprehensive 
coordinating mechanism that will represent the diverse clinical research 
interests of all the relevant stakeholders in the country. Future success will 
depend largely on the cooperative participation of all organisations and 
institutions. 
Key functions for such a coordinating mechanism would include:
1.  Creating an enabling environment to conduct research in South Africa
There is a need to establish a clear-cut working relationship between the 
universities (who do the research), the provincial authorities (who provide 
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the clinical service to the patient or research participant) and the NHLS (who 
provide the laboratory services to patients or the research participant) and to 
ensure that these three bodies are in close communication with one another, 
that the roles and expectations of each party are clearly defined, and that 
while each party carries out its particular mandate all parties are working 
towards the common goal of facilitating the conduct of clinical research in 
South Africa. In particular the NHLS has to ensure that it meets its mandate of 
supporting research and that it does not ‘profit’ from such activities. 
Additional measures to improve the operating environment for clinical 
researchers could include the realignment and improved coordination of the 
policies and operational plans of various participants, such as the DoH (now 
the Department of Higher Education and Training (DoHET) the DST, the DTI, the 
NHLS, the MRC and the provincial health departments, facilitated by the new 
Ministry of Coordination and Planning. 
The development of a national-level ‘Joint agreement’ between universities on 
the one hand, and relevant central and provincial government departments 
on the other, could lead systematically to the creation of a ‘research platform’ 
alongside the clinical and teaching platforms of the Academic Health 
Complexes as envisaged in the National Health Act of 2003.
2.  Relationship building
The often tense relations that exist between scientists and clinicians, between 
clinician-researchers and policy-makers, and between various research 
providers and key stakeholders, are a barrier to ensuring that science achieves 
its potential impact on health care in South Africa. A major challenge is to get 
all the relevant stakeholders to work together to promote clinical research.
3.  Advocacy and communication
Advocacy to promote clinical research in South Africa is clearly needed to 
ensure that it gets the appropriate share of the national research budget that 
it requires. In addition, advocacy to attract international donor funding and 
to promote North-South partnerships is essential. 
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Communication between the research community and the National treasury 
needs to be focused. Researchers should be given a forum at which to 
present their research findings, future research goals, objectives and specific 
research needs that will enable them to achieve their goals and objectives. 
The National Treasury can then combine information obtained from this 
forum with information on the burden of disease in the country to make 
better informed decisions regarding the apportioning of government funds to 
national health research. 
Increased communication between the various national departments (DST, 
DoH, DTI, DoE) will encourage interdisciplinary and innovative research at 
the very highest levels in the country. It will also ensure better coordination of 
funding of research that is mutually beneficial to all parties. 
4.  Ensuring that institutions provide technical and managerial support services 
to all their researchers
International not-for-profit consortia and other international governmental 
and non-governmental funding agencies are a rich source of funding for 
clinical research. Requests for proposals are posted on a regular basis, and 
it is often the case that these funding opportunities are missed due to the 
fact that there are no dedicated individuals within institutions whose task 
it is to coordinate and respond to these requests for proposals. There is an 
urgent need to develop capacity in the form of research administrators, grant 
writers and research project managers in order to harness the available funds, 
to assist with grant writing and to manage the utilisation of the funds in an 
appropriate and effective manner. Mentoring and tutoring of postgraduate 
and postdoctoral students in grant writing and subsequent research project 
administration and management is vital. 
The question that arises is whether the National health Research committee 
(NhRc), established by the Department of Health under the 2003 National 
Health Act, might be enabled to perform the central coordinating function 
so clearly necessary in the present situation. The NHRC has had a gestation 
period of almost two years, but little has been achieved in terms of its mandate 
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as expressed in Clause 69(3) of the National Health Act, Act 61 of 2004. The 
NHRC must: 
a. determine the health research to be carried out by public health 
authorities;
b. ensure that health research agendas and research resources focus on 
priority health problems; 
c. develop and advise the Minister on the application and implementation 
of an integrated national strategy for health research; 
d. coordinate the research activities of public health authorities. 
The NHRC has recently adopted a vision, mission and values statement:
ViSiON: The Vision of the National Health Research Committee is to become 
the key agent for priority-setting and coordination of public-sector health 
research in South Africa, through the provision of strategic, evidence-based 
and implementable advice to the Minister and Department of Health. 
MiSSiON: The Mission of the National Health Research Committee is to 
combine evidence-based positions on national health priorities with enough 
information about research activities, capacities and contexts to generate 
feasible, potentially high-impact recommendations on health research to the 
Minister and Department of Health. 
ValuES: The work of the National Health Research Committee will be done 
with integrity and will be evidence-based; it will be respectful but independent 
of the opinions and positions of its stakeholders; and it will be facilitatory in its 
approach to the fulfilment of its statutory mandate.
It should be evident that the NHRC, as conceived in the National Health Act 
of 2003, could serve as a coordinating body for the functions outlined above, 
provided its operational independence from government can be maximised 
(without affecting its overall accountability). that it has not begun to do so four 
years after promulgation of the enabling act is a great pity. if the factors that 
have prevented it so far from functioning according to its statutory mandate 
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can be removed, the panel would support this avenue; if not, another body with 
more momentum may have to be created by the stakeholders in the clinical 
research sector. in all cases, operational independence is a necessity. 
3. Establishing a South african clinical research repository/database
Currently the DoH, the MRC and some provincial authorities are collecting 
and collating information on clinical trials and research (http://www.sanctr.
gov.za; http://www.atmregistry.org). There is clearly a need for one central 
clinical research repository or database that will collect and collate data on 
all aspects of clinical research (i.e. funding, outputs, capacity development 
and career development opportunities) in South Africa. This will assist policy- 
makers to make informed decisions regarding the current and future state of 
clinical research in South Africa, in particular to determine:
a. the current level of clinical research funding in South africa;
b. the sources of clinical research funding in South africa;
c. the relationships between available funds for clinical research and 
research agenda/priority setting in South africa.
4. Creating specific clinical research facilities in health facilities
There is a real need for regional clinical research centres or hubs to be 
established, with sufficient clinical and preclinical expertise and facilities to 
work at a high level. Such facilities should be supported and funded through 
specific grants from central government (via the DoH or the MRC). Support 
for these facilities could also be obtained from the pharmaceutical industry 
and from other donors. Some of these facilities should be developed into 
large-scale research institutes, with a critical mass of principal investigators, 
postdoctoral fellows, graduate students and research assistants.
Research in primary care or community settings also needs to be developed 
to facilitate large-scale trials, cohort studies and diagnostic studies. These 
centres must have close contact with academic centres.
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Investments in such facilities will go a long way towards strengthening 
academic medicine and clinical research that will ultimately benefit the 
community at large. 
FINDINGS
1. Two per cent of the GDP of developing countries is a necessary minimum 
investment in indigenous science and technology development, with 
health research receiving at least 20% of that amount. 
a. South africa is spending more on R&d than before, but this is still under 
1% of gdp; the largest part is spent on the engineering and technological 
sciences and on the natural sciences (40% of total R&d spend, about 20% 
each), while expenditure on the health sciences is 15% of the total (about 
0.15% of gdp). the government spends a large amount on services in the 
public health sector (about 10% of all government expenditure), but much 
too little of this money is spent on health research, which is also poorly 
coordinated and inadequately documented;
b. Clinical trial expenditure by industry is not included in this figure. Most of 
the current funding for health research comes from donors outside the 
country and from the pharmaceutical industry. More than half of the total 
expenditure on clinical research is by the private (business) sector.
2. The key narrative of clinical research funding over the least two decades 
is:
a. cumulative disinvestment resulting from an abrupt withdrawal from this 
sector of the health departments of provincial governments; 
b. the absence of discounts for research tests from the business model of the 
NhlS; 
c. chronic under-funding of the MRc despite its explicit mandate for 
supporting and developing medical and clinical research capacity in the 
country;
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d. the lack of funding streams to universities that might in principle have 
been applied to meet the overall shortfall in support. 
3. Most of the external donor funding is directed at the serious local HIV 
and TB pandemics, while the pharmaceutical investment is directed 
predominantly at the profitable areas of chronic diseases of lifestyle, 
mental illness and allergy. 
4. Local and international clinical conference activity has accordingly 
begun to reflect the agendas of industry and donors rather than the health 
priorities of the country, as has the pattern of publication outputs.
RECOmmENDATIONS
1. Encourage the Department of Health (DoH) to enable the National Health 
Research Committee (NHRC), or a similar body, independently to perform 
the key functions of: 
a. creating an enabling environment to conduct research in South africa; 
b. Building better relationships between scientists and clinicians, between 
clinician-researchers and policy-making, etc; 
c. promoting clinical research in South africa;
d. communicating between the research community, the National treasury 
and the various national departments;
e. Ensuring that institutions provide technical and managerial support 
services to all their researchers;
f. improving regulatory procedures.
2. Enable more effective tracking and monitoring of funding streams for 
clinical research. 
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3. Substantially increase public funding of clinical research, applied in such 
a way that national health priorities are more effectively addressed than 
is currently the case. The DoH should allocate 2% of its allocation to health 
research.
4. Realign and increase coordination of the policies and operational plans 
of various participants such as the DoH, the DoE, the DST, the DTI, the NHLS, 
the MRC and the provincial health departments, facilitated by the new 
Ministry of Coordination and Planning. Specifically, the lagging position 
of health research (MRC) in respect of national stimulation programmes 
and interventions such as the Research Chairs Initiative, the Centres of 
Excellence programme and the major equipment programme, must be 
addressed.
5. Develop a National Joint Agreement between universities and the Depart-
ments of Health and Education, which should provide systematically for a 
‘research platform’ alongside the clinical and teaching platforms of the 
Academic Health Complexes as envisaged in the National Health Act of 
2003.
6. Create regional clinical research centres/hubs with clinical and preclinical 
expertise and facilities.
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THE ROLE OF INDUSTRY AND THE MEDICAL REGULATORY 
AUTHORITY IN PROMOTING CLINICAL RESEARCH
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in this chapter, we engage with the following questions:
1. What are the existing institutional arrangements for specific investments in 
clinical research in South Africa?
2. What kinds of interaction do we need between government, parastatal 
institutions, academia and industry to revitalise clinical research?
INTRODUCTION
There are still many diseases for which there is no cure or current treatment is 
inadequate. In addition, there are new diseases and conditions which have 
developed over the past few years such as HIV/AIDS, avian influenza, multidrug-
resistant TB, extensively drug-resistant TB and others. Although knowledge of 
these diseases is growing rapidly, some of them are very complex, and the need 
for continuing research into disease mechanisms and treatments, including 
new medicines, is immense. Thus the demand for highly trained and skilled 
research scientists and adequate financial resources dedicated to research is 
continually growing.
The global clinical trials business was worth an estimated US$50bn in 2008, 
with an annual growth of rate of 10% (http://www.pharma.org). Increased 
emphasis has been placed on the cost-effectiveness of pharmaceutical R&D, 
as well as on increased productivity to maintain the high output of recent 
years. Consequently, the pharmaceutical industry has witnessed a rapid 
expansion of outsourced clinical services in both the West and in developing 
nations, most notably India and China, as well as countries in Eastern Europe. 
A report in January 2009 by the Tufts Centre for the Study of Drug Development 
indicates that the percentage of FDA researchers outside the US has increased 
significantly over the past 10 years, while the proportion of those based in the 
US has declined significantly, i.e. to only about 54% of the FDA-regulated chief 
scientists who conducted clinical trials in 2008. 
Pharmaceutical companies around the world are seeking alternative clinical 
trial sites due to shortages of both subjects and investigators in the traditional 
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regions (US and Western Europe) as well as the cost savings which can be 
achieved by locating clinical trials in developing countries such as eastern 
Europe, India and China, the latter being two of the world’s most populous 
countries and once considered difficult markets to enter. Both countries have 
taken significant strides as emerging markets in drug development. It is no 
coincidence that over the last decade or more of economic liberalisation, 
and years of unprecedented growth, India and China are becoming 
preferred destinations among emerging countries to which multinational 
pharmaceutical and biotechnology corporations as well as NGOs are 
outsourcing many clinical trials. 
A recent study published in the New England Journal of Medicine indicates 
that in November 2007 about one third of Phase III trials and studies of industry-
sponsored trials conducted by the 20 largest US-based pharmaceutical 
companies were performed outside the US, mostly in countries in Eastern 
Europe and the Russian Federation. Some concerns have been expressed 
about trading the lower costs of drug development for medicines that may 
be less safe and less effective. There has been widespread adoption of the 
ICH-GCP Guidelines, however, which may provide some safeguards for studies 
in such countries (Glickman et al., 2009), even though .some critics have taken 
issue with the methodology of the Duke University study (Getz et al., 2009). The 
FDA is also training regulators in some countries to ensure a robust research 
and regulatory framework that will protect trial participants and ensure that 
clinical research is conducted to the highest scientific standards. 
South Africa already participates extensively in clinical research. The issue to 
be addressed is how all role-players (government, parastatal research and 
academic institutes and industry) can collaborate to make South Africa an 
attractive destination for clinical research by creating a more favourable and 
enabling environment. 
despite all that has been said in previous chapters about the problems besetting 
clinical research in the country, South africa seen from the outside still has 
an impressive array of clinical resources, a large and diverse population of 
treatment-naïve subjects to participate in clinical trials, a large diversity of 
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disease conditions, and well-trained health professionals, modern medical 
facilities and extensive infrastructure. 
In recognition of the fact that the South African regulatory system, the Ethics 
Committees, the standard of training of health care professionals and the 
available infrastructure are all appropriate for conducting clinical trials to 
international standards, reports of clinical studies conducted in South Africa 
are frequently used elsewhere to obtain marketing approval (registration) 
for medicines – the trials concerned are readily accepted by the medicines 
regulatory authorities in most developed countries.
While pharmaceutical and biotechnological companies are traditionally 
involved in the development of new medicines, including the sponsorship 
of clinical trials, NGOs worldwide are increasingly responsible for conducting 
clinical trials for new treatments to address the diseases of the developing 
world. In addition, the pharmaceutical and biotechnology industries are 
increasingly delegating the responsibility of clinical trials to contract research 
organisations (CROs); this trend is also evident in South Africa where a recent 
survey by the South African Clinical Research Association (SACRA) has 
revealed that the ratio of R&D spend between pharmaceutical houses and 
CROs is already 27:73 (available by e-mail from SACRA 2009 at Maureen@
piasa.co.za).
In terms of the National industrial policy Framework (NipF) and the industrial 
policy action plan (ipap), the South African Government has identified the 
pharmaceutical industry as a ‘priority’ industry to fuel economic growth in 
order to meet the growth objectives of aSgiSa (accelerated Shared growth 
initiative of South africa). To ensure the success of these initiatives, it is 
imperative that there is coordination and communication between different 
government departments so that all work together towards achieving the 
stated goal of sustained and positive economic growth in South Africa (PIASA, 
2009).
To quote the NIPF, “industrial policy is not the domain of a single government 
department but requires intensive coordination across a range of government 
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departments. It can only be implemented successfully if there is alignment with 
four associated and supporting sets of policies: First, a stable and supportive 
macro-economic and regulatory environment; second, appropriate skills 
development and education systems which are increasingly integrated with 
the needs of the industrial economy; third, sufficient, reliable and competitively 
priced traditional and modern infrastructure; and fourth, adequate support for 
various forms of technological effort within the economy” (National Industrial 
Policy Framework; PIASA, 2009).’
THE CRUCIAL ROLE OF THE ‘mEDICINES REGULATORY 
AUTHORITY’ IN SOUTH AFRICA
The current South African Medicines Regulatory Authority (MRA) is the 
Medicines control council (Mcc), established in terms of the Medicines and 
Related Substances Control Act, Act 101 of 1965, which has been amended 
several times, most recently in 2008 (Medicines and Related Substances 
Control Amendment Bill, No. 44D of 2008). Due to the development of a 
huge backlog in approvals of both new products for registration, change 
to existing registered product dossiers, and unacceptable delays in clinical 
trials approvals, the Minister of Health in 2006 appointed a Ministerial Task 
Team (MTT) to review the current structure and functions of the MCC and to 
recommend the most appropriate medicines regulatory structure for South 
Africa for the future. The MTT was chaired by Prof. R Green Thompson and had 
two independent experts with wide international experience. The MTT report 
(Ministerial Task Team Report, 2008) was presented to the Minister of Health 
early in 2008.
Some of the recommendations of the MTT were incorporated into the latest 
amendments to legislation. The amendments will abolish the current MCC and 
instead establish a South african health products Regulatory authority, SahRa, 
which will control all health products including evidence-based medicine 
and complementary medicines, medical devices and foods or cosmetics 
that contain scheduled substances. All medicines and other health products 
will have to be registered before they can be sold. Registration of a medicine 
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will be based on expert review of the evidence that the medicine meets 
international standards for safety, quality and efficacy, which evidence must 
be provided to the Authority by the applicant. The review is conducted by a 
panel of experts selected for their integrity, as well as their scientific expertise, 
independence and insight. All medicines approved for registration must 
be evidence and clinical practice-based. Since registration (or marketing 
approval) is the last step in the chain of development of a new medicine, it is 
crucial that the regulatory process be efficient and that approval, if justified, 
be granted without undue bureaucratic delays. 
Clinical trials to establish the safety and efficacy of new medicines are 
conducted in countries around the world. Many of the Phase III studies are 
multi-centre studies conducted in different centres or different countries 
according to the same protocol and running in parallel. Some of these studies 
are conducted in South Africa and there is every reason to believe that this 
could be increased by 250% to 500% (2½ to 5 times) (Beare Pharmaceutical 
Industry Report, 2001). 
It is generally agreed that the current timelines for approval of clinical trials 
by the MCC are simply too long (up to six months) and these delays are 
impacting on the completion dates for the dossiers needed for submissions for 
marketing approval in all countries in which a submitting company operates. 
Such delays hold up marketing approval (registration in South Africa) and thus 
entry to the market, shortening the patent life for new inventions which are 
the lifeblood of innovative pharmaceutical companies. Over the past few 
years, many clinical trials which could have been successfully conducted in 
South Africa have been moved to other countries where the approval period 
was considered more efficient and the trials could be completed within an 
acceptable time frame. 
In many countries, dialogue between the applicants for approval of registration 
or for approval of a clinical trial and the reviewers for the relevant MRA has 
become a standard feature of the approval process. This process clarifies the 
requirements and data submitted, facilitates understanding and often saves 
months of correspondence. While this is permitted in South Africa, in practice 
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it is usually extremely difficult for applicants to meet with reviewers or to clarify 
information needed for the approval process. 
A NEW APPROVAL PROCEDURE RECOmmENDED FOR 
SOUTH AFRICA? 
Most role-players involved in conducting clinical trials in South Africa, i.e. 
academic and research institutions, the pharmaceutical industry, and all 
independent Contract Research Organisations (CROs) involved in conducting 
clinical trials under contract to a sponsor either in South Africa or abroad, have 
recommended that the procedure for approval of clinical trials in South Africa 
be amended in order to address the current delays being experienced. 
Three organisations – the African Clinical Research Organisation of South 
Africa (ACROSA), the South African Association of Pharmaceutical Physicians 
(SAAPP) and the South African Clinical Research Association (SACRA)–
representing professionals involved in conducting and monitoring clinical trials 
together conducted a study of the procedures in South Africa and compared 
these with those followed by MRAs in other countries. 
From this study it appears that a process applicable in several other countries 
could be adopted in South Africa without compromising patient safety and 
with full regard to ethical considerations. 
1. Ethics committee approval
In Australia, ethics committees approve or reject clinical trials, and notify the 
relevant regulatory authority that the clinical trial has been approved by the 
ethics committee. This is similar to the system used in Ghana and Uganda, the 
only other African countries represented in the study, where the regulatory 
authorities also do not conduct routine reviews of clinical trial applications.
This approach is supported by the multinational members of the Pharmaceutical 
Industry Association of South Africa (PIASA) for future approvals, and was 
recommended to the MTT mentioned above. It is clear, however, that the 
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delegated pathway will only be appropriate in South Africa when the National 
Health Research Ethics Council (NHREC) has developed the criteria for 
accreditation of those research ethics committees which meet internationally 
acceptable standards. Thus the clinical trials industry at present accepts that 
the MCC reviews ensure the protection of vulnerable populations in South 
Africa by also ensuring protocols and that the conduct of clinical trials meets 
ethical criteria. 
2. MRa approval to conduct a clinical trial
The procedure followed in Austria, Canada, Ireland, the Netherlands and the 
US is that an application to conduct a clinical trial is submitted to the MRA and 
the company or institution can proceed with the trial if a no objection letter 
(NOL) is received from the MRA within a specified time frame, e.g. objections to 
a clinical trial application must be forwarded to the applicant within a period 
of 30 calendar days from the date of submission of the trial application to the 
MCC, failing which a no objection letter is sent to the applicant indicating 
that the study may proceed. The average time to approval in the countries 
listed above is two months. If queries or objections are raised, an additional 25 
calendar days are allocated for the review of responses; if no objections are 
raised within the specified time period, the trial is allowed to proceed.
A longer period, e.g. 25 additional calendar days, can be used for applications 
involving studies on innovative products or gene therapies to provide a longer 
review period. 
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This approach is illustrated in the diagram below:
(Source: ACROSA, SAAPP and SACRA, 2006)
This system is used in five of the 51 countries represented in the above study 
and appears to be an efficient system for getting trials approved (ACROSA, 
SAAPP and SACRA, 2006). 
In some countries the regulatory authority is required to stop or delay studies 
rather than approve them. This system works well in all countries currently 
using it, as the approval process is efficient. Within the South African MCC, the 
clinical trials department is responsible for the timely review of applications by 
the clinical trials committee, which is currently a highly problematic process. 
While it has been suggested that an alert system might be implemented 
to ensure that the Registrar of the MCC is notified every time a response 
letter is not sent within the specified 30-day period, or a reward or penalty 
system implemented to motivate the clinical trials department to meet their 
deadlines, these measures need to be carefully considered. A potential flaw in 
this system is the lodging of non-specific objections. This practice would have 
to be monitored and strongly discouraged by internal Quality Management 
Systems within the MCC. Regulations should stipulate that a trial may only be 
delayed by a specific scientific concern relating to the safety or quality of the 
investigational product or any potential hazard to the participants.
Recommended procedure for clinical trial approvals 
CTA Submission
Can proceed within
specific time frame, OR if 
company receives
no objection letter
EC application
EC approval
In many countries, ethics committee approval is required before regulatory authority • 
approval is granted. However, it is recommended that in South Africa applications be 
made simultaneously to the ethics committee and the MRA but that the MRA’s NOL 
letter not be sent until EC approval is received. 
Country (Months to approval) Austria (1.5)
Canada (2)
Ireland (2)
The Netherlands (2)
US (2)
Average (2)
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The present requirement of both a review by the Clinical Trials Committee 
(CTC) and ratification by the Council (MCC) appears to be both unnecessary 
and a waste of a very scarce resource (the clinical expertise of the CTC 
members). The CTC should be empowered to issue a NOL without additional 
ratification from the MCC, as this second step serves no useful purpose and 
currently delays an already lengthy process. In any case, the dual process 
should be eliminated once the new authority, i.e. SAHRA, is established. The 
current parallel submission and review of the MCC and ethics committee 
applications should be maintained, however. A new system along these lines 
would remove one of the major obstacles to preventing South Africa from 
attracting many clinical trials.
3. the role of industry and its limits
undergraduate training
Several multinational pharmaceutical companies offer bursaries for the 
training of undergraduates in the health sciences. The R&D-based multinational 
pharmaceutical companies in fact awarded bursaries sufficient to put 147 
professionals through the tertiary educational system in 2006. Some of the 
bursaries channel the funding through universities or professional societies 
such as the Foundation for Pharmaceutical Education (managed by a Board 
of Governors under the auspices of the Pharmaceutical Society of South 
Africa). 
postgraduate training 
Funding is offered for fellowships or master’s degrees in specific areas of 
research by several companies, and it is likely that this could be considerably 
expanded if certainty returns to the market, i.e. if a number of government 
and industry initiatives relating to issues such as pricing regulations, Black 
Economic Empowerment (BEE) and the Health Charter are resolved. 
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training in current good clinical practice (cgcp)
The pool of potential experienced clinical investigators is relatively small. 
Attempts have been made by the medical research faculties of some 
universities as well as various pharmaceutical companies and most recently 
by PIASA, a trade association representing pharmaceutical manufacturers, to 
build additional capacity and a larger skills base by offering subsidised training 
in cGCP for both potential investigators and research assistants, particularly 
those from previously disadvantaged backgrounds (Ms M. Kirkman, Personal 
Communication).
Funding of research institutions
Some pharmaceutical companies have been involved in the sponsorship of 
research institutes, such as the Lung Institute at UCT funded by Boehringer 
Ingelheim.
corporate social responsibility programmes
Many of these programmes have been running for many years, and the 
Corporate Social Responsibility (CSR) activities of ten major pharmaceutical 
companies have been valued at approximately R1.5 billion (Deloitte Report, 
2007). 
Recommendations for consideration
It is possible that the above programmes or similar new programmes may 
be expanded further, including more specific training programmes, as part 
of the commitments to be made by multinational companies in terms of the 
Health Charter. Failing determination of a specific Health Charter, industries 
are expected to conform to the requirements of the Broad-Based Black 
Economic Empowerment (BBBEE) Act. This will involve commitments to 
participate in capacity building, skills development, enterprise development 
and corporate social responsibility projects. Negotiations with both the DTI 
(the custodian of BEE implementation) and the DoH will be needed to ensure 
the most favourable outcome for the country. 
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An exciting possibility to be investigated is a form of learnership for graduates 
or those with postgraduate qualifications to be placed in the research 
facilities of large multinational companies where specific areas of learning 
could include the research methodology involved in the investigation of new 
molecules, and all the different stages of drug development including the 
clinical phases. This would require a long-term commitment (20 to 25 years) 
where the benefits would not be experienced for at least 10 to 15 years. This 
may be considered in terms of the proposals for the Health Charter for the 
private health sector concerning a commitment by the pharmaceutical 
industry to building capacity in the country and developing those specific 
scientific skills which are in short supply. 
LImITS OF INDUSTRY
South african subsidiaries of the research-based multinational 
pharmaceutical industry 
Most innovative pharmaceutical companies have a central R&D division 
generally situated at or near the head office of the company. Nearly all research 
scientists employed by the company are thus usually in one research facility. In 
some cases there is also a contract or agreement with a research institution or 
university where the faculty staff will be engaged with the company R&D staff 
in a partnership to discover and develop new medicines. In the US, the NIH 
has conducted early-stage research into a number of molecules which have 
then been the subject of an agreement with a pharmaceutical company to 
develop the medicine into a product which can be marketed. 
This central control of all research is often due to the very high costs of 
rational drug development, including the required investigations into animal 
pharmacology and toxicology, human pharmacology and pharmacokinetics, 
leading to clinical trials. The costs of developing a new chemical entity which 
can be marketed are today estimated to average US$1 billion. The company 
assumes the risk of development, and benefits from a limited period of patent 
protection, while it shares or pays royalties to the original developer of the 
molecule (GlaxoSmithKline et al., 2008). 
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The ability of South African subsidiaries of multinational pharmaceutical 
companies to determine which clinical studies will be conducted in South 
Africa is severely limited, since all decisions are made at the central R&D 
division at headquarters. As mentioned above, South African subsidiaries 
must compete against subsidiaries of the same company in other countries in 
order to attract clinical studies to South Africa. 
Some input into the selection of clinical trials suitable for South Africa will 
sometimes be considered, as will recommendations for studies into therapeutic 
areas of special interest to South Africa. If the study is specific for South Africa, 
the protocol will be discussed with the clinical department of the South 
African subsidiary and with the local principal investigator. Very few changes 
can be made to the protocol for multi-centre studies when these are being 
conducted in several different countries. 
local South african industry and research 
Most local companies are involved in the development of different 
formulations and dosage forms for generic medicines. Bioequivalence 
studies must be conducted on most of the solid oral dosage forms to ensure 
bioequivalence with the originator medicine registered in this country and 
for which the company will have supplied the required clinical evidence in 
order to obtain approval of registration by the Medicines Regulatory Authority 
(Scholtz et al., 2005). 
Key issues
1. Medicines regulatory process for approval of clinical trials
Approval of clinical trials should be left to properly constituted and accredited 
ethics committees as is done in Australia, which approve or reject clinical 
trials, and the regulatory authority is only notified of the clinical trial approved 
by the ethics committee. This is similar to the system also used in Ghana and 
Uganda. 
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Alternatively the South African MRA should amend its current procedures and 
adopt one already tried and tested in several other countries, viz. Austria, 
Canada, Ireland, the Netherlands and the US, where the company or 
institution proceeds with the trial if a no objection letter is received from the 
MRA within a specified time after an application to conduct a clinical trial 
has been submitted. The average time to approval should be less than two 
months.
Many more clinical trials could be conducted in South Africa even under 
the present regimen if there were a general recognition of South Africa as 
a ‘centre of excellence’ for the conduct of such studies. This would require 
that: 
a. the MRa and industry agree on a reasonable time to approval for clinical 
trial applications, e.g. a reduction of approval time to no longer than eight 
weeks; 
b. efficient processing be done of all applications with clearly understood 
requirements; 
c. the National Ethics Research council complete its process for accrediting 
ethics committees, and these were able to process applications in a time 
periods of less than six weeks.
2. Staffing levels in public sector hospitals
The lack of adequate staffing levels of doctors and nurses in public hospitals 
is a severely limiting factor attracting more clinical studies to this critically 
important sector. The DoH and the provincial health departments will need 
to ensure the recruitment and retention of adequate numbers of medical 
practitioners, nurses and support staff in public sector hospitals to ensure that 
it will be possible to conduct more clinical trials in public hospitals. 
3. Role of industry
It is possible that current schemes for bursaries, grants and training opportunities 
could be significantly expanded, particularly with respect to trials-specific 
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training programmes, as part of the commitments to be made by multinational 
companies in terms of the Health Charter. 
Forms of learnership for graduates or postgraduates could be developed 
in the research facilities of large multinational companies where specific 
areas of learning could include the research methodology involved in 
the investigation of new molecules, and in all the different stages of drug 
development, including all preclinical and clinical phases. This would require 
a long-term commitment (20 to 25 years) where the benefits would not be 
experienced for at least 10 to 15 years.
4. Partnerships
Local subsidiaries of multinational companies could possibly increase the 
involvement of global alliances to address diseases prevalent in the region. 
Given the existing infrastructure, the strong regulatory oversight, the international 
recognition of the competence of the training of health professionals in 
clinical research, our diverse population and disease conditions, South Africa 
could become an attractive partner for outsourcing of clinical trials with the 
potential for success similar to that of India. 
5. International competitiveness
5.1  dialogue
The recommendation for regular dialogue between the SAHRA and industry 
will have a beneficial effect and help to resolve many outstanding issues, 
which could facilitate speedier approval of clinical trials and thus assist in 
making South Africa more competitive. 
5.2  alternative procedures 
The implementation of the amendments to the legislation including the 
restructuring of the MRA, will be an ideal time to introduce one of the alternative 
procedures for approval of clinical trials as recommended in Section 1 above. 
This would place South Africa on a par with several developed countries 
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with regard to competing for a share of global clinical trials and increase its 
attractiveness as a venue for such studies. 
5.3  agreed time lines for approval 
Reasonable target time lines for approval after submission of applications to 
conduct clinical trials are to be set and agreed from time to time with industry 
(PIASA submissions 2006-2007). 
5.4  Other recommendations for measures to improve the registration process 
and times
There could be an agreement to recognise prior approval of trial proposals in 
selected countries to facilitate faster review processes, since local reviewers 
would be able to rely on a thorough evaluation by reviewers in these other 
countries. 
Where application is made for the registration of an identical product under 
another trade name for strategic marketing reasons, only one ‘master dossier’ 
could be submitted and reviewed. This would prevent the wastage of skilled 
human resources through duplication of work.
5.5  link-up with intellectual property issues and legislation/regulations
An extremely important aspect of regulation concerns the measures recently 
put in place by the South African Government for protection of intellectual 
property generated with public funding, notably the intellectual property Rights 
from publicly Financed Research and development, Act 51 of 2008, and the 
draft Regulations under the Act currently being circulated for public comment. 
The Act seeks to “provide for more effective utilisation of intellectual property 
emanating from publicly financed research and development; to establish 
the National Intellectual Property Management Office and the Intellectual 
Property Fund; to provide for the establishment of offices of technology 
transfer at institutions; and to provide for matters connected therewith.”
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The implementation of the Intellectual Property Rights Act and the finalisation 
of the Regulations must clearly engage fully with the important area of clinical 
research and trials, so that the benefits to society and the economics of 
patents and their commercialisation are maximised. The necessary interface 
between the regulatory regimens of both the ethical and intellectual property 
systems must be both efficient and effective. It is important also that the one 
system should not become an impediment to the other.
CONCLUSIONS
South Africa should again become internationally recognised as a centre 
of excellence for clinical research, including for clinical trials. Appropriate 
intellectual property protection and development is a necessary and 
important element of the infrastructure of such a platform.
This requires all role-players in government, i.e. the DoH, including the 
Directorate responsible for health research, and particularly the Medicines 
Regulatory Authority, the DST, the dti, the MRC, as well as research institutes 
and other academic centres and both the pharmaceutical industry and the 
clinical research industry to work together to achieve this. This would greatly 
improve the climate for investment in South Africa and result in better access 
to the most advanced medicines and treatments for the public in South 
Africa, as the innovative medicines of today become the generic medicines 
of tomorrow. Investment in clinical studies conducted in South Africa is likely to 
increase the knowledge and understanding of the South African market and 
regulatory systems, thus attracting investments in other areas as well.
FINDINGS
1. South Africa could be recognised as a centre of excellence for clinical trials 
which could attract more investment in trials. This would ensure retention 
of skilled scientists and retention of the ability of medical research facilities 
at universities or research institutions to continue to do basic and novel 
medicine research and attract foreign direct investment to the benefit of 
the South African economy.
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2. The present Medicines Control Council’s Clinical Trials Committee performs 
a review function on all clinical trials. This process, which has improved 
recently prior to its legislated change into a Regulatory Authority (RA), 
still experiences problems, such as approval delays, variation in reviewer 
quality and inadequate supervision of trials.
RECOmmENDATIONS
1. The new Medicines Regulatory Authority (MRA) should rigorously meet its 
statutory requirements to ensure that any medicines used in the country 
are safe and effective.
2. The MRA should rely on sound ethics review. 
3. An increase in the number of clinical trials conducted in South Africa (with 
recognition of South Africa as a centre of excellence for conducting such 
studies) would require:  
a. agreement on a reasonable time-to-approval for clinical trial applications 
(e.g. a reduction of approval time to no longer than eight weeks); 
b. efficient processing of all applications with clearly understood requirements;
c. regular dialogue between the SahRa and all role-players.
4. The regulatory process for approval of clinical trials could be expedited in 
the following ways:
a. after auditing, standardisation and accreditation of REcs by the NhREc, 
a system could be envisaged in which REcs approve or reject clinical 
trials and then notify the Ra of the clinical trial; the Ra would thus avoid 
conducting routine reviews of clinical trial applications; or
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b. Once an application to conduct a clinical trial is submitted to the MRa, the 
company or institution could proceed with the trial if a no objection letter 
was received from the RA within a specified timeframe; 
c. where application is made for the registration of an identical product 
under another trade name for strategic marketing reasons, only one 
‘master dossier’ could be submitted and reviewed;
d. there could be recognition of prior approval in selected countries;
e. the Ra should rely on the local REc for ongoing audits of studies they have 
approved.
5. The implementation of the Intellectual Property Rights Act of 2008 needs to 
be carefully and deliberately aligned with the ethical regulatory aspects 
of the system.
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in this chapter, we engage with the following question:
What kinds of interventions have been used elsewhere in the world successfully 
to address the kinds of challenges South African clinical research is facing?
INTRODUCTION
Although health research is acknowledged as indispensable for improving 
health, promoting equity and stimulating development, there is a great need 
for more discussion on how developing countries – especially those in sub-
Saharan Africa – can build up their fragile health systems and develop their 
own capacity to conduct health research (Whitworth et al., 2008).
In his paper entitled ‘Research capacity Strengthening in the South’, Thomas 
Nchida of the Global Forum for Health Research at the WHO observed that 
in the South, “(clinical) research capacity remains one of world’s unmet 
challenges (while) nations in the South bear the greatest burden of the world’s 
health problems.” Funding for clinical research in these countries is scant to 
virtually non-existent; there is a lack of appropriate research infrastructure, 
and a scarcity in both the numbers and quality of trained researchers. Clinical 
research receives little or no recognition from the state, and there is ”often a 
complete rupture between the scientist and the policy-makers in the ministries 
(of health) in the South”; health officials are often indifferent or even hostile 
to research-based health care solutions. Scientists in the South suffer from 
”demotivation, isolation from peers, poor access to the literature, (and) very 
low salaries” (Nchida, 2002). 
It must be said, however, that concerns about the threats to the development, 
promotion, conduct and translation of clinical research are not the exclusive 
domain of developing countries. While biomedical research in the North is 
generously endowed in material and human terms compared to the South, 
clinical research there is not without problems of its own. For example, a report 
in the Lancet observes that “Health and legislative systems in Europe fragment 
clinical research and dampen its competitiveness, reducing the capacity to 
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enrol patients in clinical studies, increasing the costs of clinical research, and 
hampering scientific productivity” (Nchida, 2002). Cross-border research in the 
EU is hampered by language diversity and lack of regulatory harmony among 
member states in such areas as ethical review policies, research regulations 
and legislation. There are thus many challenges in the North with which the 
South can identify. These also include the need continually to strengthen 
and retain research capacity in terms of skilled clinical researchers, to 
continually increase funding levels to keep up with technological and other 
developments, and to strengthen translational research. Many developed 
countries are continually developing and implementing measures to deal with 
these challenges, and this chapter looks at some of the strategies that may 
serve as models to address impediments to clinical research in the South.
First, it must be noted that the problems of the shortfalls in facilities and 
infrastructure, public engagement, funding and the supply of clinician scientists 
for clinical research in South Africa are fully addressed elsewhere in this report. 
Similarly, some specific models from elsewhere in the world are covered in 
earlier chapters in their context. The purpose of this chapter is to chart some 
broader initiatives from other countries to meet common challenges.
translational research
In 2003, Britain’s academy of Medical Sciences, made up of over 700 of 
the UK’s leading medical scientists from hospitals, academia, industry and 
public service, published a report entitled Strengthening Medical Research 
in which they identified “a substantial gulf between basic discoveries and 
converting such discoveries into innovations that directly benefit patients or 
prevent disease.” It attributed this disjuncture to a dramatic worldwide shift of 
focus in scientific inquiry from clinical research to laboratory investigation at 
a cellular and molecular level, following the emergence in the 1970s of the 
tools and techniques of molecular biology and the capacity to manipulate 
and transfer genes between populations. The report suggests that “this 
translational gap can only be bridged through the successful application of 
clinical research, testing and evaluating new concepts and interventions at 
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the bedside and in carefully managed clinical trials” (Academy of Medical 
Sciences, 2003). This concern is shared by researchers in the US, who have 
noted that ”growing barriers between clinical and basic research, along with 
the ever-increasing complexities involved in conducting clinical research, are 
making it more difficult to translate new knowledge to the clinic – and back 
again to the bench. These challenges are limiting professional interest in the 
field and hampering the clinical research enterprise at a time when it should 
be expanding” (http://www.nihroadmap.nih.gov).
The British Academy of Medical Sciences attribute the abovementioned 
gulf to the relative retrogression of clinical research which it attributes to five 
challenges, some of which closely resonate with conditions in the South, 
namely:
1. A lack of appropriate facilities and infrastructure;
2. A lack of appropriately trained clinical scientists and a career structure to 
support them;
3. Inadequate funding support for experimental medicine and all types of 
clinical trials;
4. A failure to utilise the opportunity provided by a national health service 
(NHS) to generate high-quality clinical data for such studies;
5. An increasingly complex and bureaucratic legal and ethical frameworks 
in the UK and EU.
The lesson to be drawn from the experience of countries with successful 
research programmes is that government commitment and partnership is 
indispensable for the innovation of an environment conducive to clinical 
research, which is well exemplified by the experience of Singapore in the 
paragraphs that follow. The NHS in the UK, the Department of Health and Social 
Services (through the NIH) in the US, and the Ministry of Health in Singapore 
all engage in partnerships with the research community through numerous 
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channels and at numerous levels in supporting clinical research, such as in 
the acquisition of research equipment and infrastructure, the funding of the 
costs of research and the training of clinical researchers, as well as through 
awards and fellowships to researchers at all levels of seniority in recognition of 
performance and achievement. The Singapore government has advanced 
three reasons for committing itself to clinical research – to translate the 
considerable biomedical research emanating from Singaporean laboratories 
into clinical applications; to inculcate a knowledge and evidence-based 
approach to health care; and to retain top medical talent in the public 
hospitals. 
This rationale has so far eluded South Africa, where the trend has been in the 
opposite direction. As described in Chapter 7, the deliberate withdrawal by 
provincial health departments in recent years from investing in clinical research-
related equipment and infrastructure, combined with the gross under-funding 
of both research-active hospitals and the main agency for public funding 
(the MRC) has all but gutted the capacity to conduct clinical research. The 
severance of pathology laboratories from the public hospitals, consolidating 
them into the autonomous, fee-for-service NHLS that charges market-related 
fees for tests performed in the pursuit of research, has significantly increased 
the cost of clinical research in the face of the extremely limited research 
funding.
translating research into policy and practice
Translational research – the purpose of which is to develop new evidence-
based therapies for patients, to improve diagnosis and prognosis, and to 
promote prevention – is of little use unless the resulting evidence-based 
interventions and techniques are integrated into the health system and 
adopted by health practitioners. The evidence from the South is that local 
clinical research outcomes rarely find their way into clinical practice. Such 
research therefore all too often begins and ends as an academic exercise to 
generate papers for publication in learned journals. In a paper from Tanzania, 
Kitua et al., (2000) observe that “neither academic nor medical and health 
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research institutions in developing countries regard it as their responsibility 
to communicate their research findings to local policy-makers, practising 
health professionals, or the public. It is optimistically assumed that key national 
decision makers will access the relevant publications, understand the research 
language, select useful, locally relevant results, and use them in planning and 
implementing sound health programmes” (Kitua et al., 2000). 
As detailed in Chapter 8, South African clinical researchers have increasingly 
elected to publish their work overseas where it is least likely to be read by 
South African practitioners or policy-makers and thus make an impact on 
local practice. The inability of clinical research to influence policy in the South 
cannot, however, be wholly be blamed on researchers. Politicians and policy-
makers have often been impervious and even hostile to evidence-based 
interventions derived from new research, as was glaringly illustrated by the 
controversies that surrounded HIV/AIDS management and prevention in recent 
years. In Singapore, Minister of Health Khaw Boon Wan recently conceded that 
previously, “research (had not been) a priority in Singapore’s Ministry of Health. 
The concern was that clinical research would lead to more costly treatment 
options.  This would increase health care costs and also fan public expectations 
for esoteric treatment for which our society might not be prepared to pay” 
(http://www.moh.gov.sg/mohcorp/speeches aspx?id=18732).
Elsewhere in the world, the uptake of clinical research outcomes in policy and 
clinical practice has hinged on several conditions: 
1. There must be a closely cooperative and mutually trusting relationship 
between the researchers and health policy-makers and implementers.
2. There must be a collaborative forum for clinical researchers to engage in 
mutual dialogue, and to empower themselves to lobby government and 
other stakeholders as a collective. One such model comes from Tanzania. 
Frustrated by the research community’s failure to influence the Tanzanian 
health policies – for instance in respect of the malaria eradication 
programme – Tanzanian clinical researchers formed a National Health 
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Forum, set up to ”act as a consultative and advisory body on health 
research to the policy and decision makers in the Ministry of Health and 
wider government” (Kitua et al., 2000). The forum has also served to foster 
greater collegiality among researchers of different affiliations, and closer 
cooperation among the various research institutions in the country.
 The US has numerous research networks of clinical research interests and 
interest groups whose programmes are accessible through the NIH’s Inventory 
for Clinical Research Networks (http:// www.clinicalresearchnetworks.org). 
One example of such a forum is the NIH’s Clinical and Translational Science 
Award (CTSA) Consortium, constituted in recognition of the conditions that 
“are making it more difficult to translate new knowledge to the clinic – 
and back again to the bench. These challenges are limiting professional 
interest in the field and hampering the clinical research enterprise at a 
time when it should be expanding.” The goal of the CTSA is ”to transform 
the local, regional and national environment for clinical and translational 
science. The CTSA is a consortium of institutions bridging basic, clinical and 
translational research to bring effective strategies and treatments into 
clinical practice more rapidly.”
3. There must be structured channels for clinical researchers to share their 
work with the Ministry of Health and other stakeholders on a regular 
basis. Such links exist in one form or another in the UK between research 
organisations and the NHS, and in the US between the NIH (and other 
research formations) and the Department of Health and Human Services. 
In South Africa, this would imply a structured and cooperative partnership 
between the research community, the DoH and other stakeholders such 
as the MRC and industry.
SOLUTIONS IN THE LITERATURE
To further explore the barriers to clinical research and the remedies that have 
been applied elsewhere in the world, the Panel has looked at a variety of 
publications on strengthening clinical research, including those from the 
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Association of Medical Colleges, the Canadian Institute of Health Research 
and the UK clinical research collaboration. Google Scholar and other literature 
sources were also searched using the keywords ‘strengthening’, ‘clinical’, 
‘research’, ‘barriers’ and ‘academic medicine’. Table 10.1 summarises the 
barriers that were identified. These were grouped into three categories: scarcity 
of skilled clinical researchers, funding and current profile of clinical research. 
These are further subdivided into sub-categories of specific categories and 
recommended interventions.
table 10.1: Barriers to the promotion of clinical research and inter-
ventions to address them
Barrier 
category
Specific barrier 
identified by the 
literature
Recommendations and interventions 
addressing these barriers
Few skilled 
clinical 
researchers
Lack of opportunity 
to acquire skills and 
knowledge in medical 
schools
Develop a combined professional/PhD • 
degree for clinician-scientist graduates 
such as the MD/PhD (US) or MB/PhD (UK)
Increase institutional support and • 
oversight for clinical research and training 
Attracting new 
clinical researchers 
and retaining clinical 
researchers
Develop mentoring programmes• 
Provide incentives for student and staff • 
undertaking research
Support the career development of • 
investigators
E.g. Mentored Patient Orientated Research 
Career Development Award of the NIH (K23)
Lack of support for senior 
researchers
Develop long-term funding for those • 
conducting research
Relief from patient care and • 
administration to increase time for 
research
E.g. Midcareer Investigator Award in Patient 
Oriented Research of the NIH (K24) 
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Barrier 
category
Specific barrier 
identified by the 
literature
Recommendations and interventions 
addressing these barriers
Funding Lack of grant schemes 
in Africa
Schemes to be supported within Africa• 
Support for clinical training fellowships • 
through South-South partnerships
E.g. Kenya and Malawi partnership between 
the DFID, the IDRC and the Wellcome Trust
Lack of institutional 
funding 
Strengthening existing institutions and • 
field sites
E.g. initiative between the UK’s MRC, health 
departments, Wellcome Trust, Wolfson 
Foundation, Cancer Research UK and British 
Heart Foundation to boost experimental 
research
Funders funding full cost of research • 
when necessary, including developing 
management and core technical staff
E.g. South-South and North-South Initiative
Lack of partnerships Develop a forum to coordinate • 
partnerships
Promote institutional partnerships• 
Promote partnerships between • 
government, industry and regulators
Staff exchange and student partnership• 
Current profile of 
clinical research
Lack of research 
agenda and a 
mechanism to 
implement such an 
agenda
Develop an advocacy body to • 
implement a research agenda
Low recognition by 
government of research 
in addressing health 
issues
Government needs to dedicate 2% • 
of GDP for funding of research and 
development
Health information systems need to be • 
supportive of clinical research
Establishment of a health entity to drive • 
the clinical research agenda
Insufficient translation of 
research into policy and 
practice
Increase funding for reporting and • 
disseminating mechanisms
E.g. The NIH Institutional Clinical and 
Translational Science Award (CTSA)
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FURTHER SOLUTIONS IN THE GLOBAL EXPERIENCE RELEVANT 
TO AFRICA 
Effective government leadership: the British example
A coordinated initiative was launched in the UK in 2005 providing £117 
million of new funding from the Medical Research Council (MRC), health 
departments, the Wellcome Trust, Wolfson Foundation, Cancer Research UK 
and the British Heart Foundation. Additional investment has subsequently 
been provided by a number of funding bodies including the Health Research 
Board of Ireland, resulting in a total of £134 million being provided to boost 
experimental medicine in the UK and Ireland. The initiative consisted of three 
separate calls for proposals and throughout the process the UK’s Clinical 
Research Consortium (CRC) funding partners have been working together 
and sharing information on proposals received. Increased support for 
experimental medicine research programmes was provided by the MRC. This 
was complemented by major funding targeted at building up the infrastructure 
underpinning experimental medicine. Infrastructure was supported through a 
joint call to fund new clinical research facilities and strengthen existing ones, 
and also through an initiative to expand a network of experimental cancer 
medicine centres. Funding decisions have been taken for all three elements 
of the coordinated initiative, resulting in 28 grants for new experimental 
medicine programmes funded through the MRC initiative, 11 new awards 
to establish new and develop existing UK clinical research facilities funded 
through a Wellcome Trust-led Clinical Research Infrastructure Initiative with 
a consortium of funders, including the Wolfson Foundation, the MRC, UK 
health departments, the British Heart Foundation and Cancer Research UK. 
An additional facility jointly funded by the Wellcome Trust and the Health 
Research Board of Ireland is being established in Dublin. There are 17 centres 
assigned as Experimental Cancer Medicine Centres, plus two designated as 
Experimental Cancer Medicine Centres in Development through a Cancer 
Research UK/Health Departments call. Taken together, these developments 
represent a considerable increase in the UK’s capability and capacity to 
conduct high-quality experimental medicine research. However, there is 
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agreement that they need to facilitate networking between these facilities to 
provide standardisation and coordination of research practice and provide 
links with the rest of the national infrastructure. As a first step, the UK Clinical 
Research Network (UKCRN), under the auspices of the UKCRC, is working closely 
with the existing clinical research facilities to develop an information system 
that maps resources and expertise in experimental medicine. Throughout 
this process the UKCRC has been working closely with industry to ensure that 
their needs are being taken into account (UK Clinical Research Collaboration 
Progress Report, 2004-2006).
Effective government leadership: the Singapore example
Singapore presents a striking example of a government that is passionate 
about clinical research and the development and retention of its researchers. 
The country has a definite career path for clinician-researchers, and moreover 
promotes and rewards performance in clinical research through special 
awards for research excellence. Furthermore, the Ministry of Health is fully 
committed to the translation and integration of research outcomes into 
clinical practice in the health service. The commitment sets Singapore apart 
among the nations of the South, and is evident in the following:
1. The Ministry of Health (MOH), jointly with the National Medical Research 
Council (NMRC), have ensured that public hospitals are appropriately 
equipped with the most up-to-date infrastructure to facilitate good clinical 
research.
2. In order to retain its top researchers, the NMRC and the MOH jointly 
sponsor awards to recognise and reward senior researchers for excellence 
in clinical research. These include:
The STaR Investigator Award, a prestigious award jointly offered by the • 
MOH, NMRC and the Agency for Science, Technology and Research 
(A*STAR), to recognise and support outstanding researchers who 
conduct research that involves integrating basic scientific discoveries 
with clinical applications;
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The Clinician Scientist Award, which is given to researchers who have•  
demonstrated a sustained, high level of productivity and leadership in 
translational and clinical research.
3. The NMRC offers capacity-building grants specifically to train clinician 
researchers, including:
The NMRC Research Training Fellowship, awarded to outstanding and • 
talented clinicians for overseas research training or to pursue a PhD in 
research in local institutions and to acquire the qualifications and skills 
to become Clinician Scientists;
NRF-MOH Scholarship to promote clinical and translational research • 
by equipping a select group of Medical Specialist Trainees with the 
academic qualifications and skills to pursue careers as Clinician 
Scientists through a structured yet flexible training route;
National University of Singapore Scholarship (MOH-funded) to equip • 
clinicians with the basic methodological and practical skills to design 
and conduct clinical investigations that are relevant to patient care, 
from new treatments and technologies to diagnostic modalities to 
effectiveness of health services.
In the words of Singapore’s Minister of Health, “Supporting clinical research and 
knowledge-driven care will help to draw and retain top doctors and medical 
talent within our public hospitals. I think you have heard this many times both 
from our own doctors who are interested in research as well as the newly 
recruited doctors from overseas whom we managed to persuade to return to 
Singapore. By meeting clinicians’ aspirations for scientific discovery, they can 
develop professionally and be more intellectually engaged in their work. We 
therefore hope that participation in research programmes will help reduce 
the brain drain of our doctors to the private sector and to other countries.”
partnerships: examples in africa
Cross-boundary schemes that are administered within African countries, with 
national governments contributing in an agreed way, are sorely needed to 
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nurture promising young scientists to become the research leaders of the 
future. Awards should be made in open, transparent competition to African 
institutions with promotion of cross-institutional, multidisciplinary research to 
build South-South linkages. Support, including training in scientific writing and 
in translating research results into policy and action, should be provided to 
promising young scientists to develop competitive proposals so that they are 
not lost to the system, and substantial re-entry grants are required to attract 
back scientists who have moved abroad. In some cases support is required 
for infrastructure and legal changes to improve institutional and national 
governance to provide an environment in which research can flourish 
(Whitworth et al., 2008).
One example of an initiative aiming to do this in Kenya and Malawi is the 
health Research capacity Strengthening initiative partnership between 
the department for international development (dFid), the international 
development and Research centre (idRc) and the wellcome trust. Two 
national task forces have been supported to develop proposals focused 
on supporting and training individual scientists through local grant-making 
capacity, strengthening key academic research and policy-making 
institutions, developing a portfolio of health system research activities and 
improving regulation and coordination of the national research environment. 
This initiative aims to re-establish research in African universities as a viable 
career pathway for young and established scientists, through the support of 
senior mentors and encouragement of a vigorous research culture (Whitworth 
et al., 2008).
While African governments have a role in providing at least basic infrastructural 
support, external funders have often failed to ensure that the full costs 
of research were generated in developing country institutions. This may 
include the cost of upgrading infrastructure and support services, such as 
research management and governance, accounting and financial reporting 
processes, information technology and library services. For research to flourish, 
there is a need to recognise that the requisite organisational framework, 
adequate human resources and access to the appropriate skills and tools are 
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all required. Therefore, in some cases it is also necessary to fund the career 
development of management and core technical support staff, and to assist 
generally with strategic capacity development plans, setting out pathways 
for capacity strengthening and setting priorities for funding (Whitworth et al., 
2008).
The Wellcome Trust has recently launched an african institutions initiative which 
aims to build a critical mass of sustainable local research capacity across 
Africa through strengthening African universities and research institutions. The 
objectives include creating equitable and sustainable South-South and North-
South partnerships and networks between institutions, building a critical mass 
of local research capacity and developing vibrant research environments 
geared to national priorities across Africa, supporting the human resources 
and infrastructure necessary for the administrative, governance, financial and 
management functions needed for institutions to deliver research excellence, 
developing and building leadership at individual, institutional and national 
levels so countries can better initiate and lead research activities, and enthuse 
young scientists to develop research careers. Awards totalling up to £30 million 
were made at the end of 2008. In addition, the Wellcome Trust has already 
made seven Strategic Awards for over £30 million for capacity-strengthening 
initiatives in Africa and the Indian sub-continent (Whitworth et al., 2008).
An inter-agency working group probably needs to be established involving 
relevant funders in order to maintain contact and promote coordination. 
Partnerships between African institutions need promoting, especially those 
between research institutions and universities. Joint appointments, joint 
supervision and research-predominant posts to give protected time for 
research, free from a heavy burden of teaching and service commitments, 
are important ways to bring research institutions and universities closer 
together. Appropriate and equitable North-South partnerships should be 
supported. This may require providing training in negotiating skills and strategic 
plan development. Guidelines and principles to ensure that these are true 
partnerships and to mitigate power imbalances have been developed and 
funders should ensure that these are followed to ensure that African institutions 
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are able to articulate their needs. For example, the European developing 
country clinical trials programme (Edctp) adheres to these principles when 
assessing funding applications for research partnerships. Other appropriate 
roles for Northern institutions include staff exchanges, student pairings, 
teaching, joint degree programmes, and helping to set up facilities and 
organisational frameworks (Whitworth et al., 2008).
An important requirement for successful partnerships is that mechanisms 
exist to track and disseminate the aggregate levels of financial support for 
clinical research provided by public funders, industry, foundations, voluntary 
organisations, health plans and insurers, academic health centres, hospitals, 
and other health care providers. Data on the funding of and participation 
in clinical research should be reported regularly by all funding entities and 
made available to groups with an interest in the vitality of clinical research. 
A national strategy should also be developed for a public-private sector 
partnership to fund the creation of broad-based clinical information systems. 
A substantial investment is needed to meet the requirements of health services 
and population-based research and the advancement of evidence-based 
medicine (Association of American Medical Colleges, 1999).
High-profile advocates are required and this could be a role for revitalised 
national academies of science, the Network of African Science Academies, 
the African Academy of Science and the African Union, among other bodies. 
There is a need to agree with politicians and policy-makers on how science 
and technology can contribute to achieving the Millennium Development 
Goals, to development more generally, and to wealth creation from product 
development through partnerships with industry and entrepreneurs. African 
governments need to better appreciate the benefits of research and to be 
prepared to commit dedicated funding to national budgets (Whitworth et 
al., 2008).
developing coordinated research agendas and implementing them
Funders can ensure that Northern institutional partners develop long-
term sustainable partnerships and support South-South networks so that 
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established institutions can assist the development of emerging institutions, 
as has been the ethos behind recent Wellcome Trust initiatives for capacity 
strengthening. African research centres need long-term support to be able to 
grow organically over time (Whitworth et al., 2008).
One good example of an advocacy body is the initiative to Strengthen health 
Research capacity in africa (iShReca) which was established following the 
meeting in Kilifi, Kenya, which brought together health researchers in Africa 
to promote the creation of self-sustaining pools of excellence capable of 
initiating and carrying out high-quality health research in Africa. Their mission 
also includes translating research products into policy and practice through 
better integrated approaches to capacity building at individual, institutional 
and system level. ISHReCA aims to provide a platform for African health 
researchers to discuss the need for health research capacity building, to 
promote an African-led agenda and negotiate this with funders and partners, 
to advocate for increased commitment of national governments and civil 
society and to reinforce at the regional and international level the urgency 
for networking and building capacity for health research in Africa (Whitworth 
et al., 2008).
The ifakara trust model has over decades developed from a site reliant 
on a Northern partner for scientific and administrative drive, with a small 
number of independent project grants, to an independent centre with a 
scientific board, which derives core funding from a large number of grants for 
individual projects for long-term stability. In this way each project contributes 
to core costs, but there is also a core grant to sustain the centre, support 
independence and avoid chasing grants regardless of whether they fit 
the strategic priorities. International funders should consider providing core 
funds to assist the development of field sites to become mature centres that 
can address national and international research priorities through research, 
training and service provision (Whitworth et al., 2008).
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Recognition by governments of the value of research in addressing 
health issues
Important lessons can be learnt from the review conducted by cooksey (2006), 
which recommended that the UK government should seek to achieve better 
coordination of health research and more coherent funding arrangements 
to support translation by establishing an Office for Strategic Coordination of 
health Research (OSchR). The office will report jointly to the Secretaries of State 
for the Department of Health and the Department of Trade and Industry, and 
will allow for strategic input from the Health Departments from the devolved 
administrations. The review recommended that the effectiveness of the joint 
reporting arrangements in practice should be reviewed in 2011 (Cooksey, 
2006).
It is essential that health information systems are supportive of clinical research 
(Silverman, 2004). In 1997, some national governments began taking action 
to introduce research-led practice in their countries. In Chile, the Ministry of 
Health has established, with support from the European Union, an office to 
promote the implementation of research findings. In Palestine, doctors are 
working with the health minister to establish a national committee on clinical 
effectiveness. In Thailand, the Ministry of Health and the National Health 
Services Research Institute are setting up an office to guide a national quality 
assurance programme. In South Africa, the MRC has committed support to the 
production of systematic reviews and evidence-based practice. In Zimbabwe 
and South Africa, researchers are working with their governments to test ways 
of getting research into policy and practice. In the Philippines, the Department 
of Health has funded projects to develop evidence-based guidelines for its 
cardiovascular disease prevention programme (Garner et al., 1998).
improved translation of research into practice
Increased funding for clinical research infrastructure and the establishment 
of reporting, tracking and disseminating mechanisms for clinical research are 
essential for strengthening clinical research. In the UK, translational research 
was recommended to be the joint responsibility of the Medical Research 
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Council-National Institute for Health Research (MRC-NIHR) with the strategy 
overseen by a new Translational Medicine Funding Board and joint working 
facilitated by the OSCHR, with MRC technology continuing to play a key role 
(Cooksey, 2006).
It is important to disseminate research findings to a variety of audiences, 
including other health professionals, lay readers, and journalists. Many 
mechanisms for implementing good practice are already available in 
developing countries. In some, guidelines and standardised treatment 
manuals are better developed than in the West. Other guidelines are likely to 
become more evidence based over time. Reviews of specific interventions 
to change professional practice, such as those by Bero et al. and those 
presented by Ross-Degnan et al. (International conference on improving the 
use of medicines, Chiang Mai, Thailand, April 1997), will help to ensure that 
change occurs, but dissemination efforts in developing countries need further 
evaluation (Garner et al., 1998).
There are a variety of new initiatives to encourage practitioners and policy- 
makers to assess and implement research evidence. Some clinicians examine 
variations in practice between themselves, for example in Thailand. A 
framework to assist clinicians to apply research evidence to their practice was 
developed in Chile at the Santiago seminar for getting research into policy. 
In the Philippines, an ongoing study is looking at the use of standardised 
clinical encounters in evaluating practice variation. Another mechanism 
being investigated through the Reproductive Health Library is to ask health 
professionals how they would use the results from a particular systematic 
review in their practice of reproductive health; if successful, this intervention 
could be used in other clinical specialties (Garner et al., 1998).
The barriers to strengthening clinical research have been discussed, and from 
what has been said above, it is evident that some barriers have been more 
adequately addressed than others. It is our hope that these models will lay the 
foundation for a South African model which would suit our context. 
C H A P T E R  1 0
M O D E L S  F O R  D E V E L O P I N G  A N D  P R O M O T I N G  C L I N I C A L  R E S E A R C H 
A D O P T E D  E L S E W H E R E  I N  T H E  W O R L D
REVITALISING CLINICAL RESEARCH IN SOUTH AFRICA225
A STUDY ON CLINICAL RESEARCH AND RELATED TRAINING IN SOUTH AFRICA
THE OVERALL LESSONS LEARNT
what has been shown in many countries is that transforming the relationship 
between clinical research and society is a serious and difficult undertaking, 
but one that stands to yield enormous dividends. Funding and implementing 
the programmes necessary to achieve this success require a commitment 
from diverse constituencies and strong confidence in the value of doing 
so. While large-scale programmes are expensive, the pay-off in the form of 
more efficient identification of the causes of illness and of both effective and 
ineffective therapies can relieve much of the financial burden. The funds 
saved by accelerating recruitment and reducing research delays may also 
be substantial. With fewer delays, study results are available more quickly, 
allowing faster progression to the next research step and accelerating the 
process of discovery and validation. Wider public involvement promotes 
greater support and funding for health-related research. Honest inquiry in 
the form of clinical research, aligned across all sectors of society, rewards 
participants, clinicians, the research community and society as a whole. It 
is our collective responsibility to integrate clinical research into the broader 
social context, helping it to achieve its full potential (Avins and Goldberg, 
2007).
FINDINGS
1. Although health research, and especially clinical research, is acknowledged 
as indispensable for improving health, promoting equity and stimulating 
development, it tends inexplicably to be neglected in sub-Saharan Africa 
in terms of planning, status and funding.
2. Much attention has been paid to promoting clinical research in the North, 
in the face of challenges similar to those afflicting the South, so it is possible 
that solutions already found elsewhere can also be applied here. These 
include maintaining the supply of skilled clinical researchers, improving 
facilities for clinical research, increasing funding and strengthening 
translational research.
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RECOmmENDATIONS
1. Government commitment and partnership is needed to revitalise clinical 
research. The Singapore government, for example, invests in clinical 
research to translate the biomedical research emanating from its highly 
competitive research institutes into clinical applications; to inculcate a 
knowledge and evidence-based approach to health care; and to retain 
the highest level of medical talent in the public hospitals.
2. There must be a closely cooperative and mutually trusting relationship 
between researchers and health policy-makers and implementers. The 
NHS in the UK, the Department of Health and Social Services (through 
the NIH) in the US, and the Ministry of Health in Singapore all engage in 
partnership with the research community through numerous channels and 
at numerous levels to support clinical research.
3. Efforts should be targeted at building indigenous research capacity. 
Singapore has a definite career path for clinician-researchers, and 
promotes and rewards performance in clinical research through special 
awards for research excellence.
4. High-profile advocates are required to promote clinical research. One 
example of an advocacy body is the Initiative to Strengthen Health Research 
Capacity in Africa (ISHReCA), bringing together health researchers in Africa 
to promote the creation of self-sustaining pools of excellence capable of 
initiating and carrying out high-quality health research in Africa.
5. Better strategic planning and coordination for health research is required. 
An example of such an initiative is the Health Research Capacity 
Strengthening Initiative partnerships in Kenya and Malawi.
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WHAT ARE THE BARRIERS TO THE CLINICAL RESEARCH 
ENTERPRISE IN SOUTH AFRICA?
1. Inadequate public engagement with clinical research
Government does not promote clinical research sufficiently in the • 
public domain;
Researchers do not engage sufficiently with issues of importance to • 
research participants and policy-makers.
2. Lack of research planning, regulation and coordination
Lack of a coordinated national plan to balance excellence on the world • 
stage (i.e., quality and impact) with relevance to local problems; 
Inefficient regulatory framework for clinical trials and registration of new • 
medicines is hindering the conduct of innovative clinical trials.
3. inadequate capacity for clinical research (human resources and 
infrastructure)
Poor teaching and matriculation rates in mathematics and science in • 
schools;
Lack of appropriately trained clinical scientists and career structure to • 
support them (i.e. ‘frozen demographics’ of ageing white male clinical 
scientists with too few young, black and woman researchers);
Lack of appropriate facilities and infrastructure (i.e. virtual absence of • 
dedicated clinical research centres).
4. Lack of adequate and appropriate funding
Inadequate funding for clinical trials and other types of clinical research • 
(e.g. MRC project grants have an upper limit of R130 000 p.a.);
Cost-recovery regime of the provincial department of health and the • 
National Health Laboratory Service prohibits investigator-driven, non-
industry clinical research in academic health complexes.
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5. Absence of monitoring and evaluation
No monitoring of adherence to standards and performance of individual • 
researchers, academic institutions, research councils, government 
departments, health industry and other funders of research.
WHAT ARE THE mAIN SOLUTIONS?
1. National Strategic planning, Regulation and coordination of clinical 
research
We propose the formation of a • South african clinical Research 
coordinating centre by the MRC to serve as an advocacy group and a 
partnership of organisations working to establish South Africa as a world 
leade;r in clinical research by harnessing the power of all stakeholders, 
including universities, government departments, the National Health 
Laboratory Service, the health industry and research councils.
The proposed • coordinating centre should be accorded maximum 
operational independence, while remaining fully accountable in the 
overall sense. Its composition and terms of reference should be carefully 
designed in order to provide it with a maximum chance of success in its 
specific operating environment.
The proposed•  coordinating centre should engage with the National 
health Research committee on how optimal planning, regulation and 
coordination of clinical research may be achieved, in consultation with 
the Departments of Health, Higher Education, Science and Technology, 
and Trade and Industry.
The•  proposed coordinating centre should interact with the newly 
established National Planning Unit in the Presidency on the planning 
needs of clinical and health research.
The•  proposed coordinating centre should seek to play an advisory 
role to the proposed Medical Regulatory Authority (successor to the 
Medicines Control Council) and the National Ethics Committee in order 
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to deal with the regulatory environment and ethical oversight for clinical 
trials and health research in general.
The proposed•  coordinating centre should ensure the alignment of 
the clinical and health research effort with the principles of essential 
national health research and other policies of the government.
The proposed • coordinating centre should oversee the maximisation 
of intellectual property development in and by the clinical research 
system.
2. Human and Infrastructural Capacity
Towards a • National clinical Scholars programme as part of the Ten-Year 
Innovation Plan of the DST:
- A target of 500 PhDs to be produced in clinical health sciences 
over the next 10 years as part of the plan by the DST to increase 
the graduation rate of PhDs in general to 6 000 per year between 
2008 and 2018, plus a target of 150 postdoctoral fellows per annum 
working in South African clinical research environments.
- A target of 30 Research Chairs in clinical research areas to help 
tackle the ‘Farmer to Pharma’ grand challenge and other strategic 
areas.
The creation of • clinical Research centres and Research institutes as 
national hubs in the academic health complexes and other sites:
- Develop a National Joint Agreement between universities and the 
Departments of Health, Education and Science and Technology, 
in order to provide a ‘research platform’ alongside the clinical and 
teaching platforms in the academic health complexes and other 
sites.
- Create a National clinical Research training coordinating initiative 
to link and coordinate clinical research training at universities, 
research councils, government and industry. This initiative will 
serve as a warehouse of education and training opportunities 
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(i.e. projects, funding, courses, degrees) and a meeting place for 
supervisors and potential students at national level.
- Establish attractive, high-capacity training programmes for under-
graduate and postgraduate students in the clinical health sciences, 
as well as for junior faculty in clinical research, as part of the human 
capital generation project of the DST’s Ten-Year Plan. 
- Fund learnerships for graduates in the research facilities of large 
multinational companies.
- Foster a clinical-plus-research academic career track (lectureships and 
professorships) in all clinical disciplines in South African institutions.
- Develop and support a network of skilled mentors who can lead the 
development of young clinical researchers.
3. National Funding Scheme for Clinical and Health Research
Raise the national R&D budget to 2% of the GDP, of which 20% should • 
be allocated to health research (DST).
Implement the Mexico declaration commitment by the national • 
Department of Health to spend 2% of the national health budget 
on research and development, and amend the Research and 
Development Tax Incentives Policy to encourage innovative R&D in 
South Africa by removing the exclusion of clinical trials (DTI).
Incenctivise the health care industry (pharmaceuticals and private • 
hospitals) to spend 2% of their turnover on research and development 
(pharmaceutical manufacturers and others).
Follow up on the recently implemented Clinical Training Enhancement • 
Initiative with a well-aligned approach to clinical research training. 
4. Monitoring and Evaluation of the Clinical and Health Research Enterprise
Evaluation of the performance of the clinical research enterprise in • 
South Africa, possibly  by the Academy of Science of South Africa, by 
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reviewing the implementation of the recommendations of this report at 
five-yearly intervals.
Monitoring by the National Health Research Committee of the efficiency • 
of research expenditure of the MRC and other statutory bodies entrusted 
with health research.
Monitoring audit by the new Monitoring and Evaluation Unit in the • 
Presidency of the government ability to meet the target of spending 
2% of GDP on research and development, and 2% of the health budget 
on health research.
A P P E N D I X  A :
BIOGRAPHICAL SkETCHES OF THE STUDY PANEL
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professor aMaBOO (aMES) dhai, MB ChB, FCOG, LLM, 
PGDipIntResEthics
Professor Dhai obtained her MB ChB degree from the University of KwaZulu-Natal. 
She specialised as an Obstetrician and Gynaecologist through the Colleges of 
Medicine of South Africa; she is a Fellow of the College of Obstetricians and 
Gynaecologists (FCOG). She subsequently obtained a Master’s degree in Law 
(LLM) from the Law School of the University of KwaZulu-Natal, and a Diploma 
in International Research Ethics from the University of Cape Town. She was 
appointed Head of Bioethics, Medical Law and Research Ethics at the Nelson 
R Mandela School of Medicine at the University of KwaZulu-Natal in 2004. In 
January 2006 she took on the position of Head of Bioethics at the University of 
the Witwatersrand Medical School and is serving as the Director. Her special 
interest is research ethics. She served as chairperson of the Research Ethics 
Committee of the University of KwaZulu-Natal for two years, and as a member 
of the Interim National Ministerial Research Ethics Committee between 2002 
and 2005, and in 2006 was appointed Deputy Chair of the National Health 
Research Ethics Council. She serves on the MRC Ethics Committee, established 
and chairs the Hospice Palliative Care of South Africa Research Ethics 
Committee and is co-chair of the Wits Human Research Ethics Committee 
(Medical). She also serves on the Medical and Dental Professions Board of the 
Health Professions Council of South Africa, is a member of the Council of the 
College of Obstetricians and Gynaecologists of South Africa, and is a member 
of the Human Rights, Ethics and Professional Development Committee of the 
Health Professions Council. Her publications in the main are on bioethics and 
medical law. 
professor pEtER FOlB, MB ChB, MD, FCP SA, FRCP Lond, FRSSAf, 
mASSAf 
Professor Folb has a doctorate in pharmacology and is a Fellow of the Royal 
College of Physicians, London (FRCP Lond). Previously he was a Senior Lecturer 
in Clinical Pharmacology at the University of London at Guy’s Hospital and 
Professor of Pharmacology at the University of Cape Town. From 1980 to 1998 
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he served as chair of the South African Medicines Control Council, the national 
drug regulatory authority. He has supervised more than 80 postgraduate 
students, and has served as a consultant to the World Bank, Médecins Sans 
Frontières and as expert adviser to the World Health Organisation (WHO) over 
many years. From 1996 to 2004 he chaired the WHO special task force for 
research into severe malaria, and from 1998 to 2004 he chaired the WHO 
scientific advisory committee on vaccine safety. Peter Folb has served, inter 
alia, as a member of the WHO Strategic Advisory Group of Experts (SAGE) 
on vaccine policies worldwide and as a member of the WHO/TDR proof of 
principle committee, which directs the scientific and strategic development 
of new drugs for neglected tropical diseases. He was previously co-director of 
the South African Medical Research Council Traditional Medicines Research 
Unit, based jointly at the University of Cape Town and the University of the 
Western Cape. From 1994 to 2003 he was director of the WHO Collaborating 
Centre for Drug Policy Research. For many years he was co-editor of Meyler’s 
Side Effects of Drugs – the international encyclopaedia of adverse drug 
events. His special interests are in the fields of clinical and experimental 
pharmacology, drug safety and the scientific basis of new drug development. 
He is a Fellow of the Royal Society of South Africa, a Fellow of the University 
of Cape Town and a Member of the Academy of Science of South Africa 
(ASSAf). He has published extensively and has authored three books on drug 
safety. Since 2004 he has been Chief Specialist Scientist at the South African 
Medical Research Council.
professor wiElaNd gEVERS, MB ChB, MA, DPhil, DSc honoris causa, 
FCP SA ad eundem, MASSAf, FTWAS 
Professor Gevers qualified in medicine in 1960, and proceeded as a Rhodes 
Scholar to Oxford University where he obtained the DPhil degree in 1966 
under Sir Hans Krebs (regulation of liver metabolism). He subsequently spent 
four postdoctoral years in the laboratory of another Nobel Prize winner, Dr Fritz 
Lipmann, at the Rockefeller University in New York (biosynthesis of peptide 
antibiotics) before returning to South Africa in 1970. He was Senior Deputy Vice-
Chancellor responsible for planning and academic process at the University 
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of Cape Town from 1992 to 2002, and Professor of Medical Biochemistry since 
1978. He was (founder) President of the South African Biochemical Society 
from 1975 to 1976, and again President from 1981 to 1982. He was President 
of the Academy of Science of South Africa (ASSAf) from 1998 to 2004. He is 
a Fellow of the Third World Academy of Sciences (elected 2002). He holds a 
Distinguished Teacher’s Award from the University of Cape Town. Prof. Gevers 
directed MRC research units at both Stellenbosch University (1970–1977) and 
the University of Cape Town (1979–1994), using biochemical, cell-biological 
and molecular genetic approaches to heart contractility, intracellular protein 
turnover and cholesterol metabolism. He was awarded the Wellcome Gold 
Medal for Medical Research and the Gold Medals of both the South African 
Society for Biochemistry and Molecular Biology, and the South African MRC. 
After his formal retirement from UCT at the end of 2002, Prof. Gevers took up 
an appointment until 31 March 2005 as the Interim Director of UCT’s Institute 
of Infectious Disease and Molecular Medicine (IIDMM). He was the Executive 
Officer of ASSAf (until 2008) and he is now the General Secretary of the 
Academy.
professor gREgORY huSSEY, MB ChB, MMed, MSc, DTM&H, FFCH, 
mASSAf 
Professor Hussey has had postgraduate training in paediatrics, public health 
and infectious diseases, and is registered as a sub-specialist in infectious 
diseases. He was appointed as Director of the Institute of Infectious Diseases 
and Molecular Medicine (IIDMM) at the University of Cape Town (UCT) in 2005. 
Prior to that, he was Professor and Head of Paediatric Infectious Diseases in the 
School of Child and Adolescent Health at UCT and a consultant to the Red 
Cross Children’s Hospital in Cape Town. His main research interest has been in 
the field of vaccine-preventable diseases and he has published extensively on 
this subject. He is currently Director of the South African Tuberculosis Vaccine 
Initiative whose mandate is to contribute to the development of novel TB 
vaccines. This initiative is funded by a number of groups, including the Gates 
Foundation via the Aeras Global TB Vaccine Foundation, the European 
Union and the US National Institutes of Health. He has been a part-time WHO 
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consultant for over a decade and serves on a number of international and 
national committees, including the WHO Tuberculosis Vaccine International 
Advisory Group, the WHO Global Advisory Committee on Vaccine Safety, 
the GSK International Data Safety Monitoring Committee for a new rotavirus 
vaccine and the South African National Advisory Group on Immunisation. 
Prof. Hussey is actively involved in postgraduate education and training and 
capacity development of health workers. He is the coordinator of the annual 
week-long residential course “Developing expertise for vaccinology in Africa”. 
In addition he is the holder of an NIH Fogarty International Global Infectious 
Disease Research Training Program for the period 2006 to 2010.
Ms MauREEN KiRKMaN, BSc (Pharm)
Ms Kirkman obtained her BSc in Pharmacy from Rhodes University. After 
two years in dispensing at the SAR&H Sick Fund and retail pharmacy, she 
moved in 1966 to the pharmaceutical industry as Managing Director, 
Technical & Regulatory at FBA Pharmaceuticals (now better known as Bayer 
Pharmaceuticals) with responsibility for production, packaging, quality 
assurance and regulatory affairs, including patents and trade marks. In 1987 
she joined Adcock Ingram, initially as the Regulatory Affairs Manager with 
responsibility for the registration of medicines and for regulatory compliance 
issues. In 1994 she became Strategic Regulatory Affairs Manager in the 
Adcock Ingram Group R&D Division responsible for strategic regulatory issues, 
which included planning the regulatory strategy and the regulatory aspects of 
clinical research, development and registration of new drugs internationally. 
These included the development of new molecules. In 1997 she joined PMA 
as Head: Scientific and Regulatory Affairs. This included all the aspects of 
new legislation that could affect the pharmaceutical industry, including the 
regulation and control of medicines, labour, training and marketing issues, 
and liaison with the Departments of Health and Trade and Industry, and with 
other trade and professional associations. She has been involved in various 
industry bodies and specialist working groups for many years, including the 
PMA Science and Technology Committee (SCITECH); PASA Legislative and 
Self-regulatory Committees for OTC (over-the-counter) medicines, the SAPRAA 
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Committee, the IMM Advisory Board for the Health Sector, LAAPI – the Labour 
Affairs Association of the Pharmaceutical Industry – and various industry expert 
working groups. Recently she was involved in the Industry Task Group set up in 
1999 to liaise with the MCC on issues affecting the pharmaceutical industry. 
She retired at the end of 2008 and now serves as an executive consultant for 
PIASA.
dr NONhlaNhla MadEla-MNtla, BCur, MCur, DCur, Cert. in Advanced 
Health Management, Diploma in Health Outcomes Research 
Dr Madela-Mntla obtained a BCur degree from MEDUNSA (1987), followed by 
MCur and DCur degrees from the then Rand Afrikaans University (1990–1995). 
She also has a certificate in Advanced Health Management from the University 
of Pretoria, a Diploma in Health Outcomes Research and Certificate in Ethical 
Issues in Clinical Research, the latter two from the Vienna School of Clinical 
Research, Austria. Her MSc Med Pharmacology is currently on hold after she 
completed the first two years. She is currently the Executive Manager for 
Human Capital Management and Development (HCMD) of the MRC. Her role 
involves human capital development for research (including disbursement of 
grants and facilitating training opportunities) within the MRC and for the wider 
academic and health research sectors, while also ensuring transformation in 
the human resource management processes and policies. She has worked as 
a health care consultant in research and training (Oasis Resources). She has 
also headed the Hospital and Community Mental Health Sub-directorate and 
later the Directorate of the Mental Health and Substance Abuse (1997–2004). 
She was a lecturer in psychiatric nursing and family medicine (at MEDUNSA) 
(1995–1997). She has served as a member of the National Essential Drugs 
Programme (EDP) Committee of the Department of Health. She is a former 
member of the Board of Psychology of the Health Professions Council of SA 
(HPCSA) (2003–2004). She is a reviewer for a number of committees for clinical 
research and grant disbursement. She is a South African representative of the 
ISHReCA (Initiative for Strengthening Health Research Capacity for Africa) 
Committee, an all-Africa committee established to interact with funders to 
coordinate capacity-strengthening initiatives in Africa. The Committee is 
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mainly funded by the Wellcome Trust, Sida, TDR and other international funders 
of various activities. She has published and presented papers both locally and 
internationally, and written chapters in two nursing science books.
professor BONgaNi M MaYOSi, BMedSci, MB ChB, FCP SA, DPhil, FESC, 
FACC, FRCP, MASSAf 
Professor Mayosi graduated with a BMedSci (1987) and MB ChB (1990) from 
the University of Natal, and trained in medicine and cardiology in Cape 
Town. He was admitted to the Fellowship of the College of Physicians of 
South Africa in 1995. In 1998, he was awarded the Nuffield Oxford Medical 
Fellow to read cardiovascular genetics at the University of Oxford (PhD thesis: 
Genetic determination of cardiovascular risk factors in families). He returned 
to the University of Cape Town (UCT) and Groote Schuur Hospital (GSH) in 
2001 where he continues to work as a physician, teacher and researcher in 
internal medicine and cardiology. He was promoted ad hominem to the rank 
of Associate Professor of Medicine in 2003, and in 2006 he was appointed 
Professor and Head of the Department of Medicine at UCT and GSH. His 
academic work focuses on heart diseases of the poor, i.e. cardiomyopathy, 
tuberculous pericarditis and rheumatic fever. Uniquely, he employs a wide 
range of investigative approaches, from molecular to clinical to population-
based methods in his efforts to improve the understanding and control of 
these health problems. In addition, he is at the forefront of efforts to close 
the ‘know-do’ gap with respect to heart diseases of the poor, encouraging 
policy-makers to increase investment in evidence-based control programmes. 
Professor Mayosi is an established international leader in his field. In 2005, he 
was awarded the National Research Foundation President’s Award (or ‘P’ 
rating) and was elected to the Membership of the Academy of Sciences of 
South Africa. He has been the president of the South African Heart Association 
since 2007. He has published extensively and has done many reviews.
professor lEtticia MOJa, MB ChB, MMed (O&G), MBA
Professor Moja obtained her MBA degree from the University of the Free State. 
She served as the Dean of the Faculty of Health Science at the University of the 
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Free State from 2003 until mid-2009, after fulfilling the role of Vice-Dean of the 
faculty from 2002. She is the first black woman to have headed a South African 
medical faculty. Prior to this she headed the Gynaecologic Oncology Unit at 
Ga-Rankuwa Hospital in Pretoria from 1997 to 2002. She firmly believes in the 
great need for training of health professionals, particularly from disadvantaged 
communities. She is passionate about unity and harmony while maintaining 
cultural differences, and is held in high regard by a broad cross-section of 
colleagues both young and old. She also serves on the Medical and Dental 
Board and is the Vice-President of the Health Professions Council of South 
Africa. She was the recipient of the Shoprite Checkers Woman of the Year 
Award (2004) and was also Chairperson of the National Committee of Medical 
Deans. She has taken up the post of Principal and Deputy Vice-Chancellor at 
the University of Limpopo, MEDUNSA campus (as of August 2009).
professor JagidESa (JacK) MOOdlEY, MB ChB, FCOG, FRCOG, MD 
Professor Moodley obtained his MB ChB from the University of Natal in 1969. He 
is a Fellow of the Colleges of Medicine (O&G) and the Royal College of O&G 
(UK). He obtained his MD degree (thesis: Aspects of the pathophysiology of 
pre-eclampsia in African women) from the University of Natal in 1989 and 
is also a fellow at this university. He is currently an Emeritus Professor at the 
University of KwaZulu-Natal and is involved in research in the Women’s Health 
and HIV Research Unit. His special interest is high-risk obstetrics, particularly 
in the aetiology and management of hypertensive disorders of pregnancy. 
Other interests include perinatal HIV, maternal mortality and audit in obstetric 
practice. In the past he has held numerous positions, and most recently 
he served on the Research Ethics Committee of the University of KwaZulu-
Natal. He has also served on a number bodies and committees. Currently 
he is the Chairperson of the National Department of Health’s Committee 
on Confidential Enquiries into Maternal Deaths (NCCEMD) and a member 
of the National Essential Drug List Committee (NEDLC). He is the advisory 
board editor for the European Journal of Obstetrics and Gynaecology and 
Reproductive Biology, Elsevier, reviewer for MRC (SA) Women’s Health and the 
International Journal of Gynecology & Obstetrics and corresponding editor, 
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Editorial Board, for the Journal of Obstetrics and Gynaecology. He was a 
finalist in the National Science and Technology Awards (2004) for Outstanding 
Contribution to Science, Engineering and Technology, in the category of 
Senior Black Researcher over the last 5–10 years. In 2006 he received the FIGO 
(International Federation of Gynecology and Obstetrics) Distinguished Service 
Award. He has over 300 publications to his name.
professor daNiEl NcaYiYaNa, MD, FACOG, FCM, MASSAf
Professor Ncayiyana obtained his medical degree from the University of 
Groningen Medical School, Holland, in 1970. Following postgraduate training 
at the Albert Einstein College of Medicine and the New York University medical 
school, he was Board-certified by the American Board of Obstetrics and 
Gynaecology, was elected Fellow of the American College of Obstetrics and 
Gynaecology (FACOG), and practiced in the US for 10 years. Back in South Africa 
(1983), he worked at Rietvlei Hospital and as Chief Medical Superintendent of 
Umtata General Hospital. He served as Dean of Health Sciences, and later 
Vice-Chancellor of the University of Transkei. Subsequently, he was Deputy 
Vice-Chancellor at UCT from 1996 to 2001 and Vice-Chancellor of Durban 
University of Technology from 2001 to 2005. Prof. Ncayiyana has been editor of 
the South African Medical Journal since 1993; he serves on the Editorial Board 
of the British Medical Journal and the web-based Medscape, and is chair of 
the Editorial Board of the Human Sciences Research Council (HSRC) Press. He 
is the founder member and first secretary of the World Association of Medical 
Editors (WAME), and is also a founder member of the Forum for African Medical 
Editors (FAME). He is an Honorary Fellow of the Colleges of Medicine of South 
Africa (FCM SA) and a Member of the Academy of Science of South Africa 
(MASSAf), and has been honorary Professor of Obstetrics and Gynaecology 
at the universities of Cape Town and Kwa-Zulu Natal. He has previously served 
as consultant in higher education governance and strategic planning in a 
variety of sub-Saharan African countries on behalf of the World Bank, USAID 
and the American Council on Education, the Ford Foundation and in health-
related projects on behalf of the WHO. He is advisor to the President/CEO of 
the HSRC. He has published extensively. 
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professor williaM picK, MB ChB, MMed, FFCH (CM), MFGP, DPH, 
DTM&H, MASSAf 
Professor Pick obtained his MB ChB from the University of Cape Town where 
he also specialised in Community Health and later became a senior specialist. 
Professor Pick was Head of the School of Public Health at the University of the 
Witwatersrand and Chief Community Physician at the Johannesburg Hospital 
until his retirement in April 2003. He has served as a member of the Health 
Professions Council, the MRC Board and the Board of the Health Systems Trust 
for a number of years. He is a Fellow of the Royal Society of Medicine, a Fellow 
of the Royal Society of Tropical Medicine and Hygiene, a former Fellow of 
the King’s Fund, and held membership of the American Association for the 
Advancement of Science and the New York Academy of Sciences. In 1990 
he was awarded a Fellowship in International Health on the Takemi Program 
at Harvard University, to which programme he returned as a Visiting Fellow 
in 1996. He also served as temporary advisor to the WHO on a number of 
occasions. In 1994 he chaired the ministerial committee on Human Resources 
for Health Care in South Africa and in 2000 led the task team that prepared 
the national strategy for Human Resources for Health. He has published widely, 
and served on the editorial boards of a large number of journals. Currently 
Professor Pick is the Chairperson of the Council for Medical Schemes. He is 
also past-President of the MRC and is a Member of the Academy of Science 
of South Africa. 
dr NaNdi SiEgFRiEd, MB ChB, MPH (Hons), FCPHM, DPhil
Dr Siegfried obtained her MB ChB degree at the University of Cape Town in 
1993 and a Master’s degree in Public Health (Honours) at the University of 
Sydney (2000), and holds a Fellowship in Public Health Medicine (2004). She 
was a Nuffield Medical Fellow at the University of Oxford from 2004 to 2007, 
where she was based at the Clinical Trials Service Unit, obtaining a DPhil degree 
in Clinical Epidemiology. She is a public health specialist and is currently Co-
director of the South African Cochrane Centre based at the MRC. She is an 
active member of the international organisation, the Cochrane Collaboration, 
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and in 2000 established the Cochrane HIV/AIDS Mentoring Programme to train 
novice African researchers in meta-analytic methods. Her current research 
focuses on the methodological quality and conduct of randomised controlled 
trials of HIV/AIDS interventions and explores the feasibility and sustainability of 
a national trials support centre to enhance the quality and conduct of trial 
research in the South African public sector. 
professor JiMMY VOlMiNK, BSc, MB ChB, DCH, MPH, DPhil, MASSAf
Professor Volmink obtained his BSc and MB ChB degrees from the University 
of Cape Town (UCT). He worked as a medical officer and district surgeon, 
among other posts. He obtained his master’s degree in public health from 
Harvard, following which he was awarded a Nuffield medical fellowship (1993) 
and completed a doctorate in cardiovascular medicine at the University of 
Oxford. He is currently Professor and Deputy Dean (Research) at the Faculty of 
Health Sciences, Stellenbosch University, and Co-Director of the South African 
Cochrane Centre, MRC. Previous appointments include GlaxoWellcome 
Chair of Primary Health Care at UCT and Director of Research and Analysis 
at the Global Health Council, Washington, DC. Prof. Volmink has a special 
interest in rigorous evaluation of the effects of health care interventions. He 
has extensive experience in the application of randomised controlled trials, 
systematic reviews and meta-analysis in evaluating strategies and therapies 
for the control of tuberculosis, HIV/AIDS and cardiovascular disease. He has 
worked with policy-makers and clinicians both globally and in South Africa to 
promote the use of research evidence in making decisions about health care 
and has taught courses in evidence-based health care to students, health 
professionals and policy-makers in many countries. He has authored more 
than 100 peer-reviewed journal articles and book chapters. He serves on 
committees and advisory boards of a number of international organisations, 
including the Wellcome Trust, WHO, the Cochrane Collaboration, the Vienna 
School of Clinical Research and the Belgian Red Cross. He is also a member of 
the advisory boards of a number of international journals and serves as a peer 
referee for several others. He is a Member of the Council of the Academy of 
Science of South Africa. 
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A P P E N D I X  B :
ABOUT THE ACADEMY OF SCIENCE OF SOUTH AFRICA
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THE ACADEMY OF SCIENCE OF SOUTH AFRICA ACT (2001): 
A STATUTORY BODY PLACED STRATEGICALLY IN THE 
NATIONAL SYSTEm OF INNOVATION 
The Academy of Science of South Africa (ASSAf) was inaugurated in May 
1996 in the presence of then president Nelson Mandela, the patron of the 
launch of the academy. It was formed in response to the need for an 
academy of science consonant with the dawn of democracy in South Africa: 
activist in its mission of using science for the benefit of society, with a mandate 
encompassing all fields of scientific enquiry in a seamless way, and including 
in its ranks the full diversity of South Africa’s distinguished scientists. The South 
African Parliament subsequently passed the academy of Science of South 
africa act, Act 67 of 2001, which came into effect on 15 May 2002. ASSAf is 
thus the official national Academy of Science of South Africa, recognised by 
Government and representing South Africa in the international community of 
science academies.
Internationally recognised science academies are similar in that they are:
self-perpetuating, • with a merit-based membership that creates an 
upward aspiration for quality and excellence in scientific endeavours;
multidisciplinary, • striving to represent science as a continuum of 
knowledge, insight and practical solutions;
independent of government, • but can be funded by government for 
performing certain tasks;
a • credible voice of science to be heard on topics of national 
concern, independent of institutional or commercial linkages, 
obligations and agendas;
linked together in an•  independent global community that can 
mobilise scientific thinking, skills and knowledge across the world.
ASSAf places particular emphasis on excellence in the application of scientific 
thinking to the problems and challenges facing South african society. It draws 
its membership from all population groups and from all scientific disciplines.
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OBJECTIVES
Scientific thinking for the good of society
According to the Act, the objectives of the academy are to:
promote common ground in scientific thinking across all disciplines, • 
for example the physical, mathematical, life, human, social and 
economic sciences;
encourage and promote innovative and independent scientific • 
thinking;
promote the optimum development of the intellectual capacity of all • 
people;
provide effective advice and facilitate appropriate action in relation • 
to the collective needs, opportunities and challenges of all South 
Africans;
link South Africa with scientific communities at the highest levels, in • 
particular within Africa, and further afield.
VISION
an engine of excellence in scholarship and intellectual cooperation
ASSAf aspires to be the apex organisation for science and scholarship in 
South Africa, internationally respected and connected, its membership 
simultaneously the aspiration of the country’s most active scholars in all 
fields of scientific enquiry, and the collective resource making possible the 
professionally managed generation of evidence-based solutions to national 
problems.
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mISSION STATEmENT
clarifying the niche of the academy
Like democratic South Africa in general, ASSAf aspires to play both a national 
and an international role, particularly with respect to the African continent. 
We see the Academy as being usefully at arm’s length from government and 
other organised sections of the state, comprising an assembly of excellent 
scholars from many disciplines who are well networked both nationally and 
internationally, and have shown their interest in and capacity for promoting the 
development of a prosperous and fully enabled society. Membership of the 
Academy (by election) is both an honour and an obligation to work individually 
and collectively (as the Academy) to ensure that decision-making requiring 
scholarly scrutiny and analysis is based on the best and most integrated 
understanding and insights available to the country. The academicians thus 
represent an organised, independent but responsive scholarly voice to help 
guide the development of the country and its people.
the mission of aSSaf is thus to:
become increasingly associated in the mind of the nation with • 
the highest levels of scholarly achievement and excellence in the 
application of scientific thinking for the benefit of society;
consolidate its infrastructure and capacity, and to expand and mobilise • 
the membership to ensure that scholars from a full disciplinary spectrum 
are available for its work, and that these are indeed both thinkers and 
doers, willing to put significant effort into the Academy’s activities;
embark on a programme of systematic studies of evidence-based • 
issues of national importance, some proposed by government or other 
sectors, and some identified by the Academy itself;
develop a sound and robust methodology for constituting consensus • 
study panels, organising their work, including conferences and 
workshops, and producing authoritative reports that are well-
disseminated and have significant impact;
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alternatively, constitute committees to oversee the Academy’s work • 
in broad areas of focus, usually expressed by the holding of national 
forums on particular key issues, leading to forum reports that have a 
significant impact on policy and practise;
publish science-focused periodicals, especially a multidisciplinary • 
journal of high quality (the South African Journal of Science) and a 
science magazine that will showcase the best of South African research 
to a wide national (and international) audience (Quest – Science for 
South Africa); and to promote the development in South Africa of an 
indigenous system of research journals of internationally recognised 
quality and usefulness;
develop productive partnerships with other organisations, especially • 
(but not only) the National Departments of Science and Technology, 
Education, Health and Agriculture; the National Advisory Council on 
Innovation; science councils; higher education institutions, etc., with a 
view to the building of capacity in science and its applications within 
the National System of Innovation (NSI);
create new and diversified sources of funding for the sustainable • 
functioning of an independent Academy;
communicate effectively with the general and specific public, as well • 
as with partners and sponsors;
develop a plan for the expansion of the activities of ASSAf in partnership • 
with the national science academies of other countries, including 
contracted partnership with the US National Academies;
play a significant role in the international science system, particularly • 
in Africa, through organisations such as the InterAcademy Panel (IAP) 
and the InterAcademy Council (IAC), the Academy of Sciences of the 
Developing World (TWAS), the International Council on Science (ICSU), 
as well as the Network of African Science Academies (NASAC), all in 
the context of the New Partnership for Africa’s Development (NEPAD).
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mEmBERS
core asset of the academy (each styled ‘MaSSaf’)
After nomination by four existing Members (at least two of whom do so from 
personal knowledge of the candidate), new Members of the Academy 
are elected in a secret ballot. The normal criterion for election is significant 
achievement in the advancement or application of science, and, in addition, 
Members should be persons who can be expected significantly to assist 
the Academy in achieving its objectives. By October 2006, ASSAf had over 
250 Members drawn by self-categorisation from the earth, economic, life, 
mathematical, physical, social, technological, education and agricultural 
sciences as well as the humanities.
COUNCIL
Steering academy activities and taking responsibility
The affairs of the Academy are governed by a Council comprising 12 
members, each of whom holds office for four years. This Council is elected by 
the Members every two years. For the sake of continuity, six Members continue 
to serve a further term, while six new Members are elected once they have 
been nominated according to the constitutional mechanism. To provide a 
better balance of race, gender or disciplinary area, the Council can co-opt 
additional Members from persons who were nominated for election to the 
Council.
The office-bearers are the President, two Vice-Presidents, a General Secretary 
and a Treasurer. Committees can be formed in order to carry out specific 
functions, but each must be chaired by a Member of the Academy or, 
preferably, of its Council. Reports drawn up by its committees or ad hoc task 
groups are approved by the Council before entering the public domain.
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INTERNATIONAL CONNECTIONS
crucial catalyst for academy-type activities
ASSAf is an active member of the IAP (InterAcademy Panel on International 
Issues), a growing organisation that embraces the national science academies 
of over 90 countries. The Academy of Sciences for the Developing World now 
has an office in Africa based in Nairobi, and the Network of African Science 
Academies, of which the President of ASSAf is a Vice-President, is also located 
in that city. ASSAf became an ‘intense partner’ of the US National Academies 
(together with the Nigerian and Ugandan Academies of Science) as part 
of the African Science Academy Development Initiative (ASADI), receiving 
a substantial five-year grant to build its capacity for generating evidence-
based advice for the government and the nation in general.
STRATEGIC PLAN AND POLICY DEVELOPmENT
the way to go
ASSAf has developed a comprehensive strategic plan following a thorough 
process for identification of its strengths, weaknesses, opportunities and 
threats. Through its governing Council, the Academy has developed policies 
and guidelines for its activities. The initiation of the ASADI partnership with the 
US National Academies prompted the generation, proposal and adoption of 
the following items:
Guidelines for proposals of science-based topics in terms of the ASSAf • 
Act;
Guidelines for proposals of science-based topics (project proposals);• 
Guidelines for the appointment of consensus study panels and forum • 
steering committees;
Policy on conferences;• 
Formation of a forum steering Committee on Science for Poverty • 
Alleviation (first example of an ASSAf ‘Board’);
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Panel for the Consensus Study on Nutritional Influences on Human • 
Immunity, with special reference to clinical tuberculosis and HIV 
infection (first ASSAf consensus study).
ASSAf’s strategic plan and the Academy’s policies and guidelines are publicly 
featured on the ASSAf website at http://www.assaf.org.za
RESEARCH PUBLISHING
the core of the quality assurance system for the dissemination of 
research findings
The Academy of Science of South Africa signed a contract in 2001 with 
the DST for various activities in connection with the strategic management 
of research journals published in South Africa. The first component was a 
comprehensive study of the present and best-possible future role of research 
journals published in South Africa, now completed through the release of a full 
report in March 2006, with evidence-based recommendations, and a range 
of follow-up project integration and implementation strategies.
SAJS
publishing the South African Journal of Science
The South African Journal of Science is the leading multidisciplinary research 
journal in Africa, and features a great diversity of original work by researchers 
throughout the country and abroad, concentrating on articles that have an 
appeal that is wider than that of single disciplines. Among the highlights of the 
volume published in 2005 were articles featuring the research at historically 
black universities supported by the Royal Society-NRF bilateral programme. 
The journal appears six times a year, and is accessible online as one of the 
e-publications managed by Sabinet.
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QUEST
publishing Quest: a quarterly magazine of high quality, presenting 
science for South africa
The Academy publishes the national science magazine Quest: Science for 
South Africa which was launched in 2004. Quest serves as a platform for 
communication about scientific research done in South Africa. It strives to 
showcase South African science in action, and is aimed at the broad scientific 
community, decision makers, the public, students, and especially the senior 
grades at secondary schools.
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